Generation of disease-relevant neurons from human pluripotent stem cells by Arber, Charles
IMPERIAL COLLEGE LONDON - DEPARTMENT OF MEDICINE 
MEDICAL RESEARCH COUNCIL, CLINICAL SCIENCES CENTRE 
 
 
 
 
 
 
GENERATION OF DISEASE-RELEVANT NEURONS 
FROM HUMAN PLURIPOTENT STEM CELLS 
 
 
 
 
 
Charles Arber 
 
 
Thesis submitted for the degree of Doctor of Philosophy 
 
 
2012  
2 
 
I declare that the work presented in this thesis is my own, unless otherwise stated. 
 
 
 
 
 
 
Charles Arber  
3 
 
Acknowledgements 
 
 I wish to say a huge thank you to all those who made this work possible. Firstly, thank you to 
Professor Meng Li for the excellent supervision, unbounded knowledge and the freedom she gave 
allowing varied and sometimes bizarre investigations that I thought were relevant. The entire Stem 
Cell Neurogenesis lab was a place of fruitful work, collaboration, discussions and fun. Xinsheng and 
Emily have some of the broadest knowledge possible; I encourage the reader to ask them anything. 
Ines always had my back and provided a lot of entertainment throughout the PhD experience. 
Thanks should go to Roberto, Jess, Nicole, Dino, Roger, IChen, Claudia, Diana, Judit, Barbara, Beata 
and Jun for making the lab a great place to spend four years. Special thanks to Emily, Xinsheng, 
Serafi, Meng and beautiful Rebecky for battling with this document with me. 
 Thank you to all my collaborators in these works, Serafi and Tristan Rodriguez were the 
brains behind the Activin story and Sophie, Andi, Claire, Steve Dunnett and Anne Rosser made all the 
animal work possible, adding weight to the in vitro data. Also thanks to Jess, Antonios and Mark 
Ungless for fighting with the neurons to show they were functional. Thanks should go to Austin 
Smith for sharing his 2F8 human iPSC line and to Kuo Hsuan Chang for the 4FHuang#1 human iPSC 
line generated in our lab. 
 I would like to acknowledge the MRC, European framework package 7 - NeuroStemCell and 
Imperial College for funding the work and also the Clinical Sciences Centre for providing a 
stimulating place to work. 
 Finally, thank you to my wonderful family and Bedford Dad for always supporting me and all 
my friends for paying their taxes. 
  
4 
 
 Abstract 
 This thesis describes investigations into exogenous factors that influence fate-choices during 
human pluripotent stem cell (PSC) differentiation in vitro. I describe novel growth factor 
environments and small molecule regimes that provide patterning signals enabling directed 
differentiation of human PSCs towards biomedically relevant neurons. I provide evidence that the 
TGFβ growth factor Activin can promote ventral telencephalic differentiation. Small adjustments in 
Activin administration can produce an over-representation of forebrain derived medium spiny 
neurons and cortical interneurons, with significance in Huntington’s disease and epilepsy 
respectively. Additionally, I manipulate the earliest growth factor environments of PSC 
differentiation to lead to broad changes in rostro-caudal patterning. Inhibiting FGF signalling leads to 
a midbrain-like phenotype that can be further differentiated towards a ventral midbrain 
dopaminergic fate, a cell type that degenerates in Parkinson’s disease. Our novel manipulations and 
differentiation protocols provide insights into early events in human development, which would 
otherwise be impossible to study. This logic can also be applied to investigate diseased states during 
human development and ageing via use of disease-specific cell lines. The mature neurons produced 
may provide a tool that can be applied to large-scale drug screening assays and toxicology testing as 
well as having the potential for cell based therapies in future years.  
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Chapter 1 Introduction 
1.1 Thesis Introduction 
 In this thesis, I shall investigate the differentiation of human pluripotent stem cells (hESCs) 
into neurons with specific relevance to certain diseased states. I aim to optimise a differentiation 
scheme to produce cells that are competent to mature into a range of neuronal cell types. Via use of 
novel exogenous growth factor combinations, I aim to alter the cellular environment in order to 
specify these disease-relevant neurons. This technique makes use of the genetic networks set in 
place for normal development. 
 The focus will be on dopaminergic neuronal populations that degenerate in Parkinson’s 
disease, GABAergic projection neurons that are lost in Huntington’s disease and cortical 
interneurons that have been theorised to be hyposplastic in epilepsy, autism, schizophrenia and 
Tourette’s syndrome. 
1.2 Development of the Neural Tube 
1.2.1 Neurulation 
 During gastrulation of the embryo, the three germ layers are specified; namely the 
endoderm, mesoderm and ectoderm. The ectoderm has the potential to form neural tissue and the 
epithelium, whereas the mesoderm and endoderm form the remaining cell types, e.g. blood lineages 
and the internal organs respectively. In the 1920s, Spemann and Mangold performed grafting 
studies between amphibian embryos and helped to define the Organiser region (also called the 
Node), a signalling region responsible for initial neural induction. Isolation and grafting of the 
Organiser onto a second embryo initiated formation of a second, complete neural axis (Figure 1.1 A) 
(Spemann and Mangold, 1924). Further work by Nieuwkoop in the 1950s and 1960s examined the 
induction of the Organiser and found a Fibroblast Growth Factor (FGF2) signal from the underlying 
tissue was critical for Organiser formation (Nieuwkoop, 1969). 
 Studies culturing dissociated tissue in vitro have demonstrated that the ectoderm has a 
default neural differentiation program and that strong Bone Mophogenetic Protein (BMP) signals are 
widely expressed to promote epithelial, rather than neural, development (HemmatiBrivanlou and 
Melton, 1997). The function of the Organiser was thus described as a disinhibitory role, whereby 
many inhibitors of epidermal-inductive BMP signals are secreted by the Organiser. In mammalian 
development, the Organiser is termed the Anterior Neuroectodermal Ridge (ANR) and BMP 
inhibitors such as Noggin and Chordin (Anderson et al., 2002; Bachiller et al., 2000; Smith and 
Harland, 1992), Wnt inhibitors such as DKK1 (Glinka et al., 1997) and TGFβ inhibitors such as 
16 
 
Follistatin (Hemmatibrivanlou et al., 1994) have all been shown to be expressed in the ANR. 
Importantly, neural tissue has a default anterior character and as the neural tube extends to the 
posterior of the embryo, further exogenous signalling is required for caudalisation of the tissue, this 
is termed the Activation-Transformation model (Figure 1.1 B) (neural induction followed by 
progressive caudalisation) (Nieuwkoop and Nigtevecht, 1954).   
 Upon neural induction, the neural plate separates from the epithelium and forms a neural 
tube; this is achieved via complex cell morphology changes (Figure 1.1 C). Cells actively divide in the 
neural tube and maturing cells are found at the extremity of the structure whereas naive cells are 
found close to the lumen in the sub ventricular zone (SVZ) (Figure 1.1 D). Understanding of cell 
diversification and structure formation has focused on morphogenetic signals, whereby changes in 
the anterior-posterior and dorso-ventral axes convey positional identities to the cells and cellular 
domains. The balance between proliferation and maturation sets the final size and structure of the 
central nervous system and the broad range of positional identities are responsible for creating the 
full complement of cell types of the nervous system.     
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Figure 1.1 Neural induction.  
(A) depicts a reproduction of the initial Organiser grafting studies of Spemann and Mangold, 
demonstrating that a donor Organiser located at the dorsal lip of the blastopore (bottom right, 
arrow, vegetal view) can induce an entirely new neural axis (bottom left) compared with the wild 
type (top). (B) shows the neural tube domain organisation in the anterior-posterior axis. More 
posterior/caudal tissues are thought to be posteriorised from a default anterior character.  (C) 
shows electron microscope images of neural tube formation, whereby the underlying notochord 
(arrow) instructs the neural plate to separate from the epithelium and form a tube structure. 
Note, the tube resembles in vitro rosette structures, discussed Chapter 1.2.2.2. (D) is a diagram of
a transverse section of the neural tube at the ventral midbrain. Depicted are the naive cell 
markers expressed close to the lumen of the neural tube and mature TH (dopaminergic) neurons 
being generated at the periphery, markers explained in Chapter 1.2.4. The SVZ is closest to the 
lumen and is proliferative (blue), the intermediate zone marks committed cells (yellow) and 
postmitotic neurons are in the marginal zone (purple) (De Robertis and Kuroda, 2004; Gale and 
Li, 2008; Gilbert, 1985; MmeCurie, 2000) 
Neural Plate 
A C 
B 
D 
Proliferative Cells 
Committed Cells 
Postmitotic Cells 
NESTIN, NGN2, 
LMX1A, FOXA2 
FOXA2, DMRT5, 
LMX1a 
TUJ1, TH, PITX3, 
FOXA2, LMX1A 
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1.2.2 Up to date: Neural Induction and the Default Model 
 Since the Xenopus experiments discussed, certain studies have reinforced the importance of 
FGF signalling for neural induction in mouse embryonic stem cells as FGF deficient cells remain 
pluripotent (Kunath et al., 2007; Stavridis et al., 2007). It appeared that neural organiser region 
induction from the mouse anterior visceral endoderm might function in a parallel manner to the 
vegetal-pole-derived FGF induction of the Organiser region in Xenopus (Nieuwkoop, 1969). 
 Further investigations have shown that this is not the case. FGF signalling has been proven 
to be critical for mouse embryonic stem cells (ESCs) to exit the pluripotent state (Kunath et al., 2007) 
and this is supported as FGF inhibition together with Wnt agonists maintain a pluripotent ground 
state (Silva et al., 2008). Importantly, it was shown that this requirement for FGF signalling is no 
longer required after epiblast formation and that inhibition of FGF, after its requirement for epiblast 
induction, actually facilitates neural induction. This is witnessed via enormous ectopic neural marker 
expression when epiblast embryos are cultured with FGF inhibitors (Di-Gregorio et al., 2007). 
 It is considered that mouse cells offer a better model to study human development than 
lower organisms; however, there are certain differences between human and mouse ESCs. Although 
human cells express many of the same key pluripotency markers, their growth factor dependencies 
are divergent. This results in the very contentious hypothesis that human ESCs represent a later, 
possibly epiblast, stage of development (Greber et al., 2010; Tesar et al., 2007). This is supported by 
the investigations of Greber et. al. who show that inhibiting FGF signalling enhances neural 
differentiation from the earliest time points of human ESC differentiation – contradicting mouse ESC 
data (Greber et al., 2011). Contrastingly, parallel studies in other groups argue that FGF signalling is 
endogenously active during early human ESC differentiation. For example, FGF2 was shown to 
facilitate neural differentiation and its blockage inhibits this process (Cohen et al., 2010), although 
neural differentiation can progress in the absence of FGF signalling. 
 Therefore, the role of FGF signalling in early differentiation is complex and may also be 
influenced by species diversity. For example, mouse and human embryos use different neural fate 
determinants (Zhang et al., 2010) and so growth factor dependency may differ. Nonetheless, it is 
clear that both human and mouse systems use inhibitors of BMP and TGFβ signalling pathways to 
initiate neural patterning in a similar disinhibitory manner to the Xenopus Organiser. Molecules such 
as Noggin, Cerberus, Lefty and Follistatin are all expressed in mammalian Organiser regions, 
described in the next section (Bachiller et al., 2000; Greber et al., 2011), and have therefore become 
important for ESC differentiation (Chambers et al., 2009), discussed in Chapter 1.6.  
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1.2.3 Secreted Growth Factor Signalling 
 Throughout development, organiser regions are responsible for establishing positional cues, 
enabling individual cells to sense their relative position in the embryo and develop into the correct 
cell type accordingly. Organiser regions are responsible for secreting soluble and lipid bound growth 
factor stimuli to which nearby cells are able to respond in a paracrine manner. This growth factor 
secretion is the basis of the morphogen model of development, whereby a cell’s respective distance 
from an organiser is tantamount to the dosage it perceives (Figure 1.2). Thus, the gradient of a 
morphogen over distance (and so the morphogen concentration) instils positional identity to the 
responding cells.  
 
 
 
 
 
 
 
 
 
 
 
 In this thesis, I shall consider growth factor stimuli relevant to the anterior neural tube. The 
Organiser regions responsible for the major patterning events in the forebrain are described thus 
(and in Figure 1.3). 
1. Anterior Neuroectodermal Ridge (ANR, also known as the Node or the rostral patterning 
centre). The ANR is initially responsible for specifying the neural tube from the 
neuroectoderm, see Chapter 1.2.1. Inhibitors of BMP, TGFβ and WNT signalling such as 
Noggin, Chordin, Follistatin and Lefty are all crucial for neural fate determination but also for 
specifying anterior neural fates (Bachiller et al., 2000; Glinka et al., 1997; Hemmatibrivanlou 
Figure 1.2 Morphogen gradients.  
Cells in close proximity to the organiser (left) receive high doses of a diffusible signal (top). As distance
from the organiser increases, dose perception reduces. This leads to the French flag hypothesis 
(bottom), as cells respond to the signal to produce three cell types relative to morphogen 
concentration, thus conveying positional identity. 
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et al., 1994; Smith and Harland, 1992). Once established, the ANR has a major role in 
secreting FGF8 to pattern the anterior neural tissues. FGF8 has been shown to be 
responsible for inducing FOXG1, a crucial telencephalic fate determinant gene (Shimamura 
and Rubenstein, 1997). 
2. Floorplate SHH secretion. SHH is a morphogen that is expressed throughout the ventral 
neural tube (Briscoe and Ericson, 2001; Ericson et al., 1995). Initial expression in the 
notochord (mesoderm derived) is responsible for subsequent neural SHH expression. SHH 
has been shown to act as a classic morphogen, whereby homeodomain proteins respond to 
SHH signals in a graded manner to set up pools of progenitor cells with distinct dorso-ventral 
spatial identities (Muhr et al., 2001).  
3. The cortical hem and dorsal roofplate. BMP and Wnt proteins expressed in the cortical hem 
are required for proper development of dorsal tissues including the cortex and neural crest 
cells (Furuta et al., 1997; Grove et al., 1998). Throughout the neural tube, antagonistic cues 
from the ventral SHH and dorsal BMP/Wnt signals specify the full complement of dorso-
ventral cell types (Ulloa and Briscoe, 2007).  
4. The midbrain hindbrain boundary (MHB, or Isthmus/Isthmic organiser). The MHB is the 
boundary demarcating the posterior limit of OTX2 expression (the forebrain and midbrain 
homeodomain protein) and anterior limit of GBX2 expression (hindbrain homeodomain 
protein). These two proteins are expressed in a mutually exclusive manner. FGF8 is a major 
secreted factor from the MHB and is responsible for the patterning of the midbrain tissues 
and the hindbrain-derived cerebellum (Ye et al., 2001). FGF8 is then responsible for 
induction of WNT1, a second major morphogen secreted by the MHB, that is also crucial for 
midbrain and hindbrain development (Danielian and McMahon, 1996). 
5. The Zona Limitans Intrathalamica (ZLI). The ZLI in the diencephalon secretes SHH signals and 
effects the proliferation, patterning and boundary formation during thalamic development 
(Echevarria et al., 2003). The ZLI may have more complex instructive properties through FGF 
signals that remain to be elucidated. 
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SHH
Wnt1
FGF8
MHB
Floorplate
ANR
ZLI
FB
MB
HB
Figure 1.3 Organiser Regions.  
Organiser regions of the developing neural tube are responsible for establishing morphogen 
gradients and conveying positional identity. The Organisers discussed in this thesis are the ANR 
at the anterior most tip of the embryo that secretes FGFs among other signals, the ZLI in the 
diencephalon that mainly secretes SHH, the MHB that secretes FGFs and Wnt signals, dorsal 
BMP and WNT secretion by the roofplate, and the floorplate that spans the ventral neural tube 
and secretes SHH signals. FB - forebrain, MB - midbrain and HB – hindbrain are depicted 
(MmeCurie, 2000; Prakash and Wurst, 2006). 
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1.2.3.1 Fibroblast Growth Factor Signalling 
 Fibroblast growth factor (FGF) signalling has been implicated in a variety of processes from 
proliferation and survival to patterning and terminal differentiation. Currently 22 FGF ligands have 
been described, with a conserved heparin sulphate binding domain. Additionally there are 4 FGF 
receptors; each with several splice variants. This diversity means that there is a great deal of 
complexity in the FGF signalling response. FGF signals are transduced via the receptor tyrosine 
kinase (RTK) cascade and so are akin to other RTK signal pathway activators such as PDGF, EGF, etc.  
 Binding of the FGF ligand leads to receptor dimerisation and autophosphorylation of the 
receptor intracellular domain (Figure 1.4). Phosphorylated serine and threonine residues then 
promote the formation of a protein complex, including GRB2 and SOS, which leads to activation of 
the signalling hub RAS-GTPase. Activation of RAS leads to the MAP kinase phosphorylation cascade 
resulting in phosphorylated ERK, which can enter the nucleus and lead to transcriptional changes in 
target genes such as ETS, c-FOS and JUN. Negative regulation of this cascade is promoted directly via 
ERK-mediated phosphatases attenuating the MAP kinase signal and also via transcriptional changes 
of negative regulators, such as SPROUTY (Kim and Bar-Sagi, 2004). FGF signalling can also effect 
secondary pathways such as the PI3 kinase pathway and PLCγ mediated IP3, leading to pleiotropic 
downstream effects.   
 In this project I use the FGF signalling inhibitor PD0325901. This small molecule prevents ERK 
phosphorylation via inhibition of kinase activity of the MAPKK/MEK molecule.  
 FGF signalling has a range of relevant effects during development. Firstly, FGF2 signals from 
the Nieuwkoop centre are pivotal for the establishment of the Spemann Organiser and so all the 
neural tissues (Chapter 1.2) (Nieuwkoop, 1969). Subsequent FGF8 signals in the ANR and the MHB 
are required for the development, proliferation and survival of forebrain (Shimamura and 
Rubenstein, 1997) and midbrain/hindbrain tissues respectively (Ye et al., 2001). FGF15/19 signals 
from the diencephalon have been shown to be complementary to ANR-derived FGF8 signals and 
function to promote proliferation and survival of caudal forebrain and diencephalic tissues (Borello 
et al., 2008). Additionally, FGF2 signals have been shown to have a caudalising effect on the embryo, 
aiding hindbrain/spinal cord development (Cox and HemmatiBrivanlou, 1995). FGF8 knockout mice 
have an enlarged OTX2-positive forebrain/midbrain, reinforcing a caudalisation effect via FGF signals 
(Sun et al., 1999).  
 In vitro, FGF2 is routinely used for maintenance of human pluripotent stem cells (PSCs), see 
Chapter 1.4. Strong doses of the growth factor are used in concert with feeder cells to maintain cell 
pluripotency. FGF2 has also been used together with EGF to promote proliferation and prevent 
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differentiation of neural stem cells (NSCs) (Tropepe et al., 1999). Subsequently, differentiation 
ensues when the growth factors are withdrawn. FGF signalling has also been demonstrated to be 
critical for initial lineage commitment and differentiation. ERK knockout ESCs are not able to exit the 
self-renewal phase, potentially due to the lack of Nieuwkoop centre inductive capacity. This FGF 
dependency has been shown to be FGF4 specific (Kunath et al., 2007; Stavridis et al., 2007), but also 
FGF5 exhibits an epiblast-specific expression pattern.  
 
Figure 1.4 FGF signalling.  
Secreted FGF ligands bind to FGF receptors leading to dimerisation and autophosphorylation on 
receptor intracellular domains. Phosphorylated receptors then recruit a complex of proteins including 
GRB and SOS to activate the signalling hub RAS. Activated RAS leads to a phosphorylation cascade 
through mitogen activated kinases leading to phosphorylated ERK; this is inhibited by the small 
molecule PD0325901. Phosphorylated ERK is able to enter the nucleus and alter expression of target 
genes, which include the negative feedback regulators SPRY and phosphatases such as DUSP. Other 
pathways such as PLCγ and PI3K are also stimulated after receptor autophosphorylation. 
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1.2.3.2 Sonic Hedgehog Signalling 
 Sonic hedgehog (SHH) signals in the ventral neural tube establish patterning in the 
dorsoventral axis via antagonising dorsal signals such as BMP (Ericson et al., 1995). Additionally, SHH 
has been shown to have a strong mitogenic activity and may be involved in correct tissue growth 
during development (Elkabetz et al., 2008; Fuccillo et al., 2006). Establishment of ventral SHH 
expression, e.g. in the floorplate of the neural tube, requires SHH expression in the underlying 
mesodermal structure the notochord.  
 SHH signals are mediated through a protein cascade in the cells receiving the signal (Figure 
1.5), for review see (Hooper and Scott, 2005; Ingham and McMahon, 2001). SHH is a secreted 
glycoprotein ligand that is palmitoylated and covalently associated with cholesterol in the secreting 
cell. This apparent lipophilic characteristic is counterintuitive for a long-range secreted morphogen; 
however a dependence on the protein Dispatched (DISP), that may displace the ligand from lipid 
rafts, suggests one mechanism for ligand activation. Also, the possible presence of two isoforms of 
SHH, a full-length unmodified version in addition to palmitoylated SHH, may account for the long 
range effects of SHH (Ingham and McMahon, 2001). In the absence of SHH, a protein kinase complex 
containing Protein Kinase A (PKA), Glycogen Synthase Kinase (GSK3β), Casein Kinase I (CKI) and 
Fused (FU), phosphorylates and inactivates GLI1/2 transcription factor effectors. In contrast, 
phosphorylation of GLI3, the negative SHH effector, leads to its cleavage and activation. Upon SHH 
binding to its receptor Patched (PTCH), a Smoothened (SMO)-mediated inhibitory signal is lifted and 
the protein kinase complex is disrupted from the microtubule cytoskeleton. The cytoplasmic pool of 
GLI1/2 is no longer inactivated via phosphorylation/cleavage and after translocation to the nucleus, 
GLI1/2 bring about positive SHH signalling effects. Active GLI signalling displaces Groucho-mediated 
inhibition of transcription to alter expression of the homeodomain SHH target genes (Muhr et al., 
2001). 
 The inhibitor of SHH signalling that I use in this project is termed Cyclopamine. This molecule 
antagonises SHH by directly binding to SMO to enforce the negative signal state (Chen et al., 2002). 
We also use the small molecule Purmorphamine which is a SHH agonist. This molecule also functions 
via binding Smo with a similar target motif to Cyclopamine, albeit with opposing effects to the SHH 
signal activity (Sinha and Chen, 2006). 
 SHH has a number of developmental roles including tooth, hair and gonadal development. 
SHH signalling has been extensively studied in the developing neural tube. Signalling in the spinal 
cord is crucial for motor neuron specification. SHH patterns the ventral midbrain which includes the 
dopaminergic cells of the basal ganglia. In the forebrain SHH induces cortical interneurons subtypes 
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and also plays a critical role in the development of the eye. Additionally to a patterning role, SHH has 
a role in proliferation of neural progenitors and maintains self-renewal (Fuccillo et al., 2006). 
 In vitro techniques have demonstrated the mitogenic capacity of SHH, specifically at the 
rosette stage of differentiation (Elkabetz et al., 2008). This translates to the neural progenitor stage, 
when cells are cycling and when SHH has its strongest patterning effect at parallel developmental 
stages in vivo. The specification function of SHH towards ventral tissues has been employed for 
relevant ventral cell type differentiation, such as cortical interneurons and projection neurons of the 
basal ganglia (Aubry et al., 2008; Maisano et al., 2012), ventral diencephalic cells (Ohyama et al., 
2005), ventral midbrain dopaminergic cells (Barberi et al., 2003; Fasano et al., 2010) and motor 
neurons of the spinal cord (Wichterle et al., 2002).  
 
Figure 1.5 SHH signalling.  
SHH is a secreted, palmitoylated protein that requires Dispatched (DISP) processing in the SHH 
producing cell. In the absence of SHH signal, Smoothened (SMO) is inhibited by Patched (PTCH), 
leading to an active protein kinase complex that includes GSK3β, PKC and CKI. GLI proteins are thus 
phosphorylated and cleaved leading to active repressors (e.g. GLI3R) or inactive SHH transducers 
(e.g. GLI1). Ligand binding to PTCH relieves the inhibition on SMO and results in disruption of the 
kinase complex. Non-phosphorylated GLI proteins remain free from cleavage, leading to active GLI1 
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and inactive GLI3. The result of SHH signalling is GLI1/2 mediated transcriptional changes to 
homeodomain factors that are grouped into two classes depending upon positive or negative 
responses to GLI1/2. SMO is the target of both the agonist Purmorphamine and antagonist 
Cyclopamine used in the study. Transcriptional changes are achieved via lifting Groucho-mediated 
(GRO) repression, adapted from (Fuccillo et al., 2006). 
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1.2.3.3 Wnt Signalling 
 Multiple Wnt family members exhibit conserved expression in the dorsal midline of the 
neural tube as well as a dorsoventral ring expression pattern in the MHB organising centre. Currently 
19 Wnt family members have been described as well as a family of 10 Frizzled (FRZ) receptor 
proteins (Rawal et al., 2006). Wnt signalling has a role in proliferation, differentiation, polarity, 
migration and cell death (Prakash et al., 2006).  
 Wnt ligands are palmitoylated glycoproteins. There are two modes of Wnt signalling, 
canonical and non-canonical. During canonical Wnt signalling (Figure 1.6), Wnt binds to FRZ in the 
extracellular domain and promotes formation of a complex including Dishevelled (DSV) and LRP 
coreceptors. Upon Wnt binding, DSV disrupts a cytoplasmic protein complex that includes AXIN 
scaffold, GSK3β and APC. This complex functions to promote proteosomal degradation of the 
transcription factor βcatenin in the off state, which is present at adherens junctions and also free in 
the cytosol. Active Wnt signalling therefore represses degradation of βcatenin, leaving the 
transcription factor free to enter the nucleus and bring about transcriptional changes via association 
with TCF and LEF transcription factors. Active signalling removes Groucho-mediated transcriptional 
repression of target genes. Negative feedback of this pathway occurs through modulation of GSK3β, 
via transcription of molecules involved in repression such as AXIN2 and via secretion of antagonists 
that either sequester Wnt (e.g. Cerberus and WIF) or bind receptor molecules and occlude Wnt 
binding, such as DKK1. Non-canonical Wnt signalling is termed the planar cell polarity (PCP) pathway 
and acts through RHO and ROCK to alter the actin cytoskeleton, cell shape and cellular morphology.  
 Wnt, along with BMP, has been shown to have a negative effect on early neurulation of the 
embryo, instead favouring formation of the epithelium (Aubert et al., 2002; Glinka et al., 1997; 
Nieuwkoop and Nigtevecht, 1954). Contrastingly, after neural induction, Wnt signals have multiple 
and varied effect throughout neural tube. Wnt1 signals are important for regionalisation in the 
embryo, for example Wnt1 is able to induce Engrailed genes that are crucial for cell survival in the 
midbrain and the hindbrain (Danielian and McMahon, 1996). Wnt1 signals from the MHB are 
subsequently critical for dopaminergic neurogenesis in the ventral midbrain (Joksimovic et al., 2009; 
Prakash et al., 2006) and this is in part by inducing the fate determinant Lmx1a (Chung et al., 2009; 
Friling et al., 2009). Wnt signals in the dorsal telencephalon are also involved in specification and 
patterning of the cortex and appear to cooperate with BMP signals from the dorsal midline. 
Importantly, Wnt deficiencies in this tissue lead to loss of dorsal structures such as the choroid 
plexus (Grove et al., 1998). Different responses to different Wnt ligands are exemplified by the 
opposing roles of Wnt1 and Wnt5a in vivo as Wnt1 has been shown to promote neurogenesis and 
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proliferation whereas Wnt5a promotes terminal differentiation in the ventral midbrain (Castelo-
Branco et al., 2003).  
 During in vitro differentiation, the lack of an active Wnt1 ligand due to its lipophilic nature 
has hindered investigations into its effect. This has forced the use of recombinant, homologous 
Wnt3a or small molecule agonists which have been used in place of Wnt1. Wnt5a, on the other hand 
is a soluble factor. The inhibitory effect of Wnt signalling during neural lineage commitment has 
been noted in differentiation studies (Aubert et al., 2002) and demonstrated via the beneficial effect 
of Wnt antagonists during initial neural commitment, such as DKK1 (Watanabe et al., 2005). 
 
Figure 1.6 Wnt Signalling.  
Wnt is a secreted morphogen that signals in a paracrine manner. In the absence of Wnt, a protein 
kinase complex containing GSK3β and APC phosphorylate cytosolic βcatenin, targeting it for 
proteosomal degradation. Wnt ligands bind via LRP and Frizzled (FRZ), which results in the 
recruitment of Dishevelled (DSV) which then disrupts the kinase complex leading to cytosolic 
accumulation of βcatenin. βcatenin then is free to enter the nucleus and bring about relevant 
transcriptional events in target genes with TCF and LEF transcription factors. Wnt signalling is 
antagonised via DKK1-mediated receptor blockade or ligand sequestration via Cerberus or WIF, 
adapted from (Reya and Clevers, 2005).  
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1.2.3.4 Retinoic Acid Signalling 
 Retinoic Acid (RA) signalling is chordate specific and so an evolutionarily recent acquisition. 
Vitamin A is absorbed from food, processed and released as retinol by such organs as the liver. 
Signalling primarily occurs in a paracrine manner, whereby RA processing tissues signal to 
neighbouring cells through exogenous RA. 
 Retinol, the alcohol form of RA, is present in the bloodstream after being secreted by the 
liver and is bound by the RA binding protein RBP4. Interactions between RBP4 and the cell surface 
receptor STRA6 leads to internalisation of retinol into the cytoplasm of responsive cells (Figure 1.7). 
Retinol is subsequently dehydrogenated to retinaldehyde via alcohol dehydrogenases and retinol 
dehydrogenases, both sets of enzymes being expressed ubiquitously. Retinaldehyde is then 
dehydrogenated once more to RA via ALDH1a1-3 enzymes. ALDH1a dehydrogenases show tissue 
specific expression that can predict RA-responsive tissues. RA then travels to neighbouring cells in an 
undefined manner, or alternatively can be bound by CRABP binding proteins cell autonomously, 
where it can translocate to the nucleus and bind two RA receptor families, RARs and RXRs. RA 
complexed to these receptors, then binds the DNA in RA response elements (RAREs) and alters 
transcription. For review see (Duester, 2008). Negative regulation of RA signalling occurs as RA is 
degraded by cytochrome enzymes, such as CYP26b, which also demonstrate discrete expression 
patterns in tissues negatively regulating RA signals.  
 The RA antagonists that I use in this project are AGN193109 and UVI3003. AGN193109 is a 
RAR antagonist whereas the UVI3003 small molecule is a RXR antagonist. The mechanism of these 
molecules is unknown, although they may function via hindering RA receptor dimerisation and also 
RA binding and so lead to disrupted RAR/RXR function. 
 The paracrine nature of RA signalling is demonstrated as mutants for ALDH1a enzymes 
exhibit cellular defects in adjacent tissues to those normally expressing the ALDH1a gene, e.g. the 
retina and the ectoderm express ALDH1a1/3 genes during eye development, however defects are 
witnessed in the periocular mesenchyme in mutant mice (Matt et al., 2005). The expression of 
ALDH1a genes and Cyp26 genes can hint to RA receptive tissues during development. For example, 
RA has a caudalising effect in the neural tube and ALDH1a gene expression in the hindbrain 
demonstrates a competence to respond here. Specifically, RA has been shown to regulate 
homeodomain Hox genes to specify caudal tissues, e.g. the presence of RAREs in the promoter of 
Hoxb1, a gene that defines the hindbrain. However, more anterior in the midbrain, CYP26b 
expression delineates a resistance to caudalising RA signals (Maden, 2007). RA also has 
developmental effects in the eye, spinal cord and forebrain. 
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 Differentiation of ESCs in vitro has long since used RA to direct neural differentiation from 
pluripotent cells, although the mechanism is not fully understood (Andrews, 1984). However, new 
data from Stavridis et. al. implicates RA in mediating changes in FGF signalling activity to instruct 
early lineage fate choices (Stavridis et al., 2010). RA has since been used in conjunction with SHH to 
specify motor neurons which are derived in the ventral spinal cord. The strong caudalising effect of 
RA together with ventralising SHH signals can drive motor neuron differentiation (Li et al., 2005; 
Wichterle et al., 2002). Also, RA has recently been implicated in differentiation of dorsal forebrain 
types (Shi et al., 2012). Finally, RA has been shown to have a strong pro-differentiation effect, 
favouring terminal differentiation of neural cultures (Chatzi et al., 2011). 
 
Figure 1.7 RA Signalling.  
The RA precursor retinol is present in the bloodstream bound by RPB4 binding protein. RBP4 interacts 
with the receptor STRA6 to internalise retinol, where two rounds of dehydrogenation occur via 
ADH/RDH and ALDH1 dehydrogenases to produce RA. RA travels to adjacent cells in an undefined 
manner bound by CRBP binding proteins, where it can enter the nucleus, be coupled to RA receptors 
RARs and RXRs and bind promoter regions via RAREs. The antagonists used in this study are 
AGN193109 and UVI3003 which disrupt RA and RAR/RXR complex formation respectively. RA is 
degraded in unresponsive cells via cytochrome enzymes such as CYP26b, adapted from (Duester, 
2008). 
  
31 
 
1.2.3.4 Activin Signalling 
 The TGFβ superfamily of signalling molecules include BMP, TGFβ, Activin, Nodal and Lefty 
ligand families. These signal pathways all use SMAD signal transducers; however receptor specificity 
and SMAD transducer subtype specificity both lead to distinct signal responses. Activin is a dimeric 
soluble protein ligand. There are 3 Activin and 2 Inhibin mature ligands, synthesised from common 
precursor proteins. Activin and Inhibin are ligands that signal through ALK2/4/7 TGFβ receptors. 
Although the role for maintenance of pluripotency and mesodermal/visceral endodermal 
differentiation has been established, we describe in this work the first investigations into a role for 
Activin in the developing neuroectoderm.  
 Secreted Activin binds to TGF type II receptors, ActRIIA and ActRIIB (Figure 1.8). Specific type 
I receptors are then recruited, ALK2, ALK4 and ALK 7. Formation of this receptor dimer leads to type I 
receptor phosphorylation on intracellular serine/threonine residues. Phosphorylated and activated 
type I receptor is then able to interact with signal transducer molecules SMAD2/3, leading to their 
phosphorylation and activation. SMAD2 and SMAD3 are common for Activin and TGFβ signalling 
whereas SMAD1/5/8 are BMP transducers. Once phosphorylated and active, SMAD2/3 bind to the 
coSMAD SMAD4, translocate to the nucleus and act as transcription factors via conserved DNA 
binding domains. These binding domains are common on the genome, once every 1024bp, therefore 
binding partners are required for effective transcriptional alterations. These binding partners include 
cFos/Jun, ATF2, TFE3, Gli3, SIP1 and most notably FOXH1 and FAST (Wrana and Attisano, 2000). 
Negative regulation of the pathway is achieved via secreted Activin binding proteins such as 
Follistatin and competing receptor binding molecules such as Inhibin, which has complementary 
signalling outcomes. Also, inactive receptors sequester Type I and II receptors and reduce signal 
potency and SMAD6 acts as a SMAD4 decoy. ERK signalling can inactivate SMAD3 and SMAD is 
targeted for proteosomal degradation once inside the nucleus, for review see (Massague and 
Wotton, 2000). 
 During dual SMAD inhibition we use SB431542 to inhibit Activin/Nodal/Lefty/TGFβ signalling. 
The action of this small molecule is to inhibit the phosphorylation of the Activin-like receptors ALK4, 
ALK5 and ALK7 (Inman et al., 2002). This functions to inhibit mesendodermal differentiation and to 
disrupt pluripotency (D'Amour et al., 2005; Xu et al., 2008). 
 During development, Activin signalling has been shown to be a strong inducer of early 
mesoderm and endodermal formation (Smith et al., 1990). Concurrently, Activin signalling has a 
function to inhibit embryonic neural differentiation, witnessed via the presence of the Activin/TGFβ 
inhibitor Follistatin in the Organiser region (Hemmatibrivanlou et al., 1994) and dominant negative 
32 
 
Activin receptors lead to enhanced neural specification (Hemmatibrivanlou and Melton, 1994). 
Importantly, Type II receptor double knockouts do have some abnormal forebrain development, 
although the authors of this study describe the phenotype as incredibly complex (Song et al., 1999). 
Activin and Inhibin have opposing roles, e.g. in the developing gonads with regards to promoting 
steroidogenesis (Woodruff and Mather, 1995). Activin has been implicated in adult neural tissues, 
whereby there is a large induction of Activin expression in response to injury in the adult brain 
(Abdipranoto-Cowley et al., 2009; Foster et al., 2004; Mukerji et al., 2007; Tretter et al., 1996). 
 In vitro, Activin has been shown to be a critical mediator of pluripotency along with FGF 
signalling. Activin signalling is important for mouse Epiblast stem cell (epiSC) and hESC maintenance, 
possibly representing later developmental stages than mESCs (Brons et al., 2007; Tesar et al., 2007; 
Xu et al., 2008). Inhibiting Activin signalling increases the efficiency of neural lineage commitment 
(Chambers et al., 2009); possibly analogous to Follistatin expression in the organiser region. Activin is 
used in mesodermal differentiation protocols due to a defined role in this developmental process 
(D'Amour et al., 2005). Other TGFβ family members have been implicated during in vitro 
differentiation, BMPs regulate epithelial and dorsal neural cell fates in a manner similar to Wnts 
(Furuta et al., 1997) and TGFβ molecules have been used as pro-survival molecules in postmitotic 
neuronal cultures (Perrier et al., 2004; Schubert et al., 1990). 
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Figure 1.8 Activin signalling.  
Soluble Activin ligand binds to type II receptor ACTRIIA or ACTRIIB leading to the recruitment of the 
type I receptor ALK2/4/7. Autosphosphorylation of the ALK intracellular domain leads to 
phosphorylation of signal transducer molecules SMAD2/3, which together with the coSMAD 
translocate to the nucleus, bind promoter regions of target genes and alter transcription. Activin is 
antagonised via Inhibin signalling or via sequestration from Follistatin. SMAD6 competes with 
SMAD2/3 for the coSMAD and SMAD3 is actively degraded in the nucleus. The antagonist SB431542 
prevents receptor phosphorylation.  
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1.2.4 Exogenous Signalling - Relevance to in vitro Differentiation 
 The aforementioned organiser regions (see Chapter 1.2.2) are critical for correct patterning 
of the developing embryo. This is demonstrated via either ectopic expression or knock-out studies 
which are able to disrupt normal development. For example, Spemann and Mangold were able to 
show that grafting a second Organiser (ANR) onto a gastrula-stage embryo was able to induce a 
second neural tube and body axis (Spemann and Mangold, 1924). Also, mice lacking SHH do not 
develop ventral structures (Chiang et al., 1996) and ectopic SHH is sufficient to specify ventral tissues 
in dorsal locations (Wilson and Rubenstein, 2000). These studies show the power of growth factor 
patterning. 
 Developmental timing greatly affects the outcome of a signalling cue. The stage of the 
embryo and the maturity of the responsive cell can lead to discrete responses. For example, early in 
development RA signalling has a strong caudalising effect, whereas after cells are committed to a 
given lineage, RA can augment maturation (Maden, 2007; Wichterle et al., 2002). A similar temporal 
dichotomy is present between SHH proliferative and patterning responses (Fuccillo et al., 2006). 
Therefore both spatial and temporal considerations are involved in growth factor application. 
 Although an exogenous signalling factor elicits transcription changes and a gene expression 
response, a critical consideration is the cell’s intrinsic competence to respond. Exogenous signalling 
requires the presence of certain transcription factors and signal transducer proteins in order to elicit 
a growth factor response. However, certain genes have an overriding master regulator identity that 
is sufficient to prime the cell to further signals or be insensitive to inhibitory signals. This is 
exemplified in forced expression studies. Fate determinants are sufficient to drive directed 
differentiation to a given cell type, e.g. LMX1a directs midbrain dopaminergic cell differentiation, but 
only in a context dependent manner (Friling et al., 2009). Reprogramming studies have shown the 
potential of this technology as certain gene combinations can switch a cell fate directly, e.g. from 
fibroblast to neuron (Caiazzo et al., 2011; Pfisterer et al., 2011; Vierbuchen et al., 2010). Additionally, 
fine tuning can be performed via an intrinsic positional identity due to intrinsic cues. An example of 
this is the OTX2/GBX2 homeodomain signatures. Responses to FGF8 signalling in the tissues are 
divergent due to the inherent homeodomain expression, grafting the MHB into the diencephalon 
leads to ectopic midbrain whereas grafting into the hindbrain produces ectopic cerebellum (Marin 
and Puelles, 1994; Martinez et al., 1991).  
 Due to the fact that in vitro differentiation is a model for in vivo development, careful 
consideration must be given to developmental process. In order to direct differentiation to desired 
cell types, critical signalling events and cell competence to respond must be considered. For this 
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reason, organiser region derived growth factor stimuli are modelled and differentiation of PSCs uses 
such growth factor stimuli to confer position cues to the differentiating cells. Therefore, a close 
knowledge of the signalling pathways, the developmental outputs and the mechanisms are all 
required to maintain careful control over differentiation schemes.   
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1.2.5 Development of the Ventral Forebrain 
 The forebrain develops from the telencephalon, the anterior most part of the neural tube. 
For this reason it is under the influence of strong signalling from the ANR (Figure 1.1, Figure 1.3). The 
major fate determinant of the entire forebrain is the forkhead transcription factor Foxg1 and this is 
directly dependent on ANR signals such as FGF8 (Shimamura and Rubenstein, 1997). Foxg1, and its 
downstream target Six3, are both critical for regionalisation and growth of all the forebrain 
structures as Foxg1 mutant mice exhibit a reduction in size of all of the forebrain structures (Xuan et 
al., 1996). 
 The first subregionalisation of the telencephalon occurs at the pallial-subpallial boundary. 
This boundary demarcates the dorsal pallium, set to be the cortex, and the ventral subpallium, the 
basal ganglia anlage (Figure 1.9). This regionalisation has been shown to be controlled by dorsal Pax6 
expression and ventral Gsx2 expression that form a mutually exclusive boundary (Toresson et al., 
2000; Yun et al., 2001). These differences are established via differential responses to ventral SHH 
signals and dorsal Wnt and BMP signalling pathways. As a result, GLI3, the negative SHH regulator, 
has a dorsal high: ventral low expression profile, consistent with ventral SHH activity (Figure 1.9 B). 
 The subpallium is further subdivided into three domains, named the lateral, medial and 
caudal ganglionic eminences (LGE, MGE and CGE respectively, Figure 1.9). The LGE develops into the 
striatum, the brain structure that is responsible for synthesising movement cues from the cortex and 
transmitting the information through the basal ganglia. The MGE and the CGE are the birthplace of 
the cortical interneurons that make up 20-30% of the cells in the cortex. These are inhibitory 
GABAergic neurons that migrate tangentially to the cortex to effect proper glutamatergic cell 
development, proliferation, migration and, in the adult, control long term potentiation, reinforcing 
cell output and strengthening signals. The CGE has been described as a caudal expansion of the LGE 
and the MGE, sharing many common marker genes (Willi-Monnerat et al., 2008). The CGE can be 
divided into dorsal and ventral tissue (dCGE and vCGE respectively) exhibiting similarity to LGE and 
MGE accordingly, e.g. MGE and vCGE sharing expression of NXK2.1 (Figure 1.9). The CGE is the 
birthplace of discrete subsets of cortical interneurons as discussed below. 
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Figure 1.9 Ventral forebrain development.  
(A) Depicts the location of the ganglionic eminences in the ventral forebrain. Arrows show the 
migration of the cortical interneurons to the dorsal tissues (blue) and the possible anterior migration 
of olfactory bulb interneurons cells from the dorsal LGE (dLGE). Note the theorised similarity between 
the CGE and the more anterior tissues. (B) Coronal sections of the telencephalon. Ventral SHH signals 
are abutted by dorsal GLI3 expression (left). This correlates to the boundary between ventral GSX2 
and dorsal PAX6 at the pallial-subpallial (P/SP) boundary.  GSX2, DLX2 and MASH1 mark the entire 
subpallial proliferative SVZ (pink), whereas NKX2.1 specifically marks the MGE and the ventral CGE 
(orange and magenta). MGE specific (LHX6/8), LGE enriched (CTIP2, FOXP2 and NOLZ1), CGE 
enriched (ZCCHC12, ER81) and pallial genes are highlighted in the coloured domains. RED lettering 
depicts the birthplace of mature neurons, not the expression domain. LGE lateral ganglionic 
A 
B 
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eminence, MGE medial ganglionic eminence, CGE caudal ganglionic eminence (d dorsal and v 
ventral), OB olfactory bulb, P/SP pallial-subpallial, POA preoptic area, CB Calbindin, PV Parvalbumin, 
SST Somatostatin, CR Calretinin. . 
 
 The entire subpallium shares ventricular zone/subventricular zone genes that are involved in 
patterning and proliferation. Gsx2 is one of the first genes witnessed in the ventral forebrain and, as 
discussed above, promotes subpallial fate via excluding dorsal PAX6. Gsx2 subsequently shares an 
expression pattern with Dlx1/2 genes that are critical for proper GABAergic patterning and later 
migration of cortical interneurons (Long et al., 2009a). The neurogenesis gene Mash1 (also called 
Ascl1) has been shown to work in an independent pathway to Dlx1/2 to promote development of 
GABAergic cells in the ventral forebrain (Long et al., 2009b). 
 The MGE has unique expression of Nkx2.1 that is not present in the LGE or the dCGE. Nkx2.1 
expression is initiated by SHH signalling (Fuccillo et al., 2004) and subsequently shows a mutual 
dependency with SHH signalling (Sussel et al., 1999). NKX2.1 further specifies cortical interneuron 
fate via promoting transcription of GABAergic interneuron fate determinant genes Lhx6/8 (Du et al., 
2008). The MGE and the cortical interneurons derived herein appear to be dependent on SHH and 
Nkx2.1 expression as Nkx2.1 knockout mice exhibit a failure to produce MGE derived cortical 
interneurons, suggesting a direct specification role (Anderson et al., 2001; Sussel et al., 1999; Xu et 
al., 2004). Another signalling pathway, FGF8, appears to be crucial for cortical interneuron 
determination, as FGF receptor knockout mice demonstrate a reduced Shh and Nkx2.1 expression 
pattern (Storm et al., 2006). 
 Cortical interneurons are divided into subfamilies depending upon marker gene expression, 
birthplace data from fate-mapping experiments and isochronic-homotopic transplants (Figure 1.10). 
The major MGE derived interneurons are Parvalbumin (PV)-expressing and Somatostatin (SST)-
expressing cells and these are dependent on NKX2.1 expression; shown by their absence in mutant 
mice (Anderson et al., 2001). NKX2.1 induces LHX6 which is expressed in migrating MGE-derived 
cortical interneurons (Du et al., 2008). The different birthplaces of these two populations within the 
MGE have suggested differential dependencies on SHH whereby higher doses specify SST 
interneurons in vivo (Xu et al., 2010). As an aside, striatal interneurons are derived in the MGE; these 
are Shh/Nkx2.1/Lhx8 dependent and typically are cholinergic rather than GABAergic (Fragkouli et al., 
2009; Zhao et al., 2003).  
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 The dCGE is the birthplace of the third major cortical interneuron subtype, Calretinin (CR) 
expressing cells. The dCGE appears to be specified independently from SHH signalling as SHH and 
Nkx2.1 knockout mice either show an enlarged CGE or increased CR neurons (Sussel et al., 1999; Xu 
et al., 2010). A small number of genes have been described that can distinguish the CGE from other 
tissues, these include Zcchc12 and Er81 (Cambray et al., 2012; Willi-Monnerat et al., 2008). Other 
smaller subsets of cortical interneurons may be SHH/NKX2.1-dependent in the ventral CGE (vCGE) 
such as Neuropeptide Y (NPY) or Reelin (RLN) expressing interneurons, however, it cannot be 
discounted that interneurons are merely migrating through the vCGE rather than being specified 
therein. 
 In their target tissues, cortical interneurons can have varied location and morphology 
depending on their relative subgroup. The interneurons are enriched in certain layers of the cortex 
as well as cortical domains, although subtypes appear at low levels distributed throughout the 
cortex. The interneurons are morphologically diverse being stellate, basket-cells, bipolar or 
chandelier-cells forming complex local circuits. Calretinin cells, which are focused on in this thesis, 
are typically bipolar, bitufted and vertically orientated.  
 The LGE is the birthplace of the striatum and developing cells migrate radially to mature into 
GABAergic projection neurons termed Medium Spiny Neurons (MSN). MSNs constitute 95% of the 
striatum and these cells function to relay voluntary movement signals from the cortex to the globus 
pallidus and the substantia nigra. During development, enrichment of marker genes such as Ctip2, 
Foxp1/2 and Nolz1 distinguish the LGE from the MGE (Arlotta et al., 2008; Chang et al., 2004; 
Takahashi et al., 2003a), as well as a lack of Nkx2.1 expression.  
 Development of the LGE appears to be dependent on SHH signalling as expression of all of 
the LGE and MGE specific genes are lost in SHH null mutants in a stage dependent manner (Chiang et 
al., 1996). Additionally, in vitro differentiation techniques demonstrate that SHH signals are 
sufficient to generate MSNs in vitro (Aubry et al., 2008; Li et al., 2009). However, recent studies 
suggest that SHH in the forebrain merely has a role to inhibit dorsal signals via inhibiting GLI3, as 
compound mutants for SHH and GLI3 show a restored ventral phenotype (Aoto et al., 2002; Rallu et 
al., 2002). Later stage knockout of the SHH pathway also shows little effect on the LGE-derived tissue 
compared with MGE tissues (Machold et al., 2003; Xu et al., 2010). 
 Mature MSNs are characterised via a spiny and multipolar morphology. The marker gene 
Darpp32 is widely used as a specific marker for MSNs; a protein that functions in responding to 
dopaminergic inputs (Svenningsson et al., 2004). Within the striatum, the MSNs are divided into two 
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pools with different projection targets and different expression profiles. One subset, the indirect 
pathway, projects to the globus pallidus and expresses Enkephalin and DRD2. Certain transcription 
factors have been implicated in development of this subtype, e.g. IKAROS (Agoston et al., 2007). The 
second group of MSNs, the direct pathway, projects to the substantia nigra and are typified via 
expression of Substance P, Dynorphin and DRD1. The overall outcome of the two projections on the 
movement circuitry of the basal ganglion is negative signals from the direct pathway and positive 
signals from the indirect pathway. Thus, a fine balance is required and disruption can lead to the 
diseased state. The striatum is organised into patch and matrix which may be relative to innervating 
dopaminergic terminals (no organisational relation to MSN subtypes), and the marker Calbindin can 
be used to mark the matrix neurons specifically (Gerfen, 1992).  
 
 
Figure 1.10 Cortical Interneuron Progenitor Pools.  
Based on expression of markers genes (NB no functional significance) cortical interneurons can be 
divided into three or more subsets. These subsets have discrete birthplaces in the ventral 
telencephalon and this presumably correlates with different growth factor dependencies. 
Parvalbumin (PV) and Somatostatin (SST) are derived from the NKX2.1-positive MGE, whereas 
Calretinin (CR) interneurons are mostly derived from the NKX2.1-negative dCGE. Neuropeptide Y 
(NPY) and other smaller subsets have been less well defined (Wonders and Anderson, 2006) 
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1.2.6 Development of the Ventral Midbrain 
 The dopaminergic cells of the ventral midbrain (vMB) form from the ventral part of the 
mesencephalon (Figure 1.1 B). This represents the most posterior part of the Otx2 homeobox 
protein expression domain. Interactions between FGF4 signalling and the OTX2/GBX2 boundary at 
the isthmus establishes the MHB as a signalling centre that is in close proximity to the ventral 
mesencephalon (Chapter 1.2.2) (Ye et al., 2001). Subsequent expression of the mesencephalic En1/2 
genes is dependent on the MHB (expressing FGF8 and Wnt1) and En1/2 expression has been shown 
to be critical for vMB dopaminergic neurogenesis and survival (Alberi et al., 2004; Simon et al., 
2001). The ventral part of the presumptive midbrain is under control of MHB-derived FGF8/Wnt 
signalling and also floorplate derived SHH signals. 
 In the majority of the neural tube the ventral floorplate is non-neurogenic, instead 
functioning in axon guidance and growth factor secretion (Charron et al., 2003; Placzek and Briscoe, 
2005). In the midbrain, however, the active Wnt signalling from the nearby MHB has been shown to 
interact with SHH and specify the floorplate to a neurogenic fate (Joksimovic et al., 2009; Ono et al., 
2007).  
 The progenitors in mesencephalic floorplate express key transcription factors that have been 
shown to be crucial for dopamine neurogenesis (Figure 1.1 D). Foxa1/2 are SHH responsive genes 
that interact with neurogenesis genes such as Ngn2 to control cell proliferation in the vMB as well as 
having a role in later dopaminergic specification (Ferri et al., 2007). Lmx1a has been shown to be 
necessary and sufficient to drive dopaminergic differentiation and this gene is responsive to SHH and 
Wnt signals (Andersson et al., 2006; Chung et al., 2009; Friling et al., 2009), demonstrated via 
expression of LMX1a in a complimentary manner to Wnt1 (e.g. in the roofplate). Cooperation 
between the genetic networks that centre on LMX1A and FOXA2 are thought to be central to the 
development of this vMB dopaminergic population; representing the crux of exogenous SHH and 
Wnt signalling (Chung et al., 2009; Lin et al., 2009). Other critical genes may be expressed in a layer 
specific manner, e.g. Dmrt5 has a role in commitment and is expressed in the intermediate zone 
(Gennet et al., 2011). 
 The midbrain dopaminergic neurons (mDA) express a number of classical marker proteins. 
Tyrosine hydroxylase (TH) is rate limiting enzyme in the synthesis of dopamine and so a marker of 
dopaminergic neurons synthesising the neurotransmitter. Coexpression of TH with FOXA2, LMX1A 
and PITX3 (a gene that is required for mDA development (Maxwell et al., 2005; Nunes et al., 2003)) is 
able to demonstrate a midbrain subtype of dopaminergic cells (figure 1.1 D). This is in contrast to 
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other dopaminergic populations in the forebrain where TH is coexpressed with alternate markers, 
e.g. NKX2.1 (hypothalamus) or ISL1 (ventral thalamus) (Yan et al., 2005).  
 Two populations of mDA arise from the development of the midbrain floorplate, namely the 
substantia nigra (SN) and the ventral tegmental area (VTA) (Bjorklund and Lindvall, 1984). SN 
dopaminergic neurons project to the striatum and control initiation of movement and postural 
reflexes. The VTA dopaminergic population project to the limbic region of the prefrontal cortex and 
is involved in reward behaviour, cognition and motivation. Thus, degeneration of these areas has 
effects in these behavioural pathways. 
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1.3 Neurodegenerative Diseases 
 Stem cell based therapy for neurodegenerative diseases (see Chapter 1.4-1.6) focus on 
replacing a cellular deficiency. Replacing a cellular deficiency via cell therapy, grafting of foetal 
tissue, and regenerative medicine (stimulating recovery in situ) hold promise for currently incurable 
diseases, where surgical, medicinal and stimulatory approaches treat the symptoms but do not 
reverse the disease progression. In this thesis, I shall investigate three cell types that are implicated 
in neurodegenerative diseases, namely midbrain dopaminergic neurons that degenerate in 
Parkinson’s disease, striatal projection neurons that degenerate in Huntington’s disease and cortical 
interneurons that are involved in epilepsy, autism and schizophrenia. 
1.3.1 Interneuronopathies 
 Cortical interneurons comprise 20-30% of the cells in the cortex and function to modulate 
cortical cell maturation, plasticity and output. Interneuronopathies are diseases resulting from a loss 
of interneurons and have wide ranging symptoms. A reduction of inhibitory interneurons has been 
theorised to lead to over-activity of the excitatory cortical neurons, and this has been associated 
with epilepsy and seizure in human patients (Kitamura et al., 2002). Also, autism has been linked to a 
reduction in GABAergic cortical interneurons, a disease characterised by frequent seizures 
(Hussman, 2001). Other psychiatric disorders such Tourette’s syndrome, bipolar disorder and 
schizophrenia have also been associated with cortical interneuron deficits (Lewis, 2000). 
 Although the study of transplanted cortical interneurons is relatively new, there is some 
evidence that cell therapy may benefit the diseased state. Interneurons are born in the ventral 
forebrain and must undertake a major tangential migration to the dorsal cortex. In a similar manner, 
grafting of naive cortical interneuron progenitors is accompanied by an extensive migration capacity 
away from the site of grafting. This is in contrast to other forebrain cell types and promotes 
interneurons as a good candidate for cell therapy (Wichterle et al., 1999). Investigations into the 
effect of grafted interneurons on the spread of seizures demonstrated that grafted MGE-derived 
interneurons reduced the spread of seizures in the rodent brain (Alvarez-Dolado et al., 2006; 
Baraban et al., 2009; De la Cruz et al., 2011; Zipancic et al., 2010). 
 The extensive migratory capacity and the ability to modulate endogenous activity promote 
cortical interneurons as a positive source of material for putative cell replacement therapies. Many 
seizure-associated diseases can be pharmacologically treated; however, the subset that is drug-
resistant represents an important target for cell-based therapy. A lack of understanding into 
interneuropathies as well as the poorly defined nature of the symptoms means that clinical trials of 
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foetal tissue is yet to be applied. However, the benefits of cell-based therapies are currently being 
investigated in model organisms.   
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1.3.2 Huntington’s disease 
 The early stages of Huntington’s disease (HD) is characterised by the preferential 
degeneration of GABAergic striatal projection neurons (MSNs) (Reiner et al., 1988). This leads to 
choreatic movements, psychiatric impairments and dementia. HD typically results in fatality 17 years 
after diagnosis. HD is an autosomal dominant genetic disorder, characterised by amplification of a 
CAG trinucleotide repeat in the Huntington gene leading to misfolded protein and toxic aggregates 
(Macdonald et al., 1993). There is currently no cure for HD. 
 Intrastriatal grafting of foetal ventral forebrain tissue (both LGE and MGE-derived) into 
rodent (Peschanski et al., 1995) and primate (Kendall et al., 1998; Palfi et al., 1998) HD models have 
restored neural circuitry and demonstrated alleviation of disease symptoms. Based on the success of 
these in vivo models, clinical trials were attempted using primary human foetal forebrain, grafted 
into HD patients (Hauser et al., 2002; Keene et al., 2007; Reuter et al., 2008; Rosser et al., 2002). 
Long lasting benefits were witnessed in a small percentage of these patients; however, the results 
were varied and suggested a need for standardisation and further refinements (Bachoud-Levi et al., 
2000a; Bachoud-Levi et al., 2000b; Bachoud-Levi et al., 2006). Nevertheless, the fact that 5 patients 
out of 22 demonstrated functional improvement and increased striatal metabolism calls for further 
studies to validate, optimise and take the technology forward.  
 The major drawback of the proof-of-principle investigation is the observation that the 
beneficial effect of the graft is temporary, as the improvements were seen to diminish after 2 years 
(Bachoud-Levi et al., 2006). Therefore, there may be a need for neuroprotection to avoid graft 
rejection or disease contraction in the grafted cells (Kordower et al., 2008). Also, investigators are 
not certain whether to attribute benefit to replacement of striatal projection neurons or enhancing 
cell support via striatal interneuron grafting, as current strategies utilise MGE and LGE tissue in the 
grafts. Therefore, further extensive investigations are called for. 
 Stem cells represent an inexhaustible source of neurons for such studies (see Chapter 1.4) 
and cell replacement therapies may provide a novel curative therapy to this currently incurable and 
fatal disease. It should be noted that as an inherited monogenic disease, other techniques to reduce 
the disease may be more relevant than cell replacement in the future such as gene therapy or 
preimplantation diagnosis (PGD) to abrogate the disease completely. 
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1.3.3 Parkinson’s disease 
 Parkinson’s disease is a neurodegenerative disease characterised by the preferential loss of 
the nigrostriatal dopaminergic system. There are a number of different genes that predict 
Parkinson’s disease prevalence; however the disease mechanism remains poorly understood. Lewy 
bodies, made up of α-synuclein aggregates, are typically seen in the cells of Parkinson’s disease 
patients prior to degeneration. Parkinson’s disease leads to a loss of motor control manifested as 
bradykinesia, hypokinesia, resting tremors and rigidity (Lang and Lozano, 1998). Parkinson’s disease 
is estimated to affect 4 million people worldwide (von Bohlen und Halbach et al., 2004). Palliative 
approaches to the symptoms include drug-based dopamine replacement therapies, such as L-DOPA 
administration, electrical deep brain stimulation and stereotactic surgery. However, there is 
currently no cure to the disease.  
 Cell-based therapies using foetal-derived dopaminergic progenitor cells have proven to 
reverse the disease in human patients. The goal is to replenish baseline dopamine levels in the 
striatum to control stimuli for movement from the cortex. Graft derived neurons have been shown 
to integrate into the host brain, survive for up to 10 years, reduce akinesia and even allow patients 
to withdraw from L-DOPA treatment (Piccini et al., 1999). Very successful open label trials in the 
1980s (Lindvall et al., 1989; Madrazo et al., 1988) were followed by less successful double-blind 
placebo trials in the 1990s (Freed et al., 2001), demonstrating age related outcomes. The disparities 
in the results are due to contrasting patient disease state, graft tissue preparation and 
transplantation technique and indicate the requirement for transplant optimisation (Torres et al., 
2007). 
 The success for a subset of these trials and the continued benefit of foetal cell grafting in 
rodent Parkinson models (Torres et al., 2008) provide a proof-of-principle for cell therapy in 
Parkinson’s disease. The fact that foetal tissue is limited (as more than three embryos are required 
for one grafting procedure) and the delicate ethical background for this cell source calls for an 
alternative source of tissue. Trials in model organism suggest that striatal grafting of PSC-derived 
dopaminergic cells is able to reverse disease progression (Yang et al., 2008). Therefore, subsequent 
to optimisation of patient selection, graft procedure and ensured safety of grafts, PSC-derived 
dopaminergic cells provide hope for Parkinson’s disease treatment in the near future.  
 Grafts are typically transplanted into the striatum, the target tissue of the dopaminergic 
neurons. This obviates any dendritic inputs to the graft cells as in a healthy situation and essentially 
limits this technology as a novel source of dopamine. Future studies may investigate grafting to the 
substantia nigra and reinnervating the striatum to completely replace the lost circuit. Foetal grafts 
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have also suffered from contaminating cell types, such as serotonergic cells causing graft-induced 
dyskinesias. Finally there is evidence that grafted tissue can contract the diseased state, as Lewy 
bodies have been witnessed in the graft cells of post-mortem patients (Kordower et al., 2008). 
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1.4 Embryonic Stem Cells 
 The 5-6 day old human embryo is termed the blastocyst and contains around 100 cells. At 
this stage there are two cell types, the trophoblast cells that progress to form the extra-embryonic 
cells (e.g. the placenta) and the inner cell mass (ICM), which form all the cells of the embryo. 
Blastocysts that are supernumerary to the IVF procedure can be donated to science whereby human 
embryonic stem cells (hESCs) can be derived from the ICM of these embryos. The culture of hESCs 
utilises the fact that ICM cells divide symmetrically to increase their numbers, while maintaining the 
potential to form all the cell types of the embryo. ‘Capture’ of the cells at the ICM stage thus confers 
the features that define hESCs in vitro; 
1. The ability to self-renew – i.e. divide symmetrically to produce more ESCs and increase the 
culture population. 
2. The cells are pluripotent – i.e. they retain the ability to develop/differentiate into any cell 
type of the embryo (although they are not totipotent as they cannot form trophoblast cells). 
 These ESC characteristics may be tested as the cells demonstrate spontaneous 
differentiation to all three germ lineages, can be clonally propagated, form teratomas when injected 
into a host and can form chimaeras and contribute to the germ line when incorporated into a host 
ICM (model organism only). 
 Since their first derivation in 1998 by James Thomson (Thomson et al., 1998), hESCs have 
been routinely cultured on mouse embryonic feeder cells (MEFs) in combination with exogenous 
FGF2 signals. This is in contrast to mouse ESCs (mESCs) which are dependent on LIF signalling and 
serum (Smith et al., 1988). This difference may relate to differing stages of development that the 
ESCs have been ‘captured’ from, or alternatively simply due to species differences. However, the 
progress made with mESCs into chemically defined, feeder-free culture conditions and an enhanced 
ground state via the 2inhibitor LIF approach (Silva et al., 2008) has not been reproduced as 
effectively in human cells. Culture of hESCs on MEFs is dependent on undefined factors secreted by 
the MEFs to maintain pluripotency. Certain studies have begun to remove the need for MEFs and 
utilise chemically defined media, however, these are expensive and have yet to be widely employed 
(Beattie et al., 2005; Xu et al., 2001; Xu et al., 2005; Yao et al., 2006).  
 Pluripotent stem cells (PSCs) have been derived from sources other than ICM embryos. 
These include adult cells that have been reprogrammed via somatic cell nuclear transfer (Wakayama 
et al., 1998; Wilmut et al., 2002) whereby an oocyte is able to reprogram an adult differentiated 
nucleus. Parthenogenesis forms PSC lines from unfertilised ova; these are homozygous for HLA and 
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so may be grafted to a range of patients due to reduced rejection issues. Finally, genetic 
manipulation can produce induced pluripotent stem cells (iPSCs) via forced expression of 
pluripotency factors, whereby mature cells are reprogrammed to PSCs (Takahashi et al., 2007; 
Takahashi and Yamanaka, 2006). These reprogrammed cells offer a new source of PSCs that can 
include disease-carrying genomes and are also readily accessible. Another reprogramming regime 
utilises cell fusion of differentiated cells with pluripotent cells to form heterodikaryons. These are 
not-suitable for differentiation studies due to their genomic instability and tetraploid nature. 
 PSCs can be stably maintained in culture for long periods where the karyotypic stability and 
the lack of contaminants such as Mycoplasma must be monitored. The self-renewal and 
pluripotency properties allow hESCs to be proposed as an alternative source of tissue for cell 
replacement studies. 
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1.5 Neural Differentiation 
 Employing PSCs for neural differentiation has a number of applications. Firstly, the normal 
developmental process can be closely examined in an accessible manner, e.g. human development is 
ethically and logistically difficult to follow and hESC differentiation provides a model for the earliest 
developmental steps. Comparisons can then be made to model organism development, e.g. marker 
gene expression and dynamics (Nelander et al., 2009; Zhang et al., 2010). Secondly, disease-specific 
ESCs (and especially iPSCs) offer a tangible model for disease aetiological testing, when compared to 
wild-type scenarios, e.g. many human disorders cannot be modelled in animals or cannot be 
accessed due to early developmental stages. Thirdly, PSC-derived neurons (and other cell types) 
offer an unlimited supply of material for toxicology testing for new drugs and high throughput drug 
screening for novel medicines. In vitro PSCs and their differentiated progeny are amenable to 
genetic manipulation, enabling reporter cell lines, selectable marker cell lines and investigations into 
forced fate determinant expression. Lastly, PSC-derived cell progeny can be used for cell-
replacement therapies, replacing a cellular deficiency in a diseased state (see Chapter 1.3). 
 Neural differentiation can be promoted in culturo via a number of different protocols. The 
process aims to simulate embryonic conditions that promote certain fate choices. Using information 
from development, these conditions can be mimicked in order to utilise genetic networks that 
normally bring about neural fate choices (see Chapter 1.2). 
1.5.1 Embryoid Body Formation 
 After withdrawal of feeders and growth factors associated with pluripotency, PSCs can be 
grown in floating 3-dimensional aggregates termed embryoid bodies (EBs). These EBs recapitulate 
embryo development as the normal processes therein are thought to be imitated. EBs can be 
formed naturally via disassociating adherent ESC cultures or alternatively via forced aggregation 
techniques increase EB size homogeneity, e.g. hanging droplet-based or centrifugation-based 
aggregation (Burridge et al., 2007; Keller, 1995). Once committed, EBs are then plated onto the 
culture dish to enable better visualisation and reduce 3-dimensional limitations such as growth 
factor deliverance and nutrient exchange. 
 Exogenous factors are added to the EBs to upregulate the relative proportion of neural 
tissue in the inherently heterogeneous aggregate. In a manner similar to the Nieuwkoop centre, 
described in Chapter 1.2.1, FGF2 signals promote the generation of organiser activity and 
subsequent neural tissue. Zhang et. al. demonstrate that FGF2 is sufficient to derive neural cells from 
human EBs and, after morphology-based isolation, can produce neural cultures with 96% purity 
(Zhang et al., 2001). 
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 Retinoic acid is also able to promote neural fate determination in mESC-derived EBs (Bain et 
al., 1995; Li et al., 1998). These studies demonstrated the first example of chemically defined 
differentiation media, using N2B27 based media, and also made use of selectable drug-resistance 
markers to reduce contaminating cell types. 
 In recent years, this technology has been extensively used by the laboratories of Sasai and 
Zhang to generate multiple neuronal cell types from hESCs. Based on the study demonstrating 
serum-free EB (SFEB) neural differentiation using knockout serum replacement, this technique has 
been employed to derive anterior neural tissues (Watanabe et al., 2007) such as pituitary (mouse) 
(Suga et al., 2011), retina (Osakada et al., 2009), cortex and striatum (Eiraku et al., 2008; Li et al., 
2009), Purkinje cells (mouse) (Muguruma et al., 2010) and midbrain dopamine cells (Yang et al., 
2008). 
 EB differentiation benefits from enabling simple and effective neural induction. The ability to 
use chemically defined media and potential bioreactor-based scalability achieved from floating 
culture method makes this technique attractive for large-scale pharmacological studies and high 
throughput screening. Drawbacks of EB-based differentiation include heterogeneity within and 
among EBs. Also, the 3D nature of the EBs means that there is a great deal of unknown signalling 
activity within the aggregate, removing some control from the researcher. 
1.5.2 Coculture Differentiation 
 Stromal cell lines have been shown to instruct ESCs to differentiate towards neurons and 
even neural subtypes when grown in coculture. This inductive capacity of the stromal cells remains 
undefined and has been termed stromal-derived-inducing-activity (SDIA). 
 The PA6 cell line derived from mouse calvaria bone stromal cells can induce up to 96% 
neural colonies in a serum free media from mouse ESCs. ESCs alone rarely differentiated to neural 
tissues, demonstrating that SDIA was actively promoting neurogenesis. This has been shown to be 
contact dependent, as PA6-conditioned media does not contain SDIA. SDIA appears to be present on 
the cell surface as PFA fixed PA6 cells maintain neural inductive capacities (Kawasaki et al., 2000). 
Interestingly, PA6 cell neural differentiation of mESCs and hESCs leads to an overrepresentation of 
dopaminergic cells and so is of use to the Parkinson’s disease research community (Zeng et al., 
2004). This lineage selection is in the absence of exogenous growth factors and purely dependent on 
SDIA action. Nonetheless, progenitor cells do remain competent to respond to morphogenetic 
conditions as BMP administration can lead to neural crest differentiation, a dorsal cell type 
(Kawasaki et al., 2002). Other cell lines that contain neurogenic SDIA include the MS5 and S2 cell 
lines. These were shown to induce neurogenesis in primate and human ESCs and rosettes picked 
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from the coculture were amenable to further patterning via exogenous growth factor administration 
(Perrier et al., 2004).  
 Coculture differentiation techniques are advantageous due to the simple and cheap 
differentiation scheme. The specific differentiation towards dopaminergic neurons offers a low-cost 
differentiation alternative without use of expensive recombinant proteins. The drawbacks of 
coculture experiment include the use of animal-derived feeder cells. These obviate the potential for 
clinical applications due to failure to comply with Good Manufacturing Procedures (GMP). Even 
though the media may be chemically defined, the interactions between stroma and ESC are 
undefined with potential variability. Also, this technique may be unpredictable and the requirement 
for manual picking of neural rosettes in some protocols increases labour-intensiveness. Nonetheless, 
the action of SDIA raises pertinent mechanistic questions and may provide useful insights into 
neural-based and lineage-directed differentiation.  
1.5.3 Monolayer Differentiation 
 Monolayer differentiation is the process of differentiating ESCs as a homogenous sheet of 
cells, adherent to the culture dish. Theoretically, the entire monolayer senses a similar condition 
throughout the culture, e.g. exogenous growth factor concentration, and can be manipulated with a 
greater degree of control by the researcher.  
 Neural induction is initiated after withdrawal of self-renewal conditions. The initial mESC 
monolayer differentiation experiments demonstrated a requirement on FGF signalling, potentially in 
a manner similar to the inductive action of the Nieuwkoop centre, as discussed in Chapter 1.2.1. 
These experiments were carried out in chemically defined media (without serum) and enable close 
investigations into single growth factors (Ying et al., 2003).  
 Recent advances on hESC monolayer differentiation have focused on SMAD inhibition. The 
BMP inhibitor Noggin has been shown to augment neural conversion of hESCs, potentially in a 
manner similar to Organiser-induced neurogenesis (Lee et al., 2007). Inhibition of other TGFβ 
signalling via a SMAD2/3 small molecule inhibitor also promotes neural differentiation, possibly 
analogous to Follistatin expression in the Organiser (Smith et al., 2008). Combining BMP inhibition 
and TGFβ inhibition, described by Chambers et. al. lead to a highly efficient, robust and synchronous 
differentiation to primitive neuroectoderm (Chambers et al., 2009). These cells produced 
patternable neural progenitors and exhibited an inherently rostral identity (Fasano et al., 2010). This 
novel protocol has been employed in numerous directed differentiation schemes already, such as 
neural crest cells (Lee et al., 2010), floorplate tissue (Fasano et al., 2010) and astrocytes (Emdad et 
al., 2012). 
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 Monolayer differentiation enables a high degree of user-control during the differentiation 
process. Homogeneous cellular environments and forced exit from pluripotency convey replicable, 
homogeneous and robust experimental regimes, enabling reliable investigations into individual 
factors. The reduction of 3D aggregates may also accelerate differentiation compared with SFEB as 
remote proliferative niches are reduced. Space constraints may limit the scalability of this technique, 
due to required adhesion, and the cost of recombinant growth factors represents a drawback. 
However, media component definition and independence from animal-derived products permit 
future GMP uses for monolayer differentiation. 
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1.6 Directed Differentiation 
1.6.1 Differentiation towards Cortical Interneurons 
 As discussed in Chapter 1.2.3, cortical interneurons are generated in the ventral forebrain 
before migrating to their dorsal target tissue. The MGE has been shown to be under the influence of 
strong SHH signals and as such, in vitro protocols have attempted to mimic this environment to 
specify cortical interneurons from PSCs. 
 A number of studies into the dorso-ventral axis identity of forebrain precursors in vitro have 
focused on SHH versus Wnt/BMP signals. Higher concentrations of SHH (or small molecule agonists) 
are able to generate Nkx2.1 expressing ventral progenitors (MGE-specific) derived from mouse and 
human ESCs (Danjo et al., 2011; Li et al., 2009). Goulburn et. al. generated an NKX2.1-driven GFP 
reporter hESC cell line (Goulburn et al., 2011). After EB differentiation in optimal concentrations of 
RA and FGF2, sorted cells were able to differentiate into cortical interneurons in vitro and in vivo 
without further exogenous signalling, demonstrating the power the NKX2.1 genetic network.  
 Maroof et. al. created an Lhx6 reporter mESC line (Maroof et al., 2010). EB-based 
differentiation was supplemented with SHH to produce Lhx6-positive progenitors (Figure 1.11). The 
sorted cell progeny was able to migrate substantially in the host brain and differentiate into SST and 
PV expressing cortical interneurons in vivo, demonstrating the MGE-like character of these cells. 
 Maisano et. al. use a mESC monolayer differentiation protocol with SHH agonist to produce 
cortical interneuron progenitors and postmitotic neurons in chemically defined media (Maisano et 
al., 2012). When precursors were transplanted into a mouse model for temporal lobe epilepsy, the 
cells integrated effectively and demonstrated functional electrophysiological properties. This raises 
the potential for cell based treatment of such seizure-based disorders. Further work is required to 
assess an ability of these cells to reverse epileptic symptoms; however, there is growing evidence 
that grafting of in vivo derived MGE progenitors are able to reduce the spread of seizures in the 
mouse brain (De la Cruz et al., 2011). 
 Calretinin cortical interneurons are generated in the CGE, an Nkx2.1-negative tissue. 
Knocking out Nkx2.1 in vivo did not reduce the number of Calretinin interneurons, suggesting an 
alternative, SHH-independent and undefined specification pathway for CGE derived cortical 
interneurons (Xu et al., 2010). Differentiation of Calretinin-positive cells has not been described and 
thus, further investigation into the specification of the CGE in vivo is required to be able to direct 
differentiation towards a Calretinin-positive cortical interneuron fate.  
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Figure 1.11 Maroof et. al. protocol for generating cortical interneurons.  
Maroof et. al. utilise an EB-based protocol followed by SHH exposure to upregulate LHX6-driven GFP 
reporter expression for FACS sorting (A). These progenitors represent the migrating interneuron 
progenitors (B). The sorted cells were then able to differentiate in vivo into postmitotic cortical 
interneurons expressing markers of different subtypes including SST and PV (C) (Maroof et al., 2010). 
  
C 
56 
 
1.6.2 Directed Differentiation of Striatal Projection Neurons 
 Much attention has been focused on MSNs of the striatum due to their degeneration in 
Huntington’s disease. Putative cell replacement therapies and drug screening strategies would 
benefit from an effective differentiation protocol to efficiently derive MSN in vitro. Groups that have 
investigated telencephalic dorso-ventral patterning have described a precise dosage of SHH - with or 
without the dorsal Wnt inhibitor DKK1 - that can preferentially induce LGE-character (Danjo et al., 
2011; Li et al., 2009). 
 Aubry et. al. utilised the MS5 coculture method to promote neurogenesis of hESCs and 
subsequently stimulated MSN directed differentiation via SHH and DKK1 treatment (Figure 1.12) 
(Aubry et al., 2008). This protocol robustly generated MSN. After transplantation into Huntington’s 
model rats, DARPP32-positive neurons were present, however, large tumourigenic overgrowths 
were witnessed from the grafts, possibly due to the mitogenic effect of SHH (Fuccillo et al., 2006) or 
contaminating undifferentiated cells. This outcome severely limits the application of these cells in 
vivo. Other SHH based studies have shown a low SHH dosage that is able to ventralise the cellular 
identity to an extent similar to the LGE (Li et al., 2009) and striatal progenitors have also been 
reportedly generated from midbrain-directed differentiation protocols that require SHH (Ferrari et 
al., 2006). These studies demonstrate an induction of MSN character from SHH-based 
differentiation.  
 Danjo et. al. used mESC derived forebrain precursors, sorted for FOXG1-reporter expression, 
to generate transplantable MSN in vitro. Patterning here is also achieved via precise SHH doses. 
Importantly, these cells were demonstrated to be functional as they were able to integrate and 
project to normal MSN target tissues, the globus pallidus and the SN (Danjo et al., 2011). 
 The field of striatal projection neuron directed differentiation has progressed relatively 
slowly in recent years. In order to progress the field to complement the success of foetal-derived 
grafting in patients, safe protocols and in vivo transplantation studies are required to further 
advance the technology. SHH signalling (in conjunction with DKK1-mediated dorsal fate inhibition) 
has been employed to facilitate correct dorso-ventral patterning and specify MSNs in culturo. It 
should be noted that some in vivo studies have demonstrated an independence of the LGE on SHH 
signalling. Smo conditional knockout mice demonstrate an upregulation of Gsx2 (Xu et al., 2010) 
(note Gsx2 expression is higher in the LGE than the MGE). Also, SHH knockout-mediated LGE 
ablation is recovered in SHH-GLI3 double mutants suggesting an action for SHH in inhibiting dorsal 
GLI3 signals (Aoto et al., 2002; Rallu et al., 2002). Lastly, there is no evidence for a direct action of 
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SHH on LGE specific genes. This leaves the possibility that alternative signalling pathways actively 
direct LGE development, enabling greater optimisation of MSN directed differentiation. 
 
 
Figure 1.12 Aubry et. al. protocol for MSN Differentiation.  
Aubry et. al. use coculture-based neural induction followed by SHH and DKK1 mediated patterning 
towards MSNs (A). The resultant cultures exhibit DARPP32-positive neurons (B) that can also be 
generated in vivo after transplantation of patterned progenitors (Aubry et al., 2008). 
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1.6.3 Midbrain Dopaminergic Directed Differentiation  
 In vitro derivation of mDA neurons has received a great deal of focus due to the association 
with Parkinson’s disease; which affects over 4 million people worldwide (von Bohlen und Halbach et 
al., 2004). The success of a subset of foetal-derived transplants into patients has lead to much 
interest in tissue derived from differentiation of PSCs.  
 As described in Chapter 1.5.2, SDIA present in ESC/PA6 coculture differentiation is sufficient 
to generate dopaminergic neurons (Kawasaki et al., 2000). These cells are able to integrate into the 
striatum of rodents and express TH. Subsequent coculture, monolayer differentiation protocols and 
EB based protocols routinely utilised treatment with SHH and FGF8 to specify vMB identity 
analogous to MHB and ventral midline signalling centre proximity (Barberi et al., 2003; Kim et al., 
2002; Lee et al., 2000; Perrier et al., 2004; Yan et al., 2005).  
 Mouse ESC differentiation has seen significant success in the last 10 years. Lee et. al. 
employed EB differentiation and were the first to demonstrate that SHH, FGF8 and ascorbic acid 
treatment could produce properly specified mDA neurons with a vMB phenotype (Lee et al., 2000). 
Barberi et. al. demonstrated that coculture-derived neurons with SHH and FGF8 treatment were able 
to repair behavioural deficits in Parkinson’s disease model rodents after transplantation (Barberi et 
al., 2003). 
 Human ESC differentiation has had mixed success using PA6/MS5-based coculture, with 
many groups seeing results that varied depending on the cell line being used and demonstrating 
failure to improve behavioural deficits in disease-model rodents, for review see (Taylor and Minger, 
2005). Noggin treatment was shown to augment the efficacy of coculture-based differentiation and 
grafted cells did reduce drug-induced rotations in Parkinsonian mice (Ben-Hur et al., 2004). Perrier 
et. al. employed a human ESC-derived differentiation scheme using stromal coculture with SHH, 
FGF8 and BDNF growth factor supplements, followed by mechanical isolation of rosette structures. 
The resultant neurons exhibited expression of marker genes, ultra-structural characteristics and 
electrophysiology of true dopaminergic neurons (Perrier et al., 2004). Yan et. al. proposed an EB-
based differentiation with additional SHH and FGF8 that was able to produce dopaminergic neurons 
exhibiting characteristics of forebrain and midbrain relative to growth factor administration (Yan et 
al., 2005). 
 Many of the early differentiation studies using human PSCs did not investigate the exact 
identity of the dopaminergic cells and it became apparent that many of the TH-positive cells 
produced in vitro did not have a specific vMB phenotype, i.e. marker gene coexpression that 
specifically demarcates mDA neurons (FOXA2, LMX1a, and PITX3). At the outset of this project, 
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effective in vitro directed differentiation techniques for human PSC remained to be optimised and 
there was especially a lack of monolayer differentiation schema for dopaminergic differentiation of 
hPSCs. 
 The vast scope of the mDA directed differentiation field has enabled a high degree of 
understanding into the correct in vitro differentiation of mDA neurons. Taken together with the 
success of foetal and ESC-derived grafts to reverse Parkinsonian disease symptoms in model 
organisms, the academic landscape is set to focus on the technical challenges of transplantation. For 
the safest possible cell-based treatments, a detailed knowledge of all developmental/differentiation 
events will enable the purest cell preparations for future patient transplantations.  
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1.7 General Aims 
 I aim to develop a differentiation protocol that can produce multipotent, neural progenitors 
with the ability to generate many neuronal cell types.  
 I hypothesise that I can manipulate the extrinsic cellular environment to direct 
differentiation towards neuronal cell types of interest. Via altering growth factor environments to 
follow in vivo developmental conditions (e.g. proximity to morphogen secreting Organiser regions), I 
aim to develop protocols that enrich mDA neurons, MSNs and cortical interneurons. 
 I theorise that the cells derived in vitro are properly functional. Together with collaborators, 
we aim to demonstrate that ESC-derived neurons express the proper range of marker genes, show 
electrophysiological properties of functional neurons and show the capacity to integrate into the 
brain of a host animal.  
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Chapter 2 Materials and Methods 
2.1 Materials 
2.1.1 Media for tissue culture 
 
Feeder media 
GMEM (Invitrogen), 10% FCS (Invitrogen), 1mM NEAA (Gibco), 1mM sodium pyruvate (Gibco), 2mM 
L-glutamine supplemented with Pen Strep antibiotics (Gibco) and 0.1mM β-mercaptoethanol 
(Gibco). 
hPSC media 
koDMEM (Invitrogen), 22% knockout serum replacement (Invitrogen), 1mM NEAA (Gibco), 1mM 
sodium pyruvate (Gibco), 2mM L-glutamine supplemented with Pen Strep antibiotics (Gibco) and 
0.1mM β-mercaptoethanol (Gibco). 
N2B27 (150ml) 
100ml DMEM F12 (Invitrogen), 50ml Neurobasal (Invitrogen), 1ml N2 supplement (Invitrogen), 1ml 
B27 without Retinol (Invitrogen), 2mM L-glutamine supplemented with Pen Strep antibiotics (Gibco) 
and 0.1mM β-mercaptoethanol (Gibco).  
MEF Conditioned Media 
Feeder free media contained 50% hESC media with 8ng/ml FGF2 and 50% MEF conditioned media. 
Conditioned media was produced from hESC media with 8ng/ml FGF2 (Peprotech) and conditioned 
on inactivated MEFs for 24 hours (3ml per 6 well plate). Adding FGF2 at this stage is critical to 
stimulate Activin secretion from the MEFs (Greber et al., 2007). More specifically, a confluent T25 of 
MEFs was used to seed an entire 6 well plate. 3ml of hESC media plus FGF2 was added per well and 
collected 24hours later. This was repeated for 7-10 days. 
2.1.2 Cell Lines Used 
 
Human ESC lines H7 and H1 were used with permission from WiCell (Thomson et al., 1998). Cell line 
H7 was used for most experiments and then repeated in other cell lines. 
Human iPSC lines 2F8 and 4FHuang#1 were employed in this thesis. The 2F8 line was a kind gift from 
Austin Smith’s group. The 4FHuang#1 cell line was generated in our lab by Kuo Hsuan Chang. 
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2.2 Methods 
2.2.1 Cell Culture  
 All cell cultures were maintained in 37°C and 5% CO2 (Sanyo). Work was carried out under a 
laminar flow hood (Nuair) and all surfaces were disinfected with 70% ethanol and following work 
adhered to sterile techniques. Cells were grown on tissue cultures plastics (Falcon) or glass coverslips 
(VWR) and coated as stated. 
2.2.1.1 MEF Cell Culture 
 MEF cells were maintained in feeder media (Chapter 2.1) and passaged using 0.025% 
trypsin. Cells were washed with PBS and 1ml of trypsin was added to each T25 flask (Sigma) followed 
by a 2 min incubation at 37°C. Cells were washed off the plate via titration with feeder media to 
quench the trypsin and centrifuged at 1300rpm for 2.5 mins (Eppendorf 5702). MEFs were routinely 
passaged at ratios of 1 in 8. 
 MEFs were inactivated using 10μg/ml Mitomycin C (Sigma) for 2-3 hours and one confluent 
T25 flask was used to fill a 6well plate of inactivated feeders. 
2.2.1.2 hPSC Culture 
 Human PSCs were seeded on inactivated feeder cells in hPSC media (Chapter 2.1) 
supplemented with 8ng/ml FGF2 (Peprotech). Half the media was changed every day. Cells were 
passaged every 5 days as follows. hPSCs were washed with PBS once and then treated with 0.02% 
EDTA for 2 mins at room temperature. EDTA was aspirated and hPSC media was added. Cells were 
manually dissociated using a serological pipette and scraping/titration, maintaining small cell 
clusters. One third of a confluent well from a 6well plate was centrifuged at 1300rpm for 2.5 mins 
(Eppendorf 5702), resuspended and added to fresh inactivated MEFs at 1/2, 1/3 and 1/6 of these 
cells (i.e. 1/6, 1/9 and 1/18 of the original well). The lowest well was ready for passaging in 5 days 
routinely. 
 H7 cells, 2F8 and 4FHuang cells were most robust and withstood passaging as small colonies 
whereas H1 cells were easiest to maintain as larger, slow growing colonies.  
2.2.1.3 Cell Freezing and Thawing 
 For storage of cells at low passage numbers, cells were passaged as normal and frozen in 
10% DMSO with hESC or Feeder media accordingly. Freezing was performed slowly with an 
overnight step at -70°C before being placed in liquid nitrogen storage tanks. Thawing of cells was 
performed as rapidly as possible with cells being centrifuged immediately at 1300rpm for 2.5 mins 
and DMSO containing media aspirated. Cells were resuspended and plated at appropriate ratios. 
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2.2.2 Monolayer Differentiation  
2.2.2.1 Monolayer Differentiation of human PSCs 
 Monolayer differentiation was initiated with as many hPSCs as possible to reduce expansion 
time in feeder free conditions. hPSCs were passaged as usual but were subject to preplating for 45 
mins on gelatin coated plates to remove MEFs due to differential adhesive dynamics (0.1% gelatin 
coating for 20 mins). hPSCs still in suspension were then transferred to matrigel coated plates 
(diluted 1in15 in koDMEM and coated for 1 hour at 37°C) and grown to confluency in feeder free 
media containing MEF-conditioned hPSC media. Once 100% confluent, the media was changed to 
N2B27 defined media and this time point was taken as day 0. H7 differentiation; The TGFβ 
antagonist SB431542 (10μM, Tocris) was added to the media from day 0 until day 5. BMP 
antagonists Noggin (100ng/ml, R&D) and Dorsomorphin (200nM, Tocris) were added from day 0 
until day 9. Passage 1 was performed at day 9-12 using 0.02% EDTA as above. Cells were split 2:3 
onto fibronectin coated plates and kept as relatively large cell clusters. Passage 2 at day 19-22 was 
performed with EDTA as above, whereas cells were split 1:1 onto poly-L-lysine and laminin coated 
plates, but titration was more vigorous than passage 1. Once the cells were neuronal, at around day 
25, BDNF (10ng/ml, Peprotech), GDNF (10ng/ml, Peprotech) and ascorbic acid (0.2mM) were added 
to aid cell survival. 
 Fibronectin coating was performed with 15μg/ml fibronectin (Millipore) in PBS for 2 hours at 
37°C. Poly-L-lysine and laminin coating was performed via 2 hour incubation of 0.002% poly-L-lysine 
(Sigma) and then 2 hour incubation of 10μg/ml laminin (Sigma), both at 37°C. 
 H1, 2F8 and 4FHuang cell lines differentiated more rapidly and so were treated with 
SB431542 for 4 days, Noggin and Dorsomorphin for 8 days and were passaged at day 9 directly onto 
poly-L-lysine and laminin coated plates, without the fibronectin coated plate stage.  
 Activin (R&D) was added during the relevant time period at either 10ng/ml (Chapter 3, 
Figure 3.1) or 25ng/ml (Chapter 4, figure 4.1). The SHH antagonist Cyclopamine was used in some 
experiments as stated (1μM, Sigma). 
 For ERK inhibitor treatment dual SMAD inhibition was halted as ERK inhibition was 
performed from day 3 until day 7 (PD0325901, 1μM, Axon). SHH C24II (200ng/ml, R&D) 
supplemented with SHH agonist Purmorphamine (1μM, Merck) was then added to the media from 
day 7 until passage 1 at day 11 (ratio of 1:2) and then SHH, Purmorphamine and FGF8 (100ng/ml, 
Peprotech) was added to the media from day 10 until day 16, (Figure 5.1).  
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2.2.2.2 Monolayer Differentiation of mouse ESCs (Serafi Cambray) 
 Briefly, mouse ESCs were maintained on gelatin coated plates (0.1%) in media containing 
10% FCS and LIF. Passaging of mESCs was performed using 0.025% trypsin, as with MEFs, (Chapter 
2.2.1.1). Monolayer differentiation was performed in Neurobasal Medium (Invitrogen) 
supplemented with B27 (1:50, Invitrogen) at low density (7,500 cell per cm2) on gelatin coated 
plates. Cells were passaged on day 5 using trypsin onto poly-D-lysine and laminin coated plates and 
Activin was added at this time point. See (Cambray et al., 2012). 
2.2.2.3 Monolayer differentiation of mouse epiSCs (Ines Jaeger) 
 Mouse epiSCs were maintained in N2B27 (N2 1:100, retinol free B27 1:50) supplemented 
with FGF2 (12ng/ml) and Activin (20ng/ml). MD was initiated in N2B27 without growth factors, with 
or without ERK inhibitor from day 0 on fibronectin coated plates. 
2.2.3 Chromosome Counting  
 hPSCs were routinely tested for karyotypic stability. Colchicine was added to the cells to 
arrest cell division (1μg/ml, Sigma) and then cells were trypsinised as with MEFs, above. Cells were 
centrifuged and resuspended in 0.5ml of 0.075M KCl for 10 mins at 37°C to allow the cells to swell. 
Cells were centrifuged and supernatant was aspirated. Cells were fixed in fresh methanol : acetic 
acid (3:1 v/v) for 30 mins at 4°C. Cells were washed twice in fixative before being dropped from 
30cm height onto coverslips, air dried and fixed with mounting media containing DAPI (Vectashield, 
Vectalabs). Images were taken on the Leica SP5 confocal microscope. Counting of metaphase 
spreads was done using Image J software on at least 20 cells per Karyotyping. Chromosome counts 
were performed on spreads where there was no overlap seen, aiding separation. The number of 
abnormal cells increased with passage number. For example, H7 cells displayed around 30% 
abnormal cells after 115 passages in total. For this reason, cells were expanded and frozen at early 
passage numbers and only used between passages 40 and 90. 
2.2.4 Immunocytochemical Staining 
2.2.4.1 Immunocytochemical staining and Immunohistochemical Staining 
 Cell cultures were washed 1 time in PBS to remove floating cells and fixed in 3.7% PFA for 15 
mins at room temperature, either on coverslips (VWR) or in tissue culture plates (Falcon) or as 
floating sections. Cells were then stored at 4°C for a maximum of two weeks in PBS or processed 
immediately for immunostaining. Fixed cells were permeabilised in PBST (PBS+0.3% Triton-X-100) via 
three washes, each for 10 mins. Cells were then blocked in PBST containing 3% BSA and 1% normal 
donkey serum for 20 mins at room temperature. Primary antibodies were then added in blocking 
solution overnight at 4°c or 2 hours at room temperature. Cells were washed three times in PBST for 
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5 mins each and then secondary antibodies were added in blocking solution for 1 hour at room 
temperature (1 in 200 Alexafluor secondary antibodies, 488/555/594/647nm, Invitrogen). Cells were 
washed once in PBST containing 1in2000 DAPI (final concentration 1μg/ml, Molecular Probes) for 10 
mins and then twice more in PBST for 10 mins each. Finally cells were mounted and fixed in 
mounting media (DAKO). 
 A list of antibodies used in this thesis is presented in Chapter 7.2. 
 For FOXG1 immunostaining, cells were washed in PBS one time, fixed in methanol acetone 
(1:1) which was prepared fresh at -20°C for 10 mins and dried for 5-10 mins. Blocking and antibody 
staining was done as above but without Triton-X-100 for all solutions. 
 Images were taken on a SP5 confocal microscope (Leica). Counting was performed on 
random fields of view from north, south, east and west of biological duplicates using Image J 
software. At least 1000 cells were counted manually from each replicate.  More specifically, at least 
4 random fields of view were selected per replicate without using the SP5 viewfinder to capture 
images. Images were confocal sections to aid individual cell visualisation. Quantification was 
performed using the Image J cell counting software, whereby counted cells may be marked 
concurrently. DAPI was always counted as well as specific markers to ensure sufficient cell numbers.  
2.2.4.2 EdU Detection 
 ClickIT EdU staining was done as per the manufacturer’s instructions (Invitrogen). Cells were 
fixed and permeabilised as normal; ClickIT reaction cocktail was added to the cells for 30 mins at 
room temperature protected from the light. Colabelling with primary antibody staining was then 
performed on the EdU stained cells as per Chapter 2.2.4.1. 
 
 
2.2.5 Quantitative PCR 
2.2.5.1 RNA Extraction  
 For RNA extraction, cell cultures were washed with PBS and RNA was harvested using 500μl 
TRI Reagent (Sigma). Cell lysates were then stored at -70°C for up to one month. Prior to RNA 
purification, lysates were incubated at room temperature for 5 mins. 
 RNA was purified as per the manufacturer’s instructions. Briefly, 100μl of chloroform was 
added to the lysate followed by 30 secs vigorous shaking. After 2 mins at room temperature, the 
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mixture was centrifuged at 12,000 x g for 15 mins at 4°C. The upper aqueous phase was then 
separated transferred to a new eppendorf. 250μl of isopropanol was then added to the supernatant, 
followed by mixing and 5 mins incubation at room temperature. The mixture was then centrifuged at 
12,000 x g for 15 mins at 4°C. The supernatant was removed and the pellet was washed in 70% 
ethanol by centrifugation at top speed for 15 mins at 4°C. RNA was then resuspended in 10-20μl of 
dd water. RNA was periodically tested for degradation on a 1% agarose gel. 
2.2.5.2 Reverse Transcription 
 RNA concentration was measured on a Nanodrop spectrophotometer ND 1000 (Labtech) 
and 2μg was taken to a new tube for reverse transcription in a final volume of 10μl dd water. RNA 
was heated to 70°C for 5 mins with 1μl random primer mix (3μg/μl, Invitrogen) and then allowed to 
cool for 5 mins at 4°C. Reverse transcription mix containing 4μl 5x first strand buffer, 1μl dNTP 
(10mM), 1μl DTT (0.1M Invitrogen), 1μl RNase OUT (Invitrogen) and 1μl superscript III Reverse 
Transcriptase (Invitrogen). Reverse transcription was performed in a PCR machine with the following 
steps: (25°C for 5 mins), (42°C for 10 mins), (50°C for 30 mins), (55°C for 10 mins), (70°C for 15 mins) 
and (4°C for 10 mins). cDNA was then diluted 10x with dd water. 
2.2.5.3 Quantitative PCR 
 Quantitative PCR was performed using SYBR MESA green mastermix. Mastermix containing 
10μl MESA green (2x, Eurogentech), 7.8μl dd water and 0.1μl of each primer pair (100μM, all custom 
made oligonucleotides, Sigma) was aliquoted to relevant wells of a 96 well plate (Biorad). cDNA was 
aliquoted accordingly using 2μl of the 10x diluted mix, above. QPCR was performed on a Biorad 
Chromo4 machine. The PCR program was as follows: (94°C for 4 mins), [(94°C for 30 secs) + (60°C for 
15 secs) + (72°C for 30 secs)] repeated 40 times. Melting curve analysis was performed from 65°C to 
95°C with a read every 0.2-1°C. 
 All qPCR data is relative to three reference genes (GAPDH, β-ACTIN and CYCLOPHILIN) and 
data was analysed using Opticon Monitor 3 software (Biorad) and Microsoft Excel. All qPCR data is 
normalised to the basal condition and error bars represent the SD of biological duplicates. Data was 
excluded if ΔCT was above 30 cycles. 
 All primers were designed using the primer Blast software (NCBI). Primers were resuspended 
in dd water to 100μM. Primer pairs were tested on cDNA from human foetal whole brain tissue with 
serial dilutions to test efficiencies. All annealing temperatures were 60°C. 
 A list of all primers used in these works is presented in Chapter 7.1. 
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2.2.6 FACS Analysis (Ines Jaeger) 
 Mouse differentiating cells were washed one time with PBS and then trypsinised. Single cells 
were resuspended in PBS with 10% FCS, washed twice with PBS and then fixed in 2% PFA in 
suspension for 15 mins at 4°C.Cells were washed and then resuspended in sorting buffer (Chapter 
2.1). Cells were strained using cell strainer caps to ensure single cell suspension (BD Falcon) and then 
analysed on a BD LSRII (Becton Dickinson Biosciences). Data was analysed on BD FACS Divaaria 
software (Becton Dickinson Biosciences) and FlowJo (TreeStar). 
2.2.7 Transplantation of hPSC-derived neural Precursors (Sophie Precious) 
 All animal work was carried out under the UK Animals Act 1986. Adult female Sprague-
Dawley rats (Harlan) were maintained lesioned with 45nM quinolinic acid unilaterally in the 
striatum. All surgery was performed under isoflurane anaesthesia. Immunosuppression was 
achieved with Cyclosporin A at 10mg/kg i.p. (Sandimmun) starting one day prior to transplantation. 
Animals were sacrificed with barbiturate overdose. 
 Activin-treated neural precursors were transported to Cardiff at 37°C in plates with surplus 
media. Cells were rinsed with PBS and dissociated using Accutase for 2 mins at 37°C (PAA 
Laboratories). The cells were centrifuged at 1000rpm for 3 mins, resuspended in 2ml N2B27, 
counted and the volume adjusted to 200,00cells/μl. 400,000 cells were transplanted into the 
striatum of each adult lesioned rat, i.e. 2μl. 
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Chapter 3 Activin Accelerates Neural Differentiation and Specifies a 
Cortical Interneuron Fate 
3.1 Introduction 
 Differentiation of human pluripotent cells (hPSCs) provides an invaluable tool for biomedical 
research. Firstly, it provides a model system to study normal and diseased human development, a 
process that would otherwise be ethically and logistically impossible to access. Secondly, cells 
produced via in vitro differentiation can provide large amounts of material for new drug toxicology 
testing or novel drug screening strategies. Lastly, the use of foetal tissue to reverse 
neurodegenerative diseases has proven to have some, albeit varied, efficacy (Bachoud-Levi et al., 
2000a; Bachoud-Levi et al., 2006; Freed et al., 2001; Lindvall et al., 1989; Madrazo et al., 1988). Using 
pluripotent stem cell derived cultures in place of foetal tissue provides ethically more agreeable and 
also limitless supplies of such tissues that may prove to have similar therapeutic effects.    
 The goal of in vitro differentiation is to recreate the in vivo developmental regimes that are 
programmed into the cells’ genetic responses. A close understanding of the developmental decisions 
made by cells in vivo and the inductive cues leading to these decisions can allow the researcher to 
recreate exogenous cellular environments and bring about similar choices to follow specific 
developmental pathways. For example, understanding the three dimensional arrangement of tissues 
and the relative proximity of organiser regions (Chapter 1.2), one can estimate the relevant 
conditions that a cell may be exposed to during normal development. Additionally, in vitro 
differentiation may provide new information about development, for example, novel genes can be 
implicated during differentiation and relayed back to in vivo development.  
 The differentiation process can be performed in three ways in vitro (see Chapter 1.5). The 
first technique for differentiation of human pluripotent stem cells is coculture with mouse stromal 
cells, which have been shown to promote differentiation in a directed manner via an undefined 
signalling activity (Barberi et al., 2003; Kawasaki et al., 2000; Perrier et al., 2004). Embryoid body (EB) 
formation is the second method for hPSC differentiation, whereby 3D aggregates of PSCs 
differentiate in a manner resembling the developing gastrula (Keller, 1995). The drawback of these 
techniques are that there are undefined signalling events from the stromal cells or within the EB, 
leading to reduced experimental control, increased heterogeneity and lower reproducibility when 
testing individual variables.  
 The third technique, Monolayer differentiation (MD), involves the seeding of cells in a 
monolayer and sustaining the adherent cells in a chemically defined media. This allows all the cells 
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to be exposed to similar morphogen concentrations throughout the culture as determined by the 
investigator.  For this study, I aim to adapt and optimise the dual SMAD inhibitor protocol in our 
hands (Chambers et al., 2009), see Chapter 2. This protocol efficiently gives rise to proneural 
populations with increased homogeneity across the culture due to effective, forced and synchronous 
entry to the neural lineage via SMAD inhibition; mimicking the manner hypothesised for in vivo 
development (Anderson et al., 2002). A number of BMP and TGFβ inhibitors (such as Noggin, 
Chordin and Follistatin) are present at the Spemann’s Organiser and are believed to be responsible 
for the initial induction of the neuroectoderm in the developing gastrula (Chapter 1.2) (Bachiller et 
al., 2000; Spemann and Mangold, 1924).  
 I then will employ the neural precursor cells produced in this protocol for investigations into 
novel growth factor environments. I shall examine the effect of exogenous Activin A treatment 
(referred to as Activin hereafter).  This molecule has been implicated as a pro-survival factor during 
in vitro differentiation (Schubert et al., 1990) and also in adult brains after exposure to insult (Foster 
et al., 2004; Mukerji et al., 2007; Tretter et al., 1996; Wu et al., 1999). However, Activin has not been 
studied in early neural developmental/differentiation paradigms. Interestingly, the expression of 
Activin subunits and their receptors have been described to be widespread in the anterior 
neuroectoderm (Feijen et al., 1994; Foster et al., 2004), with phosphorylated and active SMAD2/3 
signalling transducers seen in the ventral forebrain at early developmental stages (Feijen et al., 1994; 
Maira et al., 2010). 
 Activin is a member of the TGFβ superfamily and signals via binding to Activin Type II 
receptors recruiting Type I receptors via dimerisation. This binding leads to phosphorylation and 
activation of SMAD2 and SMAD3 transducers which together with the coSMAD, SMAD4, translocate 
to the nucleus and alter gene expression (see Chapter 1.2).  
 I shall investigate the effect of Activin treatment on anterior neural cell types, notably the 
ventral telencephalon. Cortical interneurons are the GABAergic inhibitory cells making up 20-30% of 
the cortex, whereby excitatory glutamatergic cells make up the remainder of the population. Cortical 
interneurons are required for proper modulation of cortical glutamatergic cell output (Wang et al., 
2004), e.g. long term potentiation, and are key during development for glutamatergic cell 
proliferation, migration  and establishing cortical circuitry (Hensch and Stryker, 2004; Owens and 
Kriegstein, 2002). There is interest in producing cortical interneurons in vitro for cell therapy as their 
improper functioning and cellular deficiencies have been implicated in disease (epilepsy, autism and 
schizophrenia, Chapter 1.3). Also their propensity to migrate away from the site of transplantation 
and then modulate cortical activity provides added value to transplantation studies because of the 
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ability to functionally integrate into the host; thus showing potential to replace a cell deficiency in 
the disease state (Alvarez-Dolado et al., 2006; Martinez-Cerdeno et al., 2010).   
 In vivo, cortical interneurons are produced in the ventral telencephalon during development 
before they migrate tangentially and dorsally to the cortex (Chapter 1.2.4). The ventral 
telencephalon can be divided into three domains, namely the lateral ganglionic eminence (LGE) 
which forms the striatal projection neurons, the medial ganglionic eminence (MGE) which is the 
major site of interneurogenesis and the caudal ganglionic eminence (CGE), which is a second 
birthplace of cortical interneurons and is a caudal continuation of the two more rostral tissues. 
Interneurons can be divided into three major cell subtypes; Parvalbumin (PV) and Somatostatin (SST) 
expressing cells that are produced in the MGE and induced/specified by SHH signalling and NKX2.1 
expression and also Calretinin (CR) expressing neurons that are produced in the dorsal CGE (dCGE) 
through undefined inductive signals (Wonders and Anderson, 2006).  
 I will investigate SHH and Retinoic acid (RA) signalling pathways in this chapter; see Chapter 
1.2. Canonical SHH signalling acts to ventralise the cells and also has a strong mitogenic effect. Active 
SHH signalling removes a repression on the system to allow GLI1/2 transcription factors to become 
active and alter gene expression in the nucleus (Fuccillo et al., 2006). RA can act as a caudalising 
growth factor in the neural tube, however, RA signalling can also function as a pro-differentiation 
factor; this depends on spatiotemporal setting (Maden, 2007). Exogenous retinol is converted to 
retinaldehyde which is subsequently converted to RA via the ALDH1a enzyme family. RA then binds 
receptor proteins in the nucleus to alter gene expression. 
 Activin signalling has been described to be detrimental to the earliest stages of neural 
differentiation, whereby dominant negative receptors augment the efficiency of neural lineage fate 
choice (Hemmatibrivanlou and Melton, 1994), reinforcing the presence of the Activin antagonist 
Follistatin in the Anterior Neuroectoderm Ridge (Hemmatibrivanlou et al., 1994) and the use of 
SB421543 antagonist in neural differentiation paradigms (Chambers et al., 2009). There is little 
evidence of an effect of Activin signalling in anterior neural tissues (Song et al., 1999), even though 
Activin subunits, its receptors and activated SMAD signal transducers are witnessed in the 
developing forebrain (Feijen et al., 1994; Maira et al., 2010). For this reason, we set out to 
investigate an effect of Activin stimulation on anterior neural precursors in culture and hypothesised 
a negative effect of activating this signal pathway on neural differentiation. 
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 The investigation into activin function in human ESC differentiation was performed in 
conjunction with mESC differentiation and will be cited as such, Serafi Cambray (Cambray et al., 
2012). 
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3.2 Results 
3.2.1 Optimisation of the Differentiation Protocol 
 Prior to MD, hPSCs were maintained on mouse feeder cells and in media containing 
knockout serum replacement and 8ng/ml of FGF2. The morphology of the pluripotent cells was 
confirmed with large nuclear to cytoplasmic ratio and multiple visible nucleoli (figure 3.1 A). Cells 
were routinely tested for karyotypic stability (figure 3.1 B) and screened to remain free from 
mycoplasma contamination. Immunostaining confirmed the maintenance of pluripotency markers 
OCT3/4 and TRA-1-81 (figure 3.1 C). Colonies were manually passaged every 5 days using EDTA 
disaggregation, maintaining consistent colony size, cell morphology and pluripotency.  
 To initiate differentiation, human pluripotent cells were preplated for 45 minutes on gelatin 
coated plates to remove contaminating feeder cells and then grown to confluency on matrigel 
coated plates in MEF conditioned media. When confluent, MEF-conditioned media was removed and 
differentiation was initiated in RA-free N2B27 media with the dual SMAD inhibitors (figure 3.1 D-E). 
To validate the differentiation regime, I tested the levels of pluripotency and differentiation markers 
at the mRNA and protein levels. I observed a rapid downregulation of pluripotency markers within 3 
days of differentiation and a subsequent upregulation of the neural lineage markers PAX6 and SOX1 
(figure 3.1 F-L). PAX6 is the major neural fate determinant in human neurulation, meaning its 
upregulation is pivotal in this differentiation scheme (Zhang et al., 2010). 
 Interestingly, I observed a dissimilar rate of differentiation for varying cell lines. Rosette 
structures represent immature neural progenitors forming two dimensional neural tube structures. 
These were observed at day 18-25 in the H7 hESC line whereas the H1 cell line and the iPS cell lines 
displayed rosettes and the first neurite outgrowths from day 8-10. The H7 cell line required an 
additional passage onto fibronectin coated plates from day 9 to day 19 in order to provide additional 
space and to prevent cells being lost via detaching from the plate as the cells proliferated. This 
diversity has been described between human pluripotent stem cell lines and so may be an expected 
feature when using multiple cell lines (Allegrucci and Young, 2007; Osafune et al., 2008). To test the 
effect of Activin on proneural cells, I added the signalling factor to the media at the rosette stage 
(figure 3.1 D-E). 
 With this functional neural inductive MD protocol for hPSCs in vitro, I have a model 
amenable to investigations into developmental patterning cues. This chemically defined monolayer 
differentiation enables undefined growth factors to be investigated and implicated in development 
73 
 
and also new differentiation protocols to be optimised with a view to producing neurons with clinical 
significance. 
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Figure 3.1 Human ESC culture and neural differentiation. 
(A)Bright field image of hESC colonies on feeder cells in culture. Morphology was monitored to 
maintain a small cytoplasmic to nuclear ratio and multiple, visible nucleoli. Image taken using 20x 
magnification. 
(B)Metaphase spread of hPSC, used to determine the karyotypic stability of the cells over multiple 
passages. Scale bar represents 10μm. 
(C)Immunostaining for OCT4 and TRA-1-81 in H7 hPSCs in culture, confirming the expression of key 
pluripotency factors. This was repeated in all cell lines used. Scale bar represents 75μm. 
(D)Differentiation scheme for H7 hESC line (see Chapter 2). Rosettes were visible after around day 
18. 
(E)Differentiation scheme for H1 hESC and all iPSC lines (see Chapter 2). Rosettes were seen around 
day 9. 
(F-I)Quantitative PCR to demonstrate gene transcription dynamics for pluripotency factors OCT4 and 
NANOG and neural lineage fate determinants PAX6 and SOX1, NB log scale for PAX6. Error bar 
represents SD of biological duplicates. 
(J-L)Immunostaining to demonstrate the activation of pan-neural marker PAX6 as well as the 
downregulation of the pluripotency associated factor OCT4 through time during H7 MD. Scale bar 
represents 100μm. 
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3.2.2 Activin treatment accelerates neuronal differentiation 
 Treating cells with 10ng/ml of Activin at the neural progenitor cells had a striking effect on 
differentiation (figure 3.2 A). After 6 days of activin exposure there was a clear change in the cell 
phenotype. Based on morphology, the number of cells displaying neurite extensions was increased 
in the treated cultures compared with the controls, suggesting an accelerated terminal 
differentiation. To test this, I immunostained cells 6 days after Activin treatment for Nestin and TUJ1 
to delineate neural progenitors and postmitotic neurons respectively (figure 3.2 B-C). Counting data 
demonstrated a significantly increased presence of postmitotic cells in Activin treated cultures 
(figure 3.2 D).  
 The pro-differentiation effect of Activin was reinforced via investigating the number of cells 
progressing through the cell cycle. The incorporation of the nucleotide analogue EdU reveals 
progression through S phase as EdU is assimilated in newly synthesised DNA. Cells were treated with 
Activin for 6 days and then exposed to EdU in the media for 1 hour. Detection of EdU incorporation 
revealed a significant difference between the Activin treated (12.0 ± 2%) and control cells in which 
two-times the number of cells appeared to be actively cycling (27.5 ± 6%) (Figure 3.2 E-F).  
 Therefore, I have observed an accelerated differentiation after cells at the proneural stage 
were treated with Activin, as demonstrated by an increased representation of postmitotic TUJ1-
positive neurons and a decrease in cycling cells incorporating EdU.  
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Figure 3.2 Affect of exogenous Activin on rate of neural differentiation.  
(A)Differentiation scheme for H7 cells. 
(B-C)Immunostaining to show Nestin (red, neural precursors) and TUJ1 (green, postmitotic neurons) 
after 6 days of Activin treatment from day 19 H7 MD. DAPI staining (blue) shows all nuclei. Scale bar 
represents 75μm. 
(D)Counting data to show proportion of cells that are TUJ1-postiive and Nestin-positive in the plus or 
minus Activin conditions - biological triplicates. Basal condition shows (60.5 ± 16%) Nestin and (12.1 
± 7%) TUJ1. Activin condition shows (38.9 ± 9%) Nestin and (36.1 ± 8%) TUJ1. 
(E)Nucleotide analogue EdU incorporation into actively cycling cells. Cells were treated with EdU for 
1 hour after 6 days of Activin exposure from day 19. Scale bar represents 100μm. 
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(F)Counting data of EdU incorporation into total cells (DAPI) - biological and experimental duplicates. 
Basal condition (27.5 ± 5%), Activin condition (12.0 ± 2%).  
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3.2.3 Activin accelerates terminal differentiation via inhibiting SHH signalling 
 The SHH signal has a role in ventralising cells throughout the neural tube (Ericson et al., 
1995), but it also has a known mitogenic action and has been shown to promote renewal of rosette-
stage cells (Elkabetz et al., 2008; Fuccillo et al., 2006). This effect is demonstrated as the presence of 
Cyclin D1, a defined SHH target in neural precursors (Kenney and Rowitch, 2000), is detected in the 
rosette structures in SHH treated cultures (figure 3.3 A-B). In Activin treated cultures, rosettes are 
rarely present and there is only diffuse Cyclin D1 staining (figure 3.3 C) and so we sought to 
investigate a link between SHH and Activin signalling. 
 Addition of 200ng/ml of SHH (supplemented with 1μm purmorphamine, see Chapter 2) at 
the proneural stage lead to faithful upregulation of SHH target genes PTCH1 and GLI1 seen via qPCR 
analysis (figure 3.3 D-E). Addition of Activin had little effect on the expression of these genes 
compared with the control cultures. However, when added in combination with SHH, Activin 
reduced the overall upregulation of PTCH1 and GLI1 (figure 3.3 D-E), suggesting an inhibition of SHH 
signalling-mediated stimulation.  
 To explain this reduced SHH signalling we investigated the involvement of the SHH repressor 
protein GLI3. Positive Activin signalling can lead to dissociation of GLI3 from the Activin effector 
molecule SMAD2, enabling GLI3 to negatively regulate SHH signalling (Liu et al., 1998). To test 
whether Activin can inhibit SHH signalling and accelerate differentiation in this way, we used the 
mESC GLI3 knockout cell line, Xt (figure 3.3 F). Importantly, SHH target genes Ptch1 and Gli1 
consistently show high levels of expression in this cell line compared to wild-type cells, indicating 
hyperactivity of the SHH pathway (data not shown, Serafi Cambray).  
 Immunostaining revealed that Activin treatment of these cells was not able to bring about 
the upregulation of TUJ1 seen in the wild-type cells (figure 3.3 G), suggesting a requirement of GLI3-
mediated repression of SHH signalling. To inhibit the action of SHH in the Xt cells, we added the SHH 
signalling antagonist cyclopamine to replace the absent GLI3. Although the cyclopamine treatment 
did lead to a greater number of TUJ1-positive cells, this was not to the same extent as Activin plus 
cyclopamine-treated cells, suggesting incomplete substitution of Activin treatment by cyclopamine 
(figure 3.3 G) (Serafi Cambray). 
 In conclusion, Activin signalling may repress SHH signalling, as demonstrated by the 
reduction in SHH-mediated target gene stimulation. This reduction appears to be dependent on GLI3 
mediated repression as the effect is abrogated in Xt mESC-derived proneural cells. However, there 
appears to be additional mechanisms to the Activin action as cyclopamine-mediated SHH inhibition 
cannot fully recapitulate the effect of Activin alone.  
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Figure 3.3 Activin accelerates differentiation via reducing SHH signalling. 
(A)Differentiation scheme for H7 hESC MD. 
(B-C)Immunostaining for Cyclin D1 (green, a SHH responsive gene) and Nestin (red, neural precursor 
cells) after 6 days of Activin treatment from day 19 H7 MD. Scale bar represents 75μm. 
(D-E)QPCR data from cDNA of cells treated for 6 days with Activin and/or SHH from day 19.  
(F)Differentiation scheme for Xt mESCs (Serafi Cambray). 
(G)Immunostaining and counting data from GLI3 knockout mouse ESC-derived neural progenitors. 
Cells were treated with Activin and/or cyclopamine for 5 days from day 5 of MD. Counting data 
(right) for Nestin:TUJ1 ratio suggests the degree of terminal differentiation in the different culture 
conditions. Counting data, [basal (86.7 ± 7%) Nestin (13.3 ± 2%) TUJ1], [Activin (78.3 ± 5%) Nestin 
Figure 3.3 F-G 
Experiments 
done by Serafi 
Cambray 
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(21.7 ± 4%) TUJ1], [cyclopamine (60.0 ± 4%) Nestin (40.0 ± 4%) TUJ1], [cyclopamine plus Activin (31.5 
± 3%) Nestin (70.6 ± 13%) TUJ1]. Scale bar represents 50μm. Figure part reproduced with kind 
permission from S. Cambray (Cambray et al., 2012). 
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3.2.4 Activin sensitises proneural cells to the differentiation signal RA 
 In the developing telencephalon, transcription of the RA processing ALDH1a genes is 
controlled via FOXH1 (Silvestri et al., 2008), an Activin signal transducer. For this reason I 
investigated whether Activin had an effect on RA processing to explain the maturation effect. 
 QPCR analysis revealed that expression of ALDH1a genes were upregulated in cells treated 
with Activin for 6 days (figure 3.4 A-C). Additionally, I observed a reduction in the expression of 
CYP26b1, an RA degrading enzyme.  Therefore, the cells are in a primed state to respond to retinol in 
the media (figure 3.4 B-D).   
 To further explore this role of Activin via  RA signalling, I used small molecule inhibitors that 
antagonise the nuclear RA receptors, RAR and RXR (AGN193109 and UVI3003 respectively) (Duester, 
2008). I performed staining for Nestin versus TUJ1 after treatment with Activin, exogenous retinol 
and inhibitors to investigate the differentiation status of the cultures. RA was added to the media at 
day 19 of H7 MD via use of B27 with retinol. Interestingly, in cultures lacking exogenous retinol, the 
accelerated differentiation after addition of Activin was abrogated as seen by the high proportion of 
Nestin-positive cells (figure 3.4 E). On addition of Activin in media containing retinol, the number of 
TUJ1-positive cells was significantly increased as the cells rapidly differentiated (figure 3.4 E). Lastly, 
addition of the RAR inhibitor (AGN), but not the RXR inhibitor (UVI), reversed this effect, suggesting a 
signalling cascade dependant on RA-RAR binding (figure 3.4 E-H). 
 Therefore, the observed acceleration of differentiation seen after addition of Activin appears 
to be dependent on RA signalling through RAR-dependent transcriptional changes. The data 
supports a role for Activin in sensitising proneural cells to RA signalling via upregulating the 
molecules required for processing the RA signal.  
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Figure 3.4 Activin accelerates differentiation via sensitising the cells to RA signalling. 
(A)Differentiation scheme for H7 MD, factors added include Activin, retinol within the B27 
supplement and RA receptor inhibitors. 
(B-D)QPCR analysis of 6 day Activin-treated neural cultures at day 25 of H7 MD. cDNA analysis 
suggests an upregulation of RA processing enzymes and a downregulation of RA degrading enzymes. 
(E)Counting data to represent the proportion of TUJ1 and Nestin-positive cells in cultures treated 
with Activin, RA, RAR inhibitor (AGN) and RXR inhibitor (UVI) – biological duplicates. Cells were 
exposed to conditions for 6 days after passage 2 of H7 MD – biological duplicates. [-RA -ACT (72.1 ± 
3%) Nestin (14.3 ± 2%) TUJ1], [-RA +ACT (62.6 ± 4%) Nestin (23.0 ± 3%) TUJ1], [+RA –ACT (64.0 ± 5%) 
Nestin (16.0 ± 1%) TUJ1], [+RA +ACT (35.9 ± 5%) Nestin (46.6 ± 4%) TUJ1], [+RA +ACT +UVI (32.0 ± 
6%) Nestin (42.5 ± 8%) TUJ1)], [+RA +ACT +AGN (57.1 ± 8%) Nestin (31.6 ± 7%) TUJ1], [+RA +AGN 
(69.1 ± 4%) Nestin (17.5 ± 2%) TUJ1]. 
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(F-H)Representative immunostaining to show the differentiation state (Nestin green and TUJ1 red) of 
neural cultures at the time of counting analysis from (D). Scale bar represents 50μm. 
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3.2.5 Activin promotes specification towards a Caudal Ganglionic Eminence fate 
 Having produced postmitotic neurons in vitro, I investigated the identity of these cells to test 
whether a specific neuronal subtype was enriched following the addition of exogenous Activin 
(figure 3.5 A). Differentiated cells produced via the dual SMAD inhibitor protocol are thought to have 
a telencephalic character (Fasano et al., 2010) and a number of neuronal subtypes are derived within 
the telencephalon, including dorsal glutamatergic neurons and ventral GABAergic cells. 
 First I validated the rostral identity of the proneural cells produced via the Chambers dual 
SMAD protocol (Chambers et al., 2009). FOXG1 marks the prosencephalon during early 
embryogenesis and is critical for telencephalic and optic vesicle regionalisation and development 
(Xuan et al., 1996). Expression data suggests an increase of FOXG1 (figure 3.5 B) concomitant with 
neural fate determinants SOX1 and PAX6 (figure 3.1 H-I). I also see the majority of the cells stain 
positive for FOXG1 prior to the rosette stage at day 17 of H7 differentiation (figure 3.5 C). 
 QPCR analysis after 6 days of Activin exposure demonstrated that the treated cells 
downregulate markers for the dorsal pallium such as PAX6 (figure 3.5 D). Contrarily, GSX2 and DLX2, 
makers of the ventral telencephalon, are upregulated, consistent with a subpallial fate. In support of 
this observation, the expression of GAD67, a gene responsible for the production of GABA, is also 
upregulated. Upregulation of genes associated with the dorsal CGE such as ZCCHC12 and ER81 
suggests a bias towards this region within the GSX2/DLX2 positive ventral telencephalon. I also see a 
3.8 fold upregulation of Calretinin in Activin treated cultures, demarcating the major interneuron cell 
type produced in the dorsal CGE (figure 3.5 D). 
 Immunocytochemistry of the cells revealed that the number of Calretinin-positive neurons in 
the Activin-treated cultures was vastly upregulated compared with the control condition; with 79.5 ± 
11% of the H7 neural cells expressing this interneuron marker (figure 3.5 E). These cells coexpressed 
TUJ1 (figure 3.5 E-I), demonstrating they were postmitotic neurons, they colabelled with GABA, and 
appeared to have the bipolar morphology typical of the dCGE derived cortical interneurons (figure 
3.5 J-K). These results can be recapitulated in three independent cell lines, demonstrating a 
consistent effect of Activin across cell lines with more than 60% Calretinin-positive neurons (figure 
3.5 F-I). 
 In conclusion, the data supports a directed differentiation towards a dCGE fate after Activin 
treatment. Upregulation of markers specific to the dCGE and an increase in the number of cells 
positive for Calretinin with an appropriate morphology suggests that there was a specification of 
Calretinin interneurons in the Activin treated cultures. 
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Figure 3.5 Activin directs differentiation towards a CGE-like fate. 
(A)Differentiation scheme for H7 MD. 
(B)QPCR analysis of basal MD conditions to show expression of the telencephalic marker FOXG1 
during early neural lineage commitment. 
(C)Immunostaining for FOXG1 (green) and Nestin (red) demonstrates a telencephalic character in the 
proneural cells at day 17 of H7 MD. Scale bar represents 100μm. 
(D)QPCR analysis of neuronal cultures with or without Activin treatment. Dorsal telencephalic 
markers were downregulated, such as PAX6. General subpallial markers such as GSX2 and DLX2 were 
robustly upregulated. dCGE enriched markers ZCCHC12 and ER81 were upregulated after Activin 
exposure. Mature markers of CGE-derived cortical interneurons (Calretinin) and general GABAergic 
neurons (GAD67) showed a significant upregulation after 6 days of Activin treatment at day 28 of 
MD compared to the basal condition.  
(E-H)Immunostaining of cultures treated for 6 days with or without Activin for Calretinin-positive 
neurons, Calretinin (green) marks dCGE-derived cortical interneurons and TUJ1 (red) marks all 
neurons. Scale bar is 100μm. 
(I)Counting data demonstrates the proportion of Calretinin staining in all hESC (H7 and H1) and hiPSC 
(2F8 and 4FHuang) lines tested – biological duplicates. H7 basal (8.9 ± 1%) Activin (76.0 ± 11%). H1 
basal (5.4 ± 1%) Activin (70.3 ± 9%). 2F8 basal (4.9 ± 2%) Activin (63.2 ± 16%). 4FHuang basal (4.4 ± 
2%) Activin (58.7 ± 11%).  
(J) Calretinin positive cells (green) coexpressed GABA (red), reinforcing the interneuron phenotype. 
Scale bar is 50μm. 
(K) Calretinin (green) neurons exhibited the characteristic bipolar morphology of CGE-derive cortical 
interneurons. Scale bar represents 50μm. 
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3.3 Discussion  
 In this chapter I have described a novel role of the signalling molecule Activin during human 
pluripotent stem cell differentiation; namely regulating the balance of progenitor cell proliferation 
versus terminal differentiation and also specifying the terminal neuronal fate choice. The 
significance of this molecule in forebrain patterning is supported by the expression of receptor 
proteins throughout the mouse telencephalon (Feijen et al., 1994) and activated SMAD2/3 signal 
transducers that are evident at an appropriate time of mouse development (Maira et al., 2010). 
 I have employed and developed a differentiation scheme for hPSCs. I am able to maintain 
hPSCs in the pluripotent state for an extended period in culture and then, via an adapted version of 
the dual SMAD inhibitor MD protocol (Chambers et al., 2009), I am able to initiate neural 
differentiation efficiently with a strong bias towards telencephalic precursors (figure 3.1 F-L and 
figure 3.5 B-C). The fact that the majority of the neural precursors produced via dual SMAD inhibition 
have a rostral identity is in keeping with previous studies (Fasano et al., 2010), and this may be 
explained by the use of high doses of Noggin, a known head inducer (Bachiller et al., 2000). The 
highly efficient production of neuroepithelial cells via the dual SMAD protocol is important here to 
maintain homogeneity in proneural cultures, as non neural cells may respond to Activin in other well 
described manners, e.g. to remain pluripotent (Beattie et al., 2005) or to initiate mesodermal 
differentiation (Smith et al., 1990). 
 I have implicated Activin signalling in balancing the fate of neural precursor cells. I see a 
strong pro-differentiation effect after Activin treatment at the expense of neural progenitor cell 
maintenance. Cross-talk between Activin and SHH via the GLI3 repressor molecule appears to be key 
to this balance, as SHH mitogenic signals are reduced by the Activin signal. Inherent in the pro-
differentiation effect I see is that Activin has a role in sensitising cells to extracellular retinol, 
implementing terminal differentiation. This bimodal action of promoting RA-induced maturation, 
together with the inhibition of mitotic SHH signals, implicates Activin as an important regulator in 
the differentiation process. This coordination role of Activin may be critical in normal development 
to properly control tissue growth and developmental timing as tissues switch from growth to 
maturation. The timing of Activin signal activation may thus be crucial.  
  I demonstrate that this pro-differentiation effect is consistent with fewer cycling cells in the 
Activin treated cultures via EdU incorporation (figure 3.2 E). It is noteworthy that, as the cells exit 
the cell cycle and terminally differentiate, fewer cells are undergoing cell division. For this reason, in 
the neuronal cultures, there are fewer cells present in total, e.g. as seen in figure 3.2 B-C. Also, the 
morphology of the Activin treated cells is interesting; it is clear that there is a strong signal to mature 
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due to the absence of rosette structures and also the elongated morphology of the Nestin-positive 
cells, suggestive of post mitotic cultures. Nestin marks progenitor cells, but figure 3.2 C and figure 
3.3 C both show that the cells are rapidly and actively maturating as the treated cells exhibit a more 
neuronal morphology than the cells in the basal condition.  
 The outcome of Activin treatment can be partially mimicked via the addition of cyclopamine, 
to inhibit Shh signalling (Chen et al., 2002), and 10µM exogenous RA in mouse cultures, Serafi 
Cambray (Cambray et al., 2012). In these conditions, a similar pro-differentiation effect is observed 
and confirms the bimodal mechanism of Activin treatment observed in this study. However, there 
remain possible effects of Activin that have not been addressed here, for example, SMAD3 has been 
shown to alter the cell cycle via p27kip (Garcia-Campmany and Marti, 2007), adding further functional 
levels to Activin prodifferentiation effects. Also, cyclopamine/RA treatment cannot recapitulate the 
specification towards CGE. Therefore, further investigations are required to determine the direct 
and indirect outcomes of Activin signalling leading to the effects described in this chapter.   
 Activin has a documented survival-promoting effect after insult in the adult brain (Foster et 
al., 2004; Mukerji et al., 2007; Tretter et al., 1996; Wu et al., 1999). I infer that the enhanced 
differentiation in vitro that I observe is not due to augmented survival of neurons as parallel work in 
mouse cells demonstrated similar levels of Annexin V and Casapase3 staining in treated and control 
cells (Serafi Cambray (Cambray et al., 2012)). 
 Activin also performs a role in specifying terminal differentiation in our cultures. I see an 
upregulation of genes associated with the molecular profile of the dCGE within the ventral 
telencephalon. This tissue is the birthplace of calretinin interneurons that migrate to the cortex. In 
four human PSC lines, I see over 60% of TUJ1-positive cells colabelled for Calretinin after six days of 
treatment. These cells costained for GABA and appeared to be bipolar, which is an identifiable 
characteristic of the CGE-derived cortical interneurons. Previous work producing ventral 
telencephalic cells in culture has focused on SHH patterning (Maroof et al., 2010). However, it has 
been shown that knockout of SHH signalling in vivo can lead to an increase in the Calretinin 
population (Xu et al., 2004; Xu et al., 2010). Unlike the MGE-derived interneurons that are 
dependent on SHH signalling and its target NKX2.1 (Sussel et al., 1999; Xu et al., 2004; Xu et al., 
2010), this study suggests that the dCGE may be independent of SHH signalling, but instead be 
influenced by growth factors such as Activin and other undefined signals to produce Calretinin-
positive neurons.  
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 The mouse cell work demonstrated a consistent downregulation of NKX2.1 after Activin 
treatment (Serafi Cambray) (Cambray et al., 2012), further promoting dCGE-type cells at the expense 
of the NKX2.1-positive ventral population. A downregulation of NKX2.1 was not observed in human 
cultures, which may be explained in a number of ways. Firstly, it has been proposed that human 
differentiating cells have endogenous high levels of WNT and so have a default dorsal character, 
whereas mouse cells have higher endogenous SHH levels and so more ventral phenotype (Li et al., 
2009). Therefore, Activin may downregulate NKX2.1 that is already present in mouse cultures, 
whereas in human cells, the ventralisation from dorsal character may have little effect on an already 
low NKX2.1 expression. Alternatively, having been exposed to dual SMAD inhibitors, the human cells 
may have a different endogenous signalling activity from the mouse cultures and so respond 
differently to exogenous Activin due to intrinsic factor dissimilarities. Lastly, there may just be 
species differences between mouse and human development, whereby homeobox genes have been 
employed to promote different outcomes during divergent evolution; i.e. Activin and NKX2.1 may 
have a different relationship in human and mouse development.  
 The overrepresentation of Calretinin in our neuronal cultures suggests a cortical interneuron 
phenotype; however, Calretinin is expressed promiscuously in many areas of the brain. There is a 
lack of many good markers for CGE derived interneurons, nevertheless, the cells produced here 
colabel for GABA, are not double positive for REELIN (consistent with cajal-retzius cells, data not 
shown) and appear to be bipolar in morphology, reinforcing dCGE-derived interneuron identity. 
 To test the functionality, electrophysiological studies were performed on the mouse ESC-
derived neurons. Not only did cells appear to be functional with firing action potentials and relevant 
ion channels, but the Activin treated cells displayed a higher proportion of postmitotic neurons than 
control cells, demonstrated via ability to fire multiple action potentials after depolarising current. 
This work reinforces our findings implicating Activin signalling in driving maturation, (Antonios 
Dougalis and Serafi Cambray (Cambray et al., 2012)). In addition to the electrophysiological data, 
Activin-treated, murine neural progenitor cells were transplanted into the somatosensory cortex of 
adult mice (Graham Little and Serafi Cambray), a major target tissue of calretinin interneuron 
migration. GFP-labelled transplanted cells were able to migrate away from the site of the graft and 
appeared as vertically orientated, bipolar cells; reminiscent of true Calretinin positive cortical 
interneurons. This reinforces the identity and functionality of the mouse neurons produced in vitro 
as well as showing an ability of the cells to survive, migrate away from the graft and integrate in vivo.  
 In vivo, Activin expression has been linked to areas of the adult brain after seizure (Foster et 
al., 2004). In light of our current study, it may prove interesting to investigate de novo 
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interneurogenesis in recovery or protection from seizure after such overstimulation. The authors see 
an increase in interneurons associated with recovery and revisiting this work in light of our findings 
may provide new insights into the mechanism of recovery.  
 Our results infer a novel signalling factor in the development of the CGE and the first 
directed differentiation protocol towards Calretinin-positive cortical interneurons. It will prove 
interesting to go back to in vivo models to investigate a potential signalling centre for Activin 
secreting cells and expression data. The CGE has been defined relatively recently and this current 
work will help to understand the nuances of the development of this tissue. The current work 
provides a platform for new marker discovery and the study of development, especially in the 
human system where direct in vivo investigations are impossible. The functionality of the cells also 
opens up possibilities for disease modelling with a potential view to cell therapies for 
interneuronopathies, as well as drug screening and toxicology tests. Cortical interneurons have been 
associated with epilepsy, schizophrenia and autism and potential cell therapies can be further 
studied using protocols such as this. For example, transplantation of ESC-derived cortical 
interneurons can be used to investigate the reduced spread of seizures, similar to studies using 
foetal-derived tissues (De la Cruz et al., 2011). The role of Activin in dorsoventral patterning may 
initiate further investigations in other tissues along the rostro-caudal axis.  
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Chapter 4 Activin Promotes Differentiation of hPSCs towards a Striatal 
Projection Neuron Fate 
4.1 Introduction 
 Medium spiny neurons (MSNs) are the major projection neurons of the basal ganglia and are 
found in the striatum, within the ventral forebrain. MSNs are marked by the protein DARPP32 and 
comprise 95% of the cells in the striatum (Ouimet et al., 1984). MSNs receive inputs from 
glutamatergic cortical neurons, thalamic cells and mesencephalic dopaminergic neurons and 
subsequently project to the globus pallidus and the substantia nigra (reviewed (Gerfen, 1992)). 
These circuits are involved in voluntary movement related to memory, associations, emotion and 
reward. Multiple diseases are implicated in this circuit such as schizophrenia, Parkinson’s disease 
and most notably Huntington’s disease which is characterised by an early preferential degeneration 
of the striatum and specifically the MSNs (Lange et al., 1976; Reiner et al., 1988). 
 During development, the striatal anlage is represented by a bulge in the ventral 
telencephalon and termed the lateral ganglionic eminence (LGE) due to its anterior-lateral position 
relative to the medial and caudal ganglionic eminences (MGE and CGE respectively). The MGE and 
CGE produce populations of cortical interneurons that migrate tangentially and dorsally to cortical 
target tissues, whereas the progenitors from the LGE mature radially to form the striatal projection 
neurons. The dorsal LGE is also the birthplace of a small population of interneurons that migrates 
rostrally from the LGE towards the olfactory bulb (Waclaw et al., 2009). MSNs can be tracked 
through development using a number of marker genes. GSX2 expression marks the subventricular 
zone cells of the entire ventral telencephalon and DLX1/2 has a similar expression pattern and is 
thought to be involved in the same transcriptional networks (Corbin et al., 2000). The LGE is 
distinguished from the MGE via a lack of the MGE marker NKX2.1 and expression of striatal-enriched 
genes such as CTIP2 (Arlotta et al., 2008) (which is maintained in mature MSNs), NOLZ1 (Chang et al., 
2004) and FOXP1/2 (Takahashi et al., 2003a; Takahashi et al., 2003b). Critically, these striatal-
enriched genes are not exclusive to the striatum and are often expressed in the cortex. However, a 
lack of ventral NKX2.1 and dorsal PAX6, together with the combination of these striatal expressed 
genes can be used to reinforce a striatal positional character (Flames et al., 2007; Long et al., 2009b). 
As discussed in the previous chapter, the CGE is a caudal extension of the LGE and the MGE and 
shares similarities with the two tissues in a dorsal or ventral manner respectively, e.g. GSX2, DLX2 
and NKX2.1 expression (Flames et al., 2007).  
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 The mature MSNs are most specifically marked via DARPP32 expression (dopamine and c-
amp regulated phosphoprotein, which is involved in dopaminergic signal transmission). The cells are 
morphologically distinct; given that they are multipolar, with spiny projections forming synapses 
with many cells and cell types along their axons. Spiny boutons along the neurite projections form 
synapses with glutamatergic inputs, whereas the shaft and bouton necks typically forms connections 
with dopaminergic afferents. The DARPP32-positive MSNs are subdivided into two pools depending 
on projection targets, whereby those connecting to the external segment of the globus pallidus 
express DRD2 and Enkephalin and those projecting to the ventral midbrain express DRD1, Substance 
P and DYNORPHIN. These two circuits have opposing functional outputs in the basal ganglia circuitry 
and there is a reliance on a fine balance between the two to coordinate motor control stimuli. Thus 
degeneration of the striatum in Huntington’s disease upsets this balance within the signalling loop. 
Additionally, the MSNs within the striatum are organised into a patch and matrix formation, 
whereby the patches form around innervations from the midbrain dopamine system. The marker 
Calbindin can be used to discriminate matrix MSNs from patch neurons (Gerfen, 1992). 
 The signalling factors that will be discussed in this chapter are Activin and SHH (Chapter 1.2). 
Activin is a TGFβ family member and binding of the ligand to type II receptors (ActRIIA and ActRIIB) 
recruits type I receptors ALK2, 4 and 7. This leads to SMAD2/3 transducer phosphorylation which 
recruits the coSMAD, SMAD4. This complex then translocates to the nucleus to alter gene 
expression. SHH is the major hedgehog ligand. Binding of ligand to PTCH releases SMO-mediated 
signal inhibition, leading to active signalling and results in GLI1/2 mediated transcriptional 
alterations (see Chapter 1.2). 
 There is currently no cure for Huntington’s disease. Grafts of foetal ventral forebrain tissue 
(both MGE and LGE) have demonstrated proof of principle for cell replacement therapies in patients 
with Huntington’s disease, where some functional recovery has been shown (Bachoud-Levi et al., 
2000a; Bachoud-Levi et al., 2006; Gaura et al., 2004). Therefore, there is an interest in producing 
MSNs from hPSCs as a limitless supply of cells for putative cell replacement strategies. Additionally, 
in vitro derived MSNs enable Huntington’s disease processes to be studied and screens for novel 
therapeutic drugs to be performed.  
 In vitro differentiation of MSNs has focused on ventralising forebrain progenitors using low 
doses of SHH (Danjo et al., 2011; Li et al., 2009) and additional inhibition of dorsal cell types using 
the WNT antagonist DKK1 (Aubry et al., 2008). As described in the previous chapter, SHH signalling is 
crucial to maintain NKX2.1 expression and in turn specify MGE cell types. SHH has been implicated in 
LGE specification and induction of GSX2 in these paradigms, however, this specifier role remains 
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contentious in the literature, as exemplified by the relative difficulty in producing DARPP32-positive 
neurons in culture and the observation that LGE tissue remains intact after knockout of SHH/SMO 
(Machold et al., 2003; Xu et al., 2010). Concurrently, the use of SHH in these protocols leads to a 
high mitotic index in the cultures as demonstrated by large tumour formation after grafting the cells 
into the striatum of model animals (Aubry et al., 2008; Fuccillo et al., 2006). 
 In chapter 3, I have implicated the TGFβ signalling molecule Activin in dCGE development. 
The Activin receptor molecules are expressed throughout the forebrain and the active 
phosphorylated signal transducer SMAD2 is present in the LGE as well as the CGE (Feijen et al., 1994; 
Maira et al., 2010). For this reason and also the fact that the LGE and dCGE have many genes in 
common, I decided to investigate the ability of exogenous Activin exposure to enrich an LGE 
character and produce striatal MSNs. Hitherto, Activin has been implicated in survival of neurons 
(Schubert et al., 1990) and in neurogenesis after injury in the adult brain (Abdipranoto-Cowley et al., 
2009; Foster et al., 2004; Mukerji et al., 2007; Tretter et al., 1996; Wu et al., 1999) but had little role 
suggested in neural developmental processes.  
 Thus, there is a paucity of knowledge of the developmental patterning of the LGE and 
subsequent MSNs. In this chapter, I suggest that human pluripotent stem cells can be effectively 
specified towards a MSN phenotype using an optimised exposure of the growth factor Activin A 
compared with Chapter 3. I use the dual SMAD inhibitor protocol (Chambers et al., 2009) to produce 
forebrain precursors and subsequently show that prolonged Activin exposure specifies cells towards 
a striatal phenotype. Additionally, we show the cells are functional through transplantation studies 
in Huntington’s model rats (in collaboration with Sophie Precious). 
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4.2 Results 
4.2.1 Activin Enriches an LGE Progenitor Phenotype 
 As described in the previous chapter, cells exposed to the modified dual SMAD inhibitor 
protocol (Chambers et al., 2009) exhibit anterior positional identity. This is demonstrated by the 
expression of FOXG1 at the neural progenitor stage, a critical early marker for forebrain 
development (Shimamura and Rubenstein, 1997) (figure 4.1 A, figure 3.1 and figure 3.5).   
 To investigate the effect of Activin on LGE progenitor marker expression, I treated early 
forebrain precursors at day 10 of H7 MD with 25ng/ml of Activin (figure 4.1 B), an earlier and higher 
Activin dosage compared with the interneuron differentiation protocol in chapter 3. After 8 days of 
treatment, RNA was harvested from Activin treated and control cells and qPCR was performed on 
the samples (figure 4.1 C). Similar to the previous chapter, I observed around a 4 fold increase in 
GSX2 and DLX2 transcripts compared with the basal condition. Concurrently, there was an 
upregulation of striatal-enriched genes, CTIP2 (40 fold), FOXP2 (7 fold) and NOLZ1 (2.3 fold). Activin 
induces a small downregulation of dorsal markers, e.g. PAX6 (0.6 fold).  
 Immunocytochemical studies depicted that GSX2, DLX2, CTIP2 and FOXP2 were all enriched 
in the Activin treated cultures, significantly different from the basal condition (figure 4.1 D). 50 ± 
12% of the Activin-treated cultures expressed the key striatal marker CTIP2, with 25 ± 12% 
expressing DLX2 and 16 ± 7% staining positive for FOXP2. 
 The striatal marker upregulation could be due to an active patterning role on naive cells, or 
alternatively a specific proliferation of LGE subtype progenitors already present in the cultures. To 
test this I performed nucleotide analogue EdU incorporation studies. I confirmed the Activin-induced 
reduction on total proliferation of neural progenitors, seen in chapter 3 (figure 4.1 F, figure 3.2 D-E). 
When cells were colabelled for GSX2, counting data demonstrated that the reduced EdU 
incorporation was similar within the GSX2-positive population compared with the entire culture 
(figure 4.1 E-F). This suggests that the prodifferentiation effect of Activin is not cell-type specific and 
that the increase in LGE marker expression is due to a patterning function of Activin. 
 Finally I looked at the gene dynamics of Activin treatment to infer direct target genes of 
Activin signalling. Cells treated with Activin at day 12 for 12 hours already exhibited a marked 
upregulation of GSX2, DLX2 and CTIP2 and a further 12 hours of Activin exposure lead to 
upregulation of FOXP2 and NOLZ1 (figure 4.1 G). This short-term effect of Activin hints to rapid 
transcriptional changes and may suggest direct versus indirect signalling targets. 
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 Therefore, Activin treatment of early forebrain neuroepithelial precursors can upregulate 
the expression of a subset of transcription factors that are expressed in the developing striatum. This 
patterning role appears to be consistent with downregulation of dorsal cortical markers, implicating 
Activin signalling in dorso-ventral patterning of the telencephalon. It is important to consider the 
mutual exclusivity of ventral GSX2 expression and dorsal PAX6 expression, which set up the pallial-
subpallial boundary (Toresson et al., 2000).  
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Figure 4.1 Activin patterning effect on telencephalic precursor cells. 
(A)Immunostaining for FOXG1 (green) and Nestin (red) at day 18 of untreated H7 MD. Scale bar 
represents 250μm. 
(B)Differentiation scheme to test the effects of Activin on striatal lineage choice in H7 MD. 
(C)QPCR analysis of telencephalic progenitor markers at day 20 of H7 MD treated with Activin from 
day 12. General markers for the subpallium, GSX2 and DLX2, and striatal specific markers CTIP2, 
FOXP2 and NOLZ1 are all upregulated whereas pallial specific marker PAX6 is downregulated. 
(D)Antibody staining at day 22 H7 MD and day 18 4FHuang MD with or without Activin treatment 
from day 12 and day 8 respectively, for Nestin, GSX2, DLX2, CTIP2 and FOXP2. Scale bar represents 
100μm. 
(E)Nucleotide analogue EdU incorporation and chemical staining (green) together with GSX2 (red) 
immunostaining from day 25 cultures. EdU was added to the media for 1 hour. Scale bar represents 
75μm. 
(F)Counting data for EdU incorporation into the entire cell population (DAPI staining not shown) and 
within the GSX2-positive subpopulation – biological duplicates. EdU/DAPI basal (27.5 ± 6%) Activin 
(12.0 ± 2%). EdU/GSX2 basal (53 ± 12%) Activin (18.1 ± 2%) 
(G)QPCR analysis of RNA harvested from cells treated with Activin from day 12 for 12 hours and 24 
hours. 
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4.2.2 Activin Functions in a discrete pathway from SHH to upregulate LGE phenotype 
 In chapter 3, we proposed that Activin promoted differentiation in part via suppressing SHH 
signalling (figure 3.3 C-D). Previous studies specifying LGE progenitors have all used precise doses of 
SHH to upregulate an LGE phenotype (Aubry et al., 2008; Danjo et al., 2011; Li et al., 2009). 
Therefore, I investigated whether the upregulation of LGE-specific markers by Activin treatment was 
acting independently from the ventralising morphogen SHH. 
 To infer a direct patterning effect of SHH and Activin treatment, I investigated the dose 
response of ventral telencephalic gene expression to the two morphogens. Increasing the dose of 
SHH lead to increased expression of established SHH target genes from the MGE, namely NKX2.1 and 
LHX8 (figure 4.2 A). Conversely, this was not the case for either early subpallial domain genes GSX2 
or DLX2 or striatal specific markers CTIP2 and FOXP2. Similar dose response experiments with Activin 
showed a complimentary effect, whereby MGE-specific markers showed no clear dose response to 
Activin. However, striatal-specific markers responded in a dose-dependent fashion (figure 4.2 B). 
General subpallial markers GSX2 and DLX2 showed a similar upregulation in response to Activin, 
reinforcing the results from Chapter 3. 
 To test whether Activin was acting independently from SHH, I treated cultures with the SHH 
antagonist cyclopamine in combination with Activin. Consistent with its function, 1µM cyclopamine 
treatment lead to downregulation of SHH target genes GLI1 and PTCH1 (figure 4.2 C), whereas 
Activin treatment had little effect on endogenous SHH signalling. The Activin-dependent 
upregulation of CTIP2 and GAD67 (a marker of mature subpallial GABAergic neurons) was not 
affected via cyclopamine addition (figure 4.2 C), suggesting that inhibiting SHH has little effect on 
Activin mediated expression changes of these genes. 
 Finally, I investigated whether there was a synergistic effect of Activin and SHH treatment 
(figure 4.2 D). SHH lead to augmented NKX2.1 expression, to which additional Activin treatment had 
little effect. This is in contrast to the antagonism of the two growth factors described in figure 3.3. 
GSX2 and CTIP2 were upregulated after Activin treatment, and additional SHH had no significant 
synergistic effect on this response. GAD67 expression was further increased in the SHH and Activin 
condition, consistent with the SHH mediated induction of GABAergic interneurons derived in the 
MGE, in addition to Activin-mediated induction. 
 Therefore, I can suggest that the transcriptional changes observed 6 days after Activin 
treatment appear to be independent of the SHH signalling pathway. Here I argue that LGE and 
striatal-enriched genes are not under the control of SHH compared with MGE-specific genes, but 
instead show a dose response to exogenous Activin treatment. 
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Figure 4.2 Activin and SHH signal pathway interactions. 
(A-B)QPCR analysis to investigate subpallial marker gene response to SHH from 0-100ng/ml and 
Activin from 0-40ng/ml in a dose dependent manner. Cells were treated for 7 days and RNA 
collected at day 18 of H7 MD. 
(C)QPCR analysis of Activin and cyclopamine-treated cultures. Cyclopamine effectively 
downregulated transcription of SHH responsive genes PTCH1 and GLI1 whereas there was no effect 
on Activin-mediated upregulation of CTIP2 and GAD67. Factors were added for 7 days from day 10 
H7 MD. 
(D)QPCR analysis of Activin and SHH supplemented cultures and a combination of both. Factors were 
added for 7 days from day 10 H7 MD. 
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4.2.3 Activin treatment produces medium spiny neurons in vitro 
 Having established that Activin treatment can produce an enrichment of LGE-like 
progenitors in vitro, I continued differentiation to investigate whether the upregulation of LGE-
enriched transcription factors can lead to post-mitotic MSN specification. I maintained Activin 
exposure to the endpoint and neuronal cultures were supplemented with retinol containing media 
for maturation (see Chapter 3), BDNF (10ng/ml), GDNF (10ng/ml) and ascorbic acid (200nM) to aid 
cell survival (figure 4.3 A). 
 RNA was harvested at day 36 and qPCR analysis revealed that many striatal enriched genes 
were upregulated in the Activin-treated condition (figure 4.3 B). DARPP32, ARPP21, Calbindin and 
GAD67 are all expressed in the mature projection neurons of the striatum. The upregulation of these 
genes compared to the basal condition suggested an enrichment of a striatal character in our 
cultures. I saw upregulation of genes representing the two subsets of MSNs, namely the Substance P 
(TAC1 gene) subpopulation as well as the DRD2/Enkephalin subpopulation. Dopaminergic neurons 
can induce DARPP32 expression. However I observe a reduction in dopaminergic cells, shown by a 
downregulation of the dopamine biosynthesis gene TH upon Activin treatment. Also, the cortical 
glutamatergic neuron marker vGLUT1 was similar in the Activin treated and the control cultures, 
consistent with PAX6 expression at the progenitor stage.  
 Immunostaining of the cultures revealed numerous multipolar cells reactive for DARPP32 
with branching axons (figure 4.3 C-D). DARPP32-positive cells were seen in four independent hPSC 
lines after Activin treatment and rarely witnessed in basal conditions. DARPP32 cells stained positive 
for mature striatal marker CTIP2 (figure 4.3 E). In turn, the CTIP2-positive cells were GAD65/67-
positive (figure 4.3 F), indirectly suggesting that the DARPP32 cells are GABAergic. Calbindin positive 
cells were overrepresented in the Activin treated cultures and many of these cells coexpressed CTIP2 
(figure 4.3 G). DARPP32-positive cells also expressed the late neuronal markers MAP2 and NeuN, 
demonstrating that they are postmitotic neurons (figure 4.3 H). Counting data for DARPP32 versus 
NeuN revealed that early Activin addition at day 9 lead to the highest numbers of DARPP32 neurons, 
with up to 35% of neurons being DARPP32-positive. Later Activin treatment had a less dramatic 
effect on MSN specification (figure 4.3 I). 
 Consistent with their in vivo morphology, DARPP32-positive cells appeared to have spines 
along their processes and the post-synaptic marker PSD95 accumulated along their processes, 
demonstrating the presence of synapses (figure 4.3 J-L). DARPP32 staining is weaker in spines than 
along the dendrites, meaning PSD95 and DARPP32 overlap is difficult to visualise (Ouimet and 
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Greengard, 1990). Finally, Enkephalin and Substance P staining was observed within the CTIP2 
population, suggesting that both striatal MSN subpopulations were present (figure 4.3 M-N). 
 In conclusion, prolonged Activin treatment enriches the neuronal cultures for striatal 
projection neuron features. Expression of a panel of genes as well as characteristic staining and 
morphology suggest that I specify a large proportion of GABAergic medium spiny neurons.  
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Figure 4.3 Effect of Activin patterning on neuronal cultures. 
(A)Differentiation scheme whereby Activin was added from day 9 H7 MD until the end point at day 
35. NT (neurotrophins, BDNF, GDNF and Ascorbic Acid) were added to aid cell survival in mature 
neuronal cultures.  See Chapter 2. 
(B)QPCR analysis of expression differences between Activin treated and untreated cultures relative 
to day 10, RNA was harvested at day 35. DARPP32, ARPP21 and Calbindin mark the MSN population. 
TAC1 (Substance P gene), PENK (Pro Enkephalin) and DRD2 distinguish the two MSN subtypes. 
GAD67, TH and vGLUT1 represent different neuronal types in the cultures, GABAergic, dopaminergic 
and glutamatergic respectively. 
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(C)Immunostaining for DARPP32 and CTIP2 in three hPSC lines at day 36 of H7 MD. Scale bar 
represents 75μm. 
(D)Immunostaining to show DARPP32-positive cell morphology after Activin treatment. Scale bar 
represents 30μm. 
(E)Antibody staining showing DARPP32 and CTIP2 expression in the same cells in Activin treated 
cells. Scale bar represents 75μm. 
(F)Immunostaining showing CTIP2 expression within the GAD65/67-positive GABAergic cell 
population. Scale bar represents 30μm. 
(G)Immunostaining to demonstrate CTIP2 and Calbindin coexpression from day 36 H7 MD. Scale bar 
represents 75μm. 
(H-I)Immunostaining of DARPP32 and MAP2 (neurons) and counting data for percentage of 
DARPP32-positive cells within the neuronal population – biological duplicates. Activin addition at a 
later stage resulted in fewer DARPP32-positive neurons. Scale bar represents 50μm. Basal (0%) Day 
19 Activin (10.6 ± 4%) Day 9 Activin (35.7 ± 13%). 
(J-L)Immunostaining for DARPP32 and PSD95 demonstrating spiny morphology and post synaptic 
marker localisation on the DARPP32-positive cell projections. Scale bar represents 40μm in J, 25μm 
in K and 7.5μm in L. 
(M-N)Immunostaining to demonstrate the presence of both MSN subtypes in the CTIP2-positive cell 
population, via Enkephalin and Substance P colocalisation. Scale bar represents 50μm. 
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4.2.4 Activin-Induced LGE progenitors give rise to functional MSNs in animal models of 
Huntington’s disease 
 To test the functionality of the MSNs produced from hPSCs, I dissociated day 18-20 H7 
progenitor cells that had been treated with Activin for 6-8 days and grafted them into quinolinic-acid 
lesioned adult rats (in collaboration with Sophie Precious).  
 Cells continued to mature in vivo, as demonstrated via diminishing Nestin staining seen 4 
weeks, 8 weeks and 16 weeks after grafting (figure 4.4 A-C). Nestin staining was present throughout 
the grafts at 4 weeks but was completely absent after 16 weeks. Importantly, proliferation was low 
and there was no evidence of rosette-like structures, typifying continued growth of contaminating 
undifferentiated cells. Subsequently, we saw no tumours or neural overgrowths in the 16 week rats 
(n=8). This is in contrast to previous studies in which teratoma formation hugely impacted upon the 
therapeutic potential of in vitro derived MSNs (Aubry et al., 2008).  
 DARPP32 staining was evident in small numbers 8 weeks post transplant, however after 16 
weeks, a large proportion of human nuclei (graft tissue) were positive for DARPP32 (49 ± 5%) (Figure 
4.4 D-F). FOXP2 staining was also present throughout the graft cells (figure 4.4 G-I). The DARPP32-
positive cells appeared to have processes within and extending outside the graft region (figure 4.4 J). 
Calbindin staining complimented DARPP32 staining, as this mature marker was present in small 
numbers after 8 weeks, but many of the graft cells stained positive 16 weeks post transplantation, 
35 ± 8% (figure 4.4 K-L). GABA staining within the HuNu positive graft cells (figure 4.4 M) together 
with FOXP2 and Calbindin staining; suggest that the Activin treated precursors matured into 
correctly specified MSNs in vivo.  
 I stained for other cell types in the 16 week grafts. I saw an accumulation of GFAP-positive 
glia around the graft, possibly indicating a host response to the transplant procedure (figure 4.4 N). 
Interestingly, I observed TH fibres innervating the graft, suggesting functional interactions between 
the graft and the host dopaminergic system (figure 4.4 O). I observed a small number of Calretinin-
positive cells in the graft (figure 4.4 P), consistent with Calretinin interneuron specification by 
Activin, presented in chapter 3. 
 Therefore, Activin pre-patterned LGE progenitors are able to mature into DARPP32-positive 
neurons in vivo. After 16 weeks of maturation in situ the graft coexpressed GABA, Calretinin and 
FOXP2 suggesting true striatal phenotype. Also, innervations from host tissues suggest functionality 
of the graft cells.  
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Figure 4.4 Activin treated progenitors mature in vivo to produce DARPP32-positive neurons. 
(A-C)Immunostaining to show Nestin-positive progenitors in the grafted HuNu-positive cells, from 4 
to 16 weeks after grafting. Scale bar represents 60μm. 
(D-J)Immunostaining for DARPP32 cells within the graft at 8 weeks and 16 weeks. FOXP2 staining 
was also present in the grafted DARPP32-positive cells in 16 week grafts. Scale bar represents 
250μm (E), 50μm (D), 75μm (F), 75μm (G-I), 50μm (J). 
(K-L) Calbindin staining in the graft at 8 week and 16 week post grafting. Scale bar represents 35μm 
(K) and 60μm (L). 
(M-P)Immunostaining to depict other cell types in the graft in 16 week grafts. White line represents 
graft, determined from adjacent sections. Many graft cells are GABAergic, and some express 
Calretinin (see Chapter 3). GFAP-positive glia accumulate around the graft and there is evidence for 
TH dopamine cell innervations of the graft (O). Scale bar represents 75μm (M), 100μm (N), 50μm (O-
P). 
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4.3 Discussion 
 In this chapter I have described a novel role for Activin signalling in patterning hPSCs to 
MSNs in vitro. Previous studies have demonstrated expression of Activin signalling pathway 
components and phosphorylated SMAD2 in the developing LGE (Feijen et al., 1994; Maira et al., 
2010), but have not investigated the developmental role of Activin further. In Chapter 3 we 
proposed a novel role for Activin in the induction of the dCGE, a tissue that has a number of genes in 
common with the LGE. Therefore, I adapted our protocol to enrich striatal MSNs, a cell type of much 
interest due to its degeneration Huntington’s disease, using hPSCs as a model to investigate 
development. 
 Compared with the CGE directed protocol that was described in Chapter 3, I found that an 
earlier, longer and more concentrated exposure of Activin to the telencephalic precursors lead to a 
greater upregulation of LGE-specific genes, rather than CGE-specific genes. These differences in CGE 
and LGE enrichment may infer a proximity to putative organiser regions secreting Activin, i.e. the 
LGE requires a higher dose of Activin and may be closer to the morphogen secreting tissue. 
Alternatively the tissues may respond with different inherent sensitivity to the morphogen present 
in abundance, as a lower dose is sufficient to produce Calretinin-positive interneurons compared 
with MSNs. 
 The difficulty in producing mature striatal projection neurons from in vitro differentiation 
protocols is demonstrated via the paucity of published articles. Also, primary LGE tissue quickly loses 
its character with current in vitro expansion/culture techniques. DARPP32-positive neurons have 
been produced from hPSCs in just three studies, Aubry et. al. (Aubry et al., 2008),  Li et. al .(Li et al., 
2009) very recently Ma et. al. (Ma et al., 2012). There has been one recent study using mPSCs (Danjo 
et al., 2011). This is in contrast to the significant interest in these cells due to their degeneration in 
Huntington’s disease and the evidence of functional recovery from cell replacement strategies 
(Bachoud-Levi et al., 2000a; Bachoud-Levi et al., 2006; Gaura et al., 2004). All of the published 
differentiation protocols use precise doses of exogenous SHH to pattern the precursors towards an 
LGE fate. However, the use of feeder layers (Aubry et al., 2008) or EB differentiation (Li et al., 2009; 
Ma et al., 2012) present a degree of uncertainty into the precise signalling events. Also, as discussed 
in the previous chapter, work in SHH deficient mice argues that SHH signalling is dispensible for 
dCGE and LGE development (Machold et al., 2003; Xu et al., 2010). Whereby SHH deficient mice 
(conditional Smo knockout) lack MGE-specific NKX2.1 expression but upregulate LGE-enriched GSX2 
expression (Xu et al., 2010). In addition to this, the loss of ventral telencephalic structures in Shh null 
mice is reversed with GLI3-SHH double knockout mice (Rallu et al., 2002). One can argue that SHH 
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treatment is permissive for LGE development, potentially via reducing GLI3 repression and allowing 
LGE determination in a passive manner. Alternatively, SHH may be required in a precise and early 
spatiotemporal manner during development of lateral tissues. NB Contaminating ventral 
interneuron fates are often present in the neuronal cultures after SHH-based MSN directed 
differentiations (Danjo et al., 2011). 
 In this Chapter, I propose Activin as an instructive factor, capable of driving striatal 
differentiation. This is shown via rapid upregulation of striatal relevant genes as well as a dose 
dependent patterning effect. Contrarily, zebrafish model organisms have provided evidence that 
SMAD2/3 signalling is sufficient to induce SHH signalling in the ventral forebrain (Muller et al., 2000; 
Rohr et al., 2001). However, I see no such upstream activation of SHH via Activin treatment in our 
cultures.  
 I observed an upregulation of numerous markers of the LGE after 6 days of Activin treatment 
at the protein and RNA levels (figure 4.1). Interestingly, this occurs in a dose-dependent manner with 
Activin treatment and also is unaffected with cyclopamine-mediated SHH repression (figure 4.2). 
These data argue that Activin has a specific role to pattern telencephalic progenitors in vitro that is 
novel and independent of SHH signalling. Scans of promoter regions of genes involved in striatal 
development have shown an enrichment for SMAD2/3 binding (e.g. CTIP2, GSX2, FOXP2, MEIS1, 
DARPP32) and these would be interesting to investigate further for direct activation after Activin 
treatment (rVista alignment). However, it is also possible that intermediary signals are responsible 
for the observed Activin-mediated effects. One such mediator may be FGF signalling (Gutin et al., 
2006), also implicated by Danjo et. al. (Danjo et al., 2011), where FGF8 versus FGF15/19 signalling 
has been proposed to induce anterior LGE rather than posterior fates respectively. Interestingly, 
Activin binding has been shown in the FGF15/19 promoter and Activin effects may potentially be 
mediated through FGF signalling (Guzman-Ayala et al., 2009). ChIP and luciferase promoter studies 
would prove informative to delineate a direct or indirect action of Activin. 
 I do not witness a downregulation of NKX2.1 expression in the Activin and SHH treated 
culture compared to SHH alone (figure 4.2 D). This is in contrast to the observation that Activin 
antagonises SHH and its target genes when both factors are exogenously added to the proneural 
cultures (figure 3.3 D-E). One explanation of this might be the different stages of the cells; whereby 
Activin/SHH is added to the cells at day 19 in Chapter 3 and day 11 in Chapter 4. Signal factor 
responses are known to be context dependent and influenced by transcription factor expression 
state. Alternatively, the mitogenic action of SHH described in Chapter 3 and in Cambray et. al. may 
be preventing terminal differentiation at later stages which is antagonised by supplementing Activin; 
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whereas at earlier time points, SHH may have a more prominent patterning effect (Cambray et al., 
2012; Fuccillo et al., 2006). 
 Continued Activin treatment can bring about DARPP32-positive neurons in our cultures. 
These cells are neuronal, costain for CTIP2, have a branching, spiny morphology and appear to 
create synapses throughout the length of their processes (figure 4.3). I use CTIP2 as an intermediary 
marker to propose the DARPP32 cells are GAD65/67 positive and are representing both Enkephalin 
and Substance P expressing subpopulations. This step is made necessary due to antibody species 
conflicts. Thus it appears that simple Activin treatment alone is sufficient to promote DARPP32-
positive MSN overrepresentation in our cultures. I add neurotrophins to the neuronal cultures to aid 
survival and BDNF has been proposed to promote MSN differentiation (Baydyuk et al., 2011; Ivkovic 
et al., 1997; Nakao et al., 1995). However, I have also observed DARPP32 staining in the absence of 
neurotrophin addition. The prodifferentiation role of Activin presented in Chapter 3 may lead to 
upregulation of MSN markers compared with the basal condition simply due to terminal 
differentiation state. However, I have continued differentiation to day 90 and mature basal cultures 
continue to show rare DARPP32 staining.  
 Importantly, the prodifferentiation effect that I see from Activin treatment (figure 3.2 and 
figure 4.1) has proved to be hugely beneficial for our transplantation studies compared with other 
studies. When cells were transplanted at day 18 of differentiation, the large decrease in proliferation 
meant that tumourigenesis/neuroblastogenesis/glioblastogenesis was absent in striatal 
engraftments. After engraftment of 400,000 cells, we saw an average of 122,705 cells making up the 
graft. This demonstrates a lack of proliferation but also the cell death involved with the transplant 
procedure. In contrast, other studies with cells prepared using mitogenic SHH either produced large 
tumours (Aubry et al., 2008) or continued to grow 35 fold, depicting large graft volume (Ma et al., 
2012). Alternatively, the use of the dual SMAD inhibitor protocol may reduce contaminating 
undifferentiated hPSCs, and the lack of growth may simply be due to increased homogeneity in the 
neural precursor population before Activin treatment. 
 I observed faithful differentiation of LGE-like human progenitors into DARPP32 neurons in 
the transplants, presumably due to further endogenous instructive factors in vivo. Conservative 
counts demonstrated that 49% of all HuNu cells were DARPP32-positive after 16 weeks in situ (figure 
4.4). This in vivo maturation process is slower than in vitro differentiation due to suboptimal, adult 
brain environments with reduced support cells in the lesioned striatum. This is more rapid than 
primary human foetal tissue that can take 6 months to exhibit MSN character after grafting. A lower 
proportion of the grafted cells were Calbindin-positive (35%), mirroring the in vivo state where only 
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matrix derived MSNs, outside the striosomes, express Calbindin. Interestingly, Calretinin-positive 
neurons were present in the grafts, reinforcing the role of Activin in dCGE development, our findings 
in Chapter 3. The low numbers of Calretinin-positive interneurons is presumably due to the site of 
the graft in the striatum disfavouring CGE differentiation. CTIP2 staining could not be performed on 
the graft as the rat derived antibody cannot be visualised in rat tissues due to cross-reaction of host 
immunoglobulins. 
 Our preliminary data suggests that the MSNs produced via this Activin protocol are 
functional. In vitro, I see presence of synaptic boutons and synaptic marker staining along the length 
of the DARPP32 processes, characteristic of MSNs and suggesting functional synapse formation. 
Electrophysiology was performed on these cells and the results show functional neurons with action 
potentials and GABAergic features consistent with MSNs (Jessica Risner, data not shown). 
Additionally, the interaction of the graft with the host dopaminergic system in vivo after 
transplantation, suggests that the Activin-derived MSNs are able to integrate into the lesioned rat 
striatal system. 
 Studies are ongoing into the functional recovery of the Huntington’s model animals after 
grafting. Previous investigations have shown that both MGE tissue and LGE tissue convey benefits 
when grafted into the striatum of lesioned animals and clinical studies have used whole ganglionic 
eminence (WGE) grafts (Precious and Rosser, 2012). Therefore, it will be informative to compare the 
behavioural recovery after an Activin-based protocol and the exciting recovery published by Ma et. 
al. (who use a SHH-based protocol and presumably contain a subset of interneurons, similar to WGE 
grafting) (Ma et al., 2012).  
 In conclusion, I have implicated a new player in the differentiation of MSNs in vitro. I utilise 
hPSC differentiation to model development and aid discovery of developmental mechanisms. Activin 
may thus be involved in development of this tissue and should be further investigated in vivo. 
SMAD2/3 ChIP assays would prove interesting to suggest a direct inductive capacity of Activin on 
striatal genes. The simple differentiation protocol presented here will impact on the field to improve 
current differentiation regimes and may be used for future cell replacement studies, drug screening 
and toxicology tests for striatal tissues. 
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Chapter 5 Temporal Control of FGF Signalling Specifies a Midbrain 
Dopaminergic Cell Fate 
5.1 Introduction 
 The dopaminergic neurons of the ventral midbrain have received much attention due to 
their significance in Parkinson’s disease. Midbrain dopaminergic cells are present in two populations; 
the neurons of the ventral tegmental area (VTA) are involved in the mesolimbic pathway that 
functions in emotion and reward behaviour. The substantia nigra (SN) forms the nigrostriatal 
pathway that functions to control postural reflexes and initiation of movement (Bjorklund and 
Lindvall, 1984). Degeneration of the nigrostriatal pathway is implicated in Parkinson’s disease for 
which there is currently no cure. After the merits of foetal tissue derived therapeutic approaches, 
hPSCs are being viewed as a potential source of dopamine cells for Parkinson’s disease cell therapy 
(see Chapter 1.3). 
 The differentiation of correctly specified midbrain dopaminergic (mDA) neurons from hESCs 
in vitro has proved difficult. Dopaminergic neurons, which are marked by the expression of the rate 
limiting enzyme for dopamine biosynthesis tyrosine hydroxylase (TH), are present in multiple 
locations in the brain and subgroups can be demarcated by coexpression of markers genes. Midbrain 
specific markers such as FOXA2, LMX1A and PITX3 help to identify dopaminergic neurons with a 
ventral midbrain identity. The best results from in vitro differentiation have come from transgene 
overexpression, whereby forced expression of fate determinants such as LMX1A, NURR1 and PITX3 
can produce mDA neurons, however, this can be context dependent (Andersson et al., 2006; Chung 
et al., 2005; Friling et al., 2009; Kim et al., 2003; Roybon et al., 2008). For example the timing of the 
transgene induction must be during a critical window in which the cells are competent to respond to 
such effects (Friling et al., 2009). I set out to investigate the extrinsic signalling requirements of 
differentiating hESCs to be properly specified towards this cell fate.  
 During development, it has been demonstrated that the differentiating neuroectoderm 
initially has an anterior, forebrain-like bias, but becomes progressively posteriorised to form the 
remaining neurectodermal domains; the activation/transformation model (Nieuwkoop and 
Nigtevecht, 1954). In this model, activators instruct cells to become neural with an intrinsically 
rostral identity. Further transformer factors caudalise the cells to produce subsequent posterior 
neural tissues. As discussed in earlier chapters, cells that are produced from the dual SMAD inhibitor 
protocol intrinsically have a rostral identity, presumably due to the effect of the forebrain inducer 
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molecule Noggin (Chambers et al., 2009; Fasano et al., 2010). Therefore I sought to manipulate the 
extrinsic signalling cues to specify a more caudal, midbrain phenotype. 
 In this chapter, I will focus on fibroblast growth factor (FGF) signalling. The family of FGF 
ligands signal through the receptor tyrosine kinase pathway, in which binding of a ligand to the 
receptor leads to phosphorylation cascades through ERK kinases leading to phosphorylated ERK, 
which effects transcriptional alterations of target genes (see Chapter 1.2.2).  
 FGF signalling is known to be required for telencephalic development and is expressed in the 
anterior neurectodermal ridge, the rostral tip of the developing embryo (Paek et al., 2009). 
Specifically, FGF8 signalling has been demonstrated to be critical in inducing FOXG1 expression, a key 
transcription factor for forebrain development (Shimamura and Rubenstein, 1997). Additionally, the 
role of FGF2 in posterior spinal cord development is well documented and exogenous FGF2 can 
induce caudalisation of the neural tube (Cox and HemmatiBrivanlou, 1995).  
 With regards to the midbrain, after formation of the neural tube, FGF (possibly FGF4) and 
Wnt signalling is vital for normal formation of the Midbrain Hindbrain Border (MHB) (Olander et al., 
2006; Shamim et al., 1999; Ye et al., 2001). Subsequent FGF8 signals from the MHB have a 
morphogenetic function in neural fate specification in the proximal tissues, i.e. ventral midbrain and 
cerebellum (Marin and Puelles, 1994; Martinez et al., 1991). However, in contrast to forebrain and 
spinal cord discussed above, preceding MHB formation there are low levels of ERK phosphorylation 
in the presumptive midbrain (Corson et al., 2003; Lunn et al., 2007).  
 In vitro it has been shown that ERK signalling is required for ESCs to exit the self-renewal 
phase, as demonstrated by the inability of ERK2 knockout cells to differentiate into neural or 
mesodermal lineages while maintaining pluripotency (Kunath et al., 2007; Stavridis et al., 2007). 
Conversely, FGF2 is applied to neural progenitor cells and pluripotent cells to maintain proliferative, 
multipotent state and differentiation can only ensue when FGF2 is withdrawn (Tropepe et al., 1999; 
Xu et al., 2005; Zhang et al., 2001). For later specification of mDA cells, many protocols routinely use 
FGF8 in conjunction with the ventralising factor SHH, in an attempt to mimic endogenous 
morphogen conditions of the ventral midbrain where MHB-derived FGF8 has a proliferative role as 
well as a patterning effect (Barberi et al., 2003; Kim et al., 2002; Lee et al., 2000; Marin and Puelles, 
1994; Perrier et al., 2004). Therefore, FGF signalling is very much context dependent and can lead to 
pleiotropic effects.  
 These dynamic spatiotemporal patterns of FGF signalling and the detrimental effect 
described on early neural fate choice (Di-Gregorio et al., 2007) lead us to investigate the action of 
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exogenous FGF in differentiating hESCs. I aimed to examine whether recapitulating the ERK activity 
seen during midbrain development would bring about specification of true mDA neurons in our 
cultures.  
 This work has been carried out in conjunction with parallel studies of mouse epiblast stem 
cell (epiSC) cultures by Ines Jaeger and will be cited as such. The work has been published as an 
efficient way to produce mDA neurons and has since been recapitulated in two similar studies, see 
Chapter 5.3 (Jaeger et al., 2011).  
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5.2 Results 
5.2.1 Effects of ERK Inhibition after Neural Induction 
 Human ESCs were differentiated using the modified dual SMAD protocol, as described in 
Chapter 2, followed by treatment with 200ng/ml recombinant human SHH and 100ng/ml FGF8. 
Under these conditions dopaminergic neurons were present in large numbers in the neuronal 
cultures, as confirmed by the expression of the rate limiting enzyme in dopamine biosynthesis, TH 
(Figure 5.1 A-B). However, when looking at the markers for in vivo positional identity of these 
dopaminergic neurons, the number of TH cells coexpressing mDA specific markers, such as FOXA2, 
was very low. Further investigation into the relative in vivo positional identity of these cells revealed 
many TH-positive cells coexpressed NKX2.1 and ISL1, characteristic of the dopamine populations of 
the hypothalamus and the thalamus repectively (Marin et al., 2005) (figure 5.1 A-B).  
 To recapitulate in vivo ERK-phosphorylation status described in Chapter 5.1, I treated the 
cells with the small molecule ERK inhibitor PD0325901 (henceforth referred to as PD), inhibiting 
phosphorylation and so activation of ERK. PD was added on day 3 of monolayer differentiation after 
exit from the pluripotent state, as ERK signalling is required for exit from the pluripotent state 
(Kunath et al., 2007) (figure 3.1, figure 5.1 C). It is worth noting that this may, or may not, be a 
mouse specific phenomenon and requires more detailed analysis in hPSCs (Cohen et al., 2010; 
Greber et al., 2011). When the cells were treated with PD from day 3 until day 7, qPCR analysis 
revealed that neural differentiation was supported and accelerated as seen by early upregulation of 
neural lineage makers PAX6 and SOX1 compared with non-PD treated cultures. Cells did not revert 
to the pluripotent state as they demonstrated similarly low expression of pluripotency markers 
(figure 5.1 D-F). 
 In differentiating mouse cells, accelerated neural conversion after PD treatment was 
confirmed using the SOX1-GFP mouse epiSC line, which expresses GFP driven by the transcriptional 
promoter of the early pan-neural marker SOX1. Cells treated with ERK inhibitor upregulated the 
SOX1:GFP at earlier time points compared with the basal condition, with peak expression at day 3 in 
treated cells and day 5 in control cultures (figure 5.1 G-H, Ines Jaeger).  
 Immunocytochemical analysis of the cells at the neural progenitor stage, day 11 of H1 MD, 
revealed a striking difference between the PD treated and the control cells. The proportion of Nestin 
positive progenitors that coexpressed the forebrain/midbrain marker OTX2 was greater in the 
treated cultures (figure 5.2 A). Additionally, the key ventral midbrain fate determinants FOXA2 and 
DMRT5 were similarly enriched in the PD treated cultures (figure 5.2 B-C).   
115 
 
 Gene expression was analysed by qPCR for the PD-treated and control neural progenitors. 
The upregulation of the forebrain/midbrain marker OTX2, and the transcription factors FOXA2 and 
DMRT5 seen at the protein level was mirrored at the mRNA level at day 7-11 of H7 MD (figure 5.2 D-
F). LMX1a and MSX1 are additional transcription factors central to mDA development and these 
genes also appear to have an early upregulation in the PD treated cultures (figure 5.2 G-H).  
 Interestingly, FOXG1 which is critical for telencephalic development is significantly 
downregulated at the transcriptional level (figure 5.2 I) and the downregulation of SIX3, also marking 
the forebrain domain, reinforces this result (figure 5.2 J). Additionally, the hindbrain homeobox 
marker GBX2 shows a striking downregulation (figure 5.2 K). 
 Next I investigated the effect of ERK inhibition on the active signalling pathways in the PD 
treated populations. As one might expect, the addition of PD leads to lower FGF8 expression within 
the cultures (figure 5.2 L). The expression of SHH and WNT1 suggest changes in the activity of 
endogenous signalling within the cultures (figure 5.2 M-N) and the action of these pathways is 
supported by known target gene upregulation; FOXA2 for SHH signalling and LMX1a/LEF1 for active 
WNT signalling (figure 5.2 F, G, O). These qPCR results indicate an early stimulation of Wnt signalling 
concurrent with ERK inhibition as well as a sensitisation to SHH signals upon PD withdrawal. 
 These data suggest that during the proneural phase of monolayer differentiation, treatment 
with the ERK inhibitor brings about gross changes in prominent signalling pathways and also fate 
determinant expression profiles. Importantly, I see an increase in the number of cells expressing key 
ventral midbrain fate determinants as well as an increase in SHH and Wnt1 signalling, a combination 
central to mDA development. 
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Figure 5.1 Basic mDA differentiation protocol and early events after ERKi. 
(A-B)Immunostaining of d35 neuronal cultures for dopaminergic (TH green) subtype markers; 
showing (A) characteristic thalamic (ISL1 red) and (B) hypothalamic (NKX2.1 red) staining and 
midbrain staining (FOXA2 blue). Cells were differentiated with the dual SMAD inhibitor protocol and 
treated with SHH and FGF8 similar to the published protocol (Chambers et al., 2009). Scale bar 
represents 75μm. 
(C)Represents the ERKi-based differentiation protocol for H7 MD. 
Figure 5.1 G-H 
Experiments 
performed by 
Ines Jaeger 
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(D)QPCR of early neural differentiating cultures after ERKi. RNA was collected at day 7 after 
treatment with SMADi (dual SMAD inhibitors) followed by PD-supplemented (ERK inhibitor) or basal 
media. 
(E)FACS sorting of SOX1:GFP reporter mouse epiSCs after N2B27-based MD with or without PD from 
day 0. Reproduced with kind permission from Ines Jaeger. 
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Figure 5.2 Effects of ERK inhibition on neural progenitor phenotype. 
(A-C)Immunostaining of PD treated or non-treated progenitors at day 11 of H1 MD for Nestin (green) 
costained with OTX2, FOXA2 and DMRT5 (red).  Scale bar represents 75μm. 
(D-O)QPCR analysis of ERKi mediated transcriptional changes early during differentiation relative to 
day 3 cultures before ERKi. Anterior-posterior markers (D, I-K), dorso-ventral markers (E-H) and 
signalling pathways (L-O). RNA was collected from day 7 and 11.  
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5.2.2 Formation of Ventral Midbrain Dopaminergic Neurons 
 To investigate the phenotype of the postmitotic neurons generated after early ERK 
inhibition, I continued monolayer differentiation to completion using the classic signalling conditions 
for mDA differentiation; i.e. treatment with SHH (supplemented with 1μm purmorphamine) and 
FGF8 followed by maturation with neurotrophrins; BDNF, GDNF and AA (figure5.1 C). Therefore, I 
aimed to mimic in vivo ERK status described in Chapter 5.1 by activating FGF signalling later during 
differentiation, at the time when cells are patterned by signals from the MHB.  
 Having seen an upregulation of midbrain specific markers at the proneural stage, I looked at 
the identity of the postmitotic dopaminergic neurons via immunocytochemistry. Colabelling of TH 
with FOXA2 suggested that many of the dopaminergic neurons in the PD treated cultures were 
specified towards a ventral midbrain positional identity (figure 5.3 A). This is in contrast with the 
basal condition where FOXA2/TH colabelled cells were very seldom observed, notwithstanding 
expression of these proteins in neighbouring cells. Counting data for the two conditions 
demonstrates that there is an increase in the total number of TH-positive cells in the PD-treated 
cultures (53 ± 14%) compared to the control cultures (27.9 ± 9%). Crucially, the number of these TH 
cells coexpressing FOXA2 is significantly higher with PD treatment (77.9 ± 4%) than without ERK 
inhibition (7.3 ± 4%) (Figure 5.3 B-C). 
 In the PD-treated cultures, immunocytochemistry revealed that many TH-positive neurons 
displayed double staining for PITX3 and LMX1a, both key transcription factors expressed in mature 
mDA neurons in addition to FOXA2 (figure5.3 D-E). Other dopaminergic cell types were also present 
in these cultures, as NKX2.1 and ISL1 staining was evident in the TH population (figure5.3 F-G). 
However, the increase in FOXA2/TH-positive colabelled cells via PD treatment may be at the expense 
of the NKX2.1/TH-positive population, suggested by the decrease in this staining characteristic of 
hypothalamic dopaminergic cells (figure5.3 H).  
 Thus, the data supports that, for the first time in our hands, I have been able to produce 
dopaminergic neurons that are adequately specified towards a ventral midbrain phenotype. 
Coexpression of ventral midbrain specific transcription factors suggests that precise regulation of 
ERK activity allows us to bring about early lineage fate choices, that later enrich for mDA neurons in 
culture. 
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Figure 5.3 Phenotype of postmitotic cultures after early ERKi-based terminal differentiation. 
(A)Immunostaining to depict neurons (TUJ1, blue), dopamine cells (TH, green) and floorplate cells 
(FOXA2, red) in day 35 cell cultures with or without early ERK inhibition. Scale bar represents 75μm. 
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(B-C)Cell counting data for dopaminergic cells in the neuronal population (TH/TUJ1) and midbrain 
dopamine cells within the dopamine population (FOXA2/TH) with or without ERK inhibition (note 
this data is an average from experimental replicates). TH/TUJ1 -PD (27.9 ± 9%) +PD (53.3 ± 14%). 
FOXA2/TH -PD (7.3 ± 4%) +PD (77.9 ± 4%).  
(D-E)Immunostaining for mature cell markers of mDA neurons (PITX3 and LMX1a, red). Scale bar 
represents 50μm. 
(F-G)Immunostaining to determine proportions of dopaminergic subtype prevalence, depending on 
marker costaining, after early ERK inhibition. Scale bar represents 75μm. 
(H)Counting data to depict the relative proportions of dopaminergic neuron subtypes from day 35 
immunostained cultures (note this data is from one experiment and error bars represent SD of 
random fields). ISLET/TH -PD (28.4 ± 10%) +PD (31.2 ± 10%). NKX2.1/TH -PD (59.3 ± 8%) +PD (36.3 ± 
7%). FOXA2/TH -PD (1.3 ± 1%) +PD (32.1 ± 10%). 
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5.3 Discussion 
 In this chapter, I have presented data supporting a central role of ERK signalling in the 
differentiation of hESCs towards midbrain dopaminergic neurons. For the first time, I was able to 
produce dopaminergic neurons expressing marker genes that suggest a correct, ventral midbrain 
positional identity by controlling ERK activity in a stage-specific manner.  
 The dual SMAD inhibitor protocol has been shown to accelerate exit from self-renewal and 
entry to the neural lineage in a more homogenous manner than previous techniques (Chambers et 
al., 2009; Chiba et al., 2008). This may provide a high degree of competency to respond to growth 
factor signals in a synchronous manner and ERK inhibition further strengthens the neural lineage 
choice as early markers of neural lineages are further upregulated (figure5.1 D-H). This observation 
complements studies in hESCs by Greber et. al. where FGF inhibition was shown to facilitate neural 
lineage fate choice (Greber et al., 2011). 
 Inhibiting ERK signalling after initial neural induction leads to a sharp increase of signalling 
factors and endogenous fate determinants that have a key role in the developing ventral midbrain. 
Parallel work in mESCs demonstrated that the effect of ERK inhibition was primarily due to inhibiting 
the FGF receptor tyrosine kinase pathway. Using a second inhibitor, PD173074 that specifically 
blocks ERK signalling at the FGF receptor, we found the same outcome was seen compared with ERK 
inhibition using PD0325901 (Ines Jaeger) (Jaeger et al., 2011). Thus, the effect of inhibiting ERK is 
primarily due to inhibiting the ERK-mediated FGF signalling pathway and a change in subsequent 
signalling environments leads to interesting questions about the presumptive in vivo positional 
identity of the cells in culture. 
 In model organism development, FGF8 signalling can induce Foxg1 expression, which in turn 
is responsible for regional specification in the forebrain (Shimamura and Rubenstein, 1997). More 
caudally, the homeodomain gene Gbx2 marks the hindbrain and spinal cord (Ye et al., 2001) and 
Gbx2 has been shown to be induced by strong FGF8 signals from the MHB (Liu et al., 1999). Thus, 
FGF signalling may directly specify these domains meaning early ERK inhibition may lead to a 
reduction of GBX2-positive cells as well as FOXG1-positive cells directly. Taken together with the fact 
that OTX2 expression is upregulated, the lack of FOXG1 and GBX2 demonstrates a homeodomain 
genetic environment that is permissive for midbrain patterning. Also, it has been demonstrated that 
Wnt1 signalling can induce OTX2 expression (Prakash et al., 2006), and the upregulation of WNT1 
seen via PD treatment may provide further OTX2 specification.  
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 FGF signals from the ANR have been shown to be mutually exclusive and opposing from 
dorsal, cortical Wnt and BMP signals (Shimogori et al., 2004). Therefore, an initial downregulation of 
dominant FGF8 signalling via ERK inhibition may be permissive for more posterior domains. Notably, 
in frogs, Noggin is a known head-inducer (Bachiller et al., 2000) expressed in the Spemann organiser.  
Treating cultures with Noggin downregulates BMP4 (Anderson et al., 2002; Ohkubo et al., 2002), 
possibly explaining the anterior nature of the cells after the dual SMAD protocol via an upregulation 
of FGF signalling. 
 Importantly, the observed upregulation of SHH transcripts and target genes immediately 
after PD withdrawal hints that the cells are primed to respond to SHH signalling. SHH morphogen 
signals have been demonstrated to have a ventralising role throughout the neural tube and oppose 
dorsal Wnt and BMP signals (Ericson et al., 1995). Wnt signals are central to roofplate development; 
however, the ventral midbrain is a unique tissue where development is dependent on both factors. 
This explains the expression of Wnt target genes both in roofplate and ventral midbrain such as 
Lmx1a (Andersson et al., 2006). The activity of both signalling networks leads to the proposed two 
regulatory loops: SHH-FOXA2 (Perez-Balaguer et al., 2009) and WNT1-LMX1a (Chung et al., 2009; 
Prakash et al., 2006). It is contentious whether these loops are interconnected or have opposing 
roles (Joksimovic et al., 2009).  
 Having been exposed to early ERK inhibition and subsequent patterning factors SHH and 
FGF8, I observed authentic postmitotic midbrain dopamine neurons. This effective mDA patterning 
in the PD-treated cultures may be at the expense of the more anterior NKX2.1-postiive population 
because of reduced FGF signalling. It should be noted that the percentage of FOXA2/TH cells in 
Figure 5.3 H is inconsistent with Figure 5.3 C. This is because the data from Figure 5.3 H is from one 
biological experiment, rather than replicates, highlighting the potential variability for in vitro 
monolayer differentiation. 
 The induction of fate determinant transcription factors is the functional outcome of the 
user-mediated exogenous growth factor control. Upregulation of these key developmental genes is 
the ultimate goal to harness the transcriptional networks leading to proper differentiation of 
intended cell types. Thus, the early expression of genes such as FOXA2, LMX1A and DMRT5 are 
critical for the ERK inhibitor differentiation mechanism (Gennet et al., 2011; Lin et al., 2009). The 
importance of upregulation of LMX1a and FOXA2 is exemplified by their inclusion in the factors 
necessary for direct reprogramming of fibroblasts to mDA neurons and hint to a master regulatory 
role (Caiazzo et al., 2011; Pfisterer et al., 2011). 
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 I use known target genes of growth factors and the expression of the endogenous proteins 
to infer dominant and active signalling pathways in our cultures. This is relevant to compare the two 
conditions, however, further experiments into the mechanisms of ERK inhibition would benefit from 
improved readout techniques, such as TOPFLASH TCF Wnt reporter assays and luciferase 
experiments to evaluate active signalling pathways. 
 In vivo data supports a lack of FGF signalling in the early developing midbrain. Knockout of 
FGF8 has been shown to increase OTX2 expression domains and reduce GBX2-positive tissues (Storm 
et al., 2006; Sun et al., 1999). Further in vivo investigations into specific FGF ligand signalling, 
relevant knockout studies and expression data in light of the current work will be illuminating and 
not only help to explain the results seen here, but further define the mechanisms of mDA 
development.  
 Recent studies support our findings, in that early exposure of cells to SHH, Wnt agonists and 
FGF8 leads to efficient generation of properly patterned mDA neurons (Kirkeby et al., 2012; Kriks et 
al., 2011). Whereas, Fasano et. al. (Fasano et al., 2010) demonstrate that early SHH exposure is 
sufficient to induce floor plate tissue,  Kriks et. al. (Kriks et al., 2011) provide evidence that the 
GSK3β inhibitor CHIRON, a Wnt signalling agonist, is critical at these early time points to specify an 
mDA character. Interestingly, this study replicates the importance of Wnt signalling in inducing 
LMX1A/FOXA2 coexpression seen in TH-positive cells. Also, they provide evidence that FGF8 is 
detrimental for OTX2 expression, that dual SMAD inhibition alone upregulates a cortical phenotype 
and that SHH and FGF8 treatment alone specifies hypothalamic tissue types. Without considerations 
into the initial anterior-posterior positional identity of differentiating cells, we and others now show 
that mDA fate determination is ineffective.  
 The strategy described in this chapter represents an important step in the production of 
mDA cells in vitro. Understanding the in vivo processes that bring about ventral midbrain 
development allows us to recreate these pathways in culture. Thus, inhibition and reactivation of 
ERK in differentiating cells upregulates key fate determinants relevant for ventral midbrain 
development and enables specification of properly patterned mDA neurons. The functionality of 
these cells has been supported in further studies; firstly the cells exhibit proper electrophysiological 
properties of functional neurons and a pacemaker properties consistent with mDA neurons (Jessica 
Janiczek) (Jaeger et al., 2011) and also, the cells have been grafted into Parkinsonian mice, shown to 
differentiate correctly and integrate into the host striatum (data not shown, Ines Jaeger and Sophie 
Precious).  
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Chapter 6 Discussion 
6.1 Summary 
 In this thesis, I have provided evidence for the validation of human pluripotent stem cell 
(hPSC) differentiation towards disease-relevant neurons. I have adapted the highly effective neural 
inductive capabilities of the novel dual SMAD inhibitor protocol from Chambers et. al. into a scheme 
based on N2B27 (Chambers et al., 2009; Ying et al., 2003). This has the benefit of being simpler to 
employ and potentially is quicker than KSR-based strategies (Gerrard et al., 2005; Shi et al., 2012). 
Consequently, I have demonstrated the effective generation of PAX6-positive, SOX1-positive neural 
precursor cells. Additionally, I confirm the highly rostral identity of the progenitors produced herein 
via investigations into the positional information of the cells (Chambers et al., 2009; Elkabetz et al., 
2008; Fasano et al., 2010) and discuss the role of Noggin and other SMAD inhibitors in preferentially 
specifying a rostral neural identity. 
 This technology allows further investigations into signalling pathways in a controlled 
manner. The monolayer character if this protocol in chemically defined, xeno-free N2B27 media 
enables the researcher to have close control over the factors exposed to the differentiating hPSCs. 
Subsequently, via regarding in vivo developmental information as a parallel guide for in vitro 
differentiation, it is possible to implicate growth factors or signalling environments that are able to 
preferentially produce mature neurons of special interest relating to neurodegenerative diseases. 
Synthesis of in vivo information to control cellular patterning in the anterior-posterior and the dorso-
ventral axes provides effective and directed cell patterning. Here I have focussed on Calretinin-
positive cortical interneurons which have been implicated in seizure, epilepsy and schizophrenia, 
DARPP32-positive medium spiny neurons that degenerate in Huntington’s disease and midbrain 
dopaminergic neurons that degenerate in Parkinson’s disease. 
 Novel growth factors and new spatiotemporal roles for known growth factors can be closely 
investigated using the chemically defined MD in this thesis. Data gained in vitro can be used to 
further define in vivo development, i.e. the flow of information can be two way. This becomes 
especially relevant for human development, with difficulty accessing early developmental events. 
For example, I investigate Activin signalling in neural development which has previously not been 
described. This data can then be relayed to the in vivo paradigm in future studies.  
 I use a panel of genetic markers to track differentiation and imply positional information 
within our cultures via immunocytochemical staining and quantitative PCR. Readouts for major 
signalling pathways allow us to (1) deduce relative activity of endogenous signalling pathways, (2) to 
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investigate the subsequent effects on critical intrinsic fate determinants and (3) come up with 
inferences relative to the developing embryo. In collaboration with others, we argue the neurons 
produced are functional, firstly via electrophysiological data, hinting to synapse formation and ion 
channels and  secondly via integration into host brains, suggesting proper functionality of in vitro 
derived neurons and speculations into future cell replacement therapies. 
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6.2 Context 
 This work has benefitted from the novel dual SMAD inhibitor protocol as the effective and 
synchronous nature of the cultures enable detailed analysis of exogenous factors with a high degree 
of confidence, reproducibility and robustness. The low heterogeneity reported via this technique has 
since been utilised in numerous settings to study the in vitro differentiation of a number of 
neuronal/proneural cell types, see Chapter 1.5.3 (Emdad et al., 2012; Fasano et al., 2010; Lee et al., 
2010). This technology is enabling many researchers to study hPSC differentiation and the number of 
studies is set to increase rapidly. Also, this protocol produces neurons more rapidly than previous 
protocols, as dual SMAD inhibition initiates differentiation forcibly and the monolayer character 
reduces the formation of proliferative niches.    
 I present evidence for new protocols to produce three disease-relevant neuronal subtypes. I 
generate Calretinin cortical interneurons with an efficiency of more than 60% in culture. I produce 
medium spiny neurons that develop in vivo to make up 49% of grafted cells. And I produce more 
than 75% authentic midbrain TH cells within our cultures. All produced in chemically defined, xeno-
free media and more rapidly than previous protocols. 
 These works signify the first Calretinin targeted differentiation protocol. The field of cortical 
interneurons remains relatively novel due to complexity of subpopulations, migration capacities and 
final widespread location. Current differentiation studies have been based on SHH to reproduce 
MGE-like character; however, Calretinin-positive dCGE tissue appears to be independent from SHH 
signalling (Xu et al., 2010). Therefore the implication of Activin signalling in these works provides a 
novel platform for future work both in vitro and in vivo.  
 I demonstrate a chemically defined, xeno-free and rapid induction of MSN fate with Activin 
signalling. This is in contrast to previous feeder cell-based strategies (Aubry et al., 2008). During 
preparation of this work, Ma et. al. published an EB, SHH-based regime that produces MSNs that can 
repair Huntington’s behavioural symptoms in disease model mice (Ma et al., 2012). This provides 
validation for cell-based therapies for Huntington’s disease and also reinforces the interest in the 
field that we exhibit.  Our work is the first SHH-free scheme (potentially reducing proliferation of 
grafted cells) and I provide arguments that Activin is the first factor to exhibit direct induction of 
LGE-specific genes. It remains a pertinent question whether grafting LGE or MGE tissue is optimal for 
behavioural recovery of Huntington’s disease symptoms as both tissues have displayed recovery in 
animal models (Precious and Rosser, 2012). Comparing an Activin-based protocol and the Ma et. al. 
SHH-based protocol (which produces some MGE-like cells) will prove informative in this facet.  
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 I also demonstrate an efficient scheme to produce mDA neurons with the correct regional 
identity. These cells will enhance behavioural studies in disease model animals and bring the field 
closer to clinic. Other studies since this work was published have also produced dopaminergic 
neurons with correct midbrain identity (Kirkeby et al., 2012; Kriks et al., 2011).  These works recreate 
the early requirement of Wnt signalling. Excitingly the patterned precursors have been utilised for 
functional recovery in two rodent models of Parkinson’s disease and also demonstrated appropriate 
in situ differentiation in primate models. 
 Thus the three schemes reported in this thesis represent novel, relevant and important 
advances in the field of human PSC differentiation. 
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6.3 General Concepts 
 The use of hPSCs to model disease and produce cells for pharmaceutical and biomedical 
applications relies heavily on the parallels inferred from in vivo development. Differentiation is a 
model for normal development and exogenous factors are used in a manner to mimic positional 
cues and instructive events within the embryo. Human development is a process that is 
unobtainable in utero and so hPSCs provide an invaluable tool to study this process. I use analogies 
from mouse development and the limited data from in vivo investigations to propose factors critical 
for human development.  
 As such, I employ the dual SMAD inhibitor protocol that functions to specify neural tissue. 
This is based on work over the last 50 years implicating TGFβ inhibitors and other inhibitors of 
epithelial induction in this patterning event. As such I produce tissue that is characteristically 
anterior due to the activation transformation model, whereby caudal tissue is produced from, and 
subsequent to, anterior neural tissue induction. 
 In chapter 5, I am able to effectively alter the positional identity of these cells at early time 
points. Using the ERK inhibitor protocol that is presented, I am able to control endogenous signalling 
within the cultures to promote specific developmental domains, namely the mesencephalon. This is 
shown to be crucial for differentiation of midbrain dopaminergic cells, as without this regionalisation 
step, midbrain TH cells are sparingly produced and the cells retain diencephalic/telencephalic 
character.  
 In chapters 3 and 4, I make use of the anterior positional identity of the progenitor cells 
produced from the dual SMAD inhibitor protocol to investigate novel signalling events in the ventral 
forebrain. Activin signalling has not been studied in detail during development, but active signal 
transducers have been shown in the LGE and CGE (Feijen et al., 1994; Maira et al., 2010), prompting 
this work. It is perplexing that this previous work was not further investigated but new stem cell 
technologies may have enabled access to these previously inaccessible developmental events. 
 Development has been proposed to progress in the three stages; regionalisation, 
specification and terminal differentiation (Gale and Li, 2008). This may translate to in vitro 
differentiation as; competence, commitment and maturation. In this thesis, the three chapters 
address these processes. By controlling FGF/ERK signalling, I am able to alter the 
regionalisation/competence of the precursors, influencing further differentiation. After this, I use 
different growth factors to alter specification/commitment towards differentiation lineages. This is 
addressed in chapters 3 and 4 whereby Activin is shown to promote specific fates within the ventral 
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telencephalon. Also in chapter 5 SHH and FGF8 treatment confers this specification/commitment 
step for mDA neurons. Lastly, maturation and survival has been promoted in these studies using 
neurotrophins to aid survival but also in a new manner using Activin-mediated terminal 
differentiation (with or without RA). 
 It is important to understand that the reductionist approach applied here may become 
superseded by whole genome techniques in the future. Inspecting individual genetic pathways can 
provide caveats and misleading results as well as providing a partial understanding of the cellular 
environment. Techniques such as microarrays, ChIP-on-chip and ChIP-seq allow entire gene panels 
to be elucidated, e.g. SMAD2/3 ChIP-seq would provide a list of genes that are under the control of 
Activin signalling and may provide further evidence for CGE or LGE developmental relevance and a 
direct action. Future studies will rely more heavily on such bioinformatic approaches.  
 It will be interesting to investigate Activin action in vivo. Having described its relevance using 
our in vitro model, Activin signal origins (such as Organiser regions) and other responsive tissues can 
be investigated in the developing embryo. It will be interesting to see if Activin effects maturation in 
all cells and is ubiquitous in late stage neural development or whether it is more specific to the 
telencephalon and is unique in specifying subpallial differentiation. 
 In sum, all of the in vitro differentiation work is inherently linked to in vivo development. The 
use of signalling molecules relates to active signalling in vivo and transcription factor marker 
information is taken from developmental studies. Thus, in order to create neurons of interest in 
culture, developmental processes must be closely adhered to.  
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6.4 The Future 
 The disease-relevant neurons produced via these three novel protocols have the potential to 
be used in several ways. Firstly, the development of human and mouse embryos can be closely 
investigated outside the uterus. This enables normal development to be tracked, individual genes to 
be tested, knocked-out, knocked-down and knocked-in, as well as cellular environments to be 
investigated, such as inhibitors or novel signals. For example, the gene responsible for Activin and its 
negative counterpart Inhibin, INHBA, can be altered at the dose level within the cells to potentially 
limit or promote MSN/Calretinin interneuron differentiation in vitro.  
 Secondly, the diseased state can be understood. Comparing mutant genes or disease specific 
iPSCs to the wild-type scenario will allow a greater characterisation of the disease process, especially 
if this is a developmental impairment. Human PSC differentiation can thus enable advancement of 
our understanding of diseases, deficiencies, mutations and infections. For example, it may be 
interesting to test FGF signalling and point mutations present in the wider human population to 
investigate early events that affect ventral midbrain development, potentially predisposing 
individuals to Parkinson’s disease. 
 Neurons produced in vitro can be of use to biotechnology companies and pharmaceutical 
industries in two ways. Firstly, new drugs can be tested in a preclinical manner as a first port of call 
for toxicology screening. This reduces the need for animal testing, solving ethical hurdles, but also 
greatly reducing cost. The second manner is drug discovery. The use of reporter genes will allow 
small molecule libraries to be screened to investigate candidate compounds. For example, the ERK 
inhibition protocol can be used to produce progenitor cells that will enable screening for novel 
compounds that promote midbrain dopaminergic differentiation or survival. These drugs may then 
be used in vivo to promote endogenous recovery or slow disease progression for Parkinson’s disease 
from resident adult neural stem cells pools or remaining mDA neurons respectively.  
 It is possible that the functionality of the cells will prove sufficient to reverse 
neurodegenerative disease models. Cell replacement therapy with these in vitro derived cells of 
interest may then be employed to treat currently incurable diseases in patients. Transplant studies 
of human foetal tissue have provided evidence for some efficacy in reversing Parkinson’s and 
Huntington’s diseases. These proof-of-principle studies have shown variation and the success is still 
contentious. However, a number of patients have benefited and shown functional recovery and also 
model organisms show robust recovery after cell grafting. This implicates hPSCs as a source of 
limitless neurons for cell therapy. Additionally, these cells may be engineered or patient derived to 
abrogate the need for immunosuppression. Much work is needed to understand and prove the 
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efficacy of foetal tissue transplants, but assuming the correct site, patient, disease stage, graft cell 
stage and other criteria are found where cell therapy can be functional, hPSC-derived neurons, such 
as the DARPP32 cells, Calretinin cells and the midbrain TH cells presented here, constitute a superior 
source of cells for therapy.  
 These differentiation processes may be applied to produce many cell types in the laboratory, 
such as other disease-relevant cells. Early domain specification, subsequent regionalisation based on 
in vivo understanding and consequent maturation may produce any given cell type. Neurons 
generated in this manner will be valuable to diseases that have an undefined cause; as monogenetic 
diseases such as Huntington’s may be addressed in other ways. It is the opinion of the author that 
this technology from PSCs will remain valid and more functional than direct reprogramming to given 
cell types (Caiazzo et al., 2011; Pfisterer et al., 2011; Vierbuchen et al., 2010). Direct generation from 
other cell types will suffer from lack of cell numbers, efficiency and instability of genomic material, 
limiting its clinical relevance; however, it still remains an interesting academic exercise.   
 More speculatively, these cells may be used to form cell circuits in vitro, similar to basal 
ganglia circuits. For example, when combined with glutamatergic differentiation protocols, cells can 
be placed on a chip in a circuit such that an ON state stimulates a glutamatergic projection cell to 
fire, GABAergic projection cell firing can constitute an OFF signal, dopaminergic projections can 
synthesise the two signals to produce a final OUTPUT signal and GABAergic interneurons can add 
layers of complexity to the information processing. This may result in biological computer chips that 
can store and process large amounts of information as the complexity increases, but also enables 
electrophysiological studies into synapse functionality and cell to cell interactions. For example, the 
effect of the site of a synapse can be tested (cell soma versus dendrite extremities). 
 With a clinical view, the protocols presented here should be taken forward to further 
optimise efficiency, reduce heterogeneity and augment safety, so that if the biomedical field 
becomes ready, hPSC-derived neurons are ready for treatment of incurable diseases. 
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Chapter 8 Appendices  
8.1 Primers used for qPCR 
 
Note all primers listed require 60°C annealing temperature. 
 
Marker Category GENE Forward Primer Reverse Primer Amplicon 
housekeeping     
 GAPDH atgacatcaagaaggtggtg cataccaggaaatgagcttg 177bp 
 CYCLOPHILIN ggcaaatgctggaccaaacac ttcctggacccaaaacgctc 147bp 
 B ACTIN tcaccaccacggccgagcg tctccttctgcatcctgtcg 351bp 
     
pluripotency     
 OCT3/4 ttctggcgccggttacagaacca gacaacaatgaaaatcttcaggaga 218bp 
 NANOG gcttgccttgctttgaagca ttcttgactgggaccttgtc 256bp 
 SOX2 catggcaatcaaaatgtcca tttcacgtttgcaactgtcc 119bp 
     
epiblast     
 FGF5 tgt gtc tca ggg gat tgt agg gaa aac gct ccc tga act tg 125bp 
 GBX2 ctcgctgctcgccttctc gccagtcagattgtcatccg 169bp 
 OTX2 tgccaaaaagaagacatctcca aagctgggctccagatagacac 137bp 
     
pan neural     
 MASH1 gtcctgtcgcccaccatctc ccctcccaacgccactgac 251bp 
 NESTIN agcaggagaaacagggcctac ctctggggtcctagggaattg 218bp 
 NGN2 tcaagaagacccgtagactgaagg gtgagtgcccagatgtagttg 169bp 
 SOX1 ggaaggtcatgtccgaggcc acttgtccttcttgagcagcg 138bp 
 TUJ1 catggacagtgtccgctcag caggcagtcgcagttttcac 175bp 
     
ap axis EMX1 accggaggacaaagtacaaac tagtcattggaggtgacatcg 148bp 
 EN1 gactcgcagcagcctctc gcctggaactccgccttg 179bp 
 EN2 cggctcgtggtgtttctaacc   aggtcctacaagtcgccgg   79bp 
162 
 
 FOXG1 tggcccatgtcgcccttcct gccgacgtggtgccgttgta 77bp 
 HOXB4 commercially obtained from qiagen qt00236390  
 IRX2 gcccttctacggcaactacac aattgtgacacctacttgcattg 297bp 
 LDB1 cgatgtgaagatgtcagtgggctg atccctatccagcatggtgcc 133bp 
 SIX3 caactggtttaagaaccggc ttaccgagaggatggaggtg 218bp 
     
dv axis     
 DLX2 actacccctggtaccaccagac tctgctctcagtctctggcgagttctc 186bp 
 GSX2  tcactagcacgcaactcctg ttttcacctgcttctccgac 117bp 
 FOXA2 att gct ggt cgt ttg ttg tg tgt acg tgt tca tgc cgt tc 189bp 
 PAX6 aacagacacagccctcacaaaca cgggaacttgaactggaactgac 275bp 
 NKX2.2 cagaaccaccgctacaagatga gctgtaggcagaaaagggaatg 186bp 
 NKX2.1 cgcatccaatctcaaggaat tgtgcccagagtgaagtttg 170bp 
 NKX6.1 caaggatccattttgttggaca ggaaccagaccttgacctgact 181bp 
 PAX2 caggcatcagagcacatc gtcacgaccagtcacaac 165bp 
 ISL1 aagcgcaggaagagagactg ccaagagacccaggatttca 125bp 
 PAX7 ctcctcaggtgatgagcatcttg agataatcaacagcagtctggccg 271bp 
 HELT accaaggacacgaagtacgc gctgataggagaaatccggc 118bp 
     
dopaminergic     
 LMX1B cttaaccagcctcagcgact tcaggaggcgaagtaggaac 118bp 
 MSX1 actcctcaagctgccagaagat ttacggttcgtcttgtgtttgc 156bp 
 DMRTA2 cta cct ccg gat ccc tct tc tct cgg att atc ctg cca tc 152bp 
 TH gagtacaccgccgaggagattg gcggatatactgggtgcactgg 279bp 
 NURR1 tcggcagagttgaatgaatg gaaattaaaggtggacagtgt 140bp 
 LMX1A gagaccacctgcttctaccg gcccgcataacaaactcatt 122bp 
 PITX3  NEW ctgttgcaggacgcactagcc cctctggaaggtcgcctctag  278bp 
     
signalling     
 ALDH1A1F ccagacttacctgtcctactc gctcctcctcagttgcaggat 127bp 
 ALDH1A2F ctcgctgcagctcctgccg cacttgctctcctgtggctg 233bp 
163 
 
 AXIN2 2F gctttaaacttggaaggggg gatgacgcaacatggtcaac 271bp 
 CYP26F cgcgacaagagctgcaagct ccaacaaatgcgtcttgaaca 148bp 
 DKK1 1F aaggttctgtttgtctccgg ccttctccacagtaacaacgc 172bp 
 FGF8 tctgcctccaagcccaggtaactg cggctgagctgatccgtcac 91bp 
 GLI1 tgaggcccttcaaagccc gtatgacttccggcacccttc 101bp 
 GLI3 2F tcccccatcagcaactattc gtttctcctggcttgcaaag 153bp 
 GRG4/TLE4 cagtatccccatcagccagtttcc gctggactaatcggggcatc 265bp 
 LEF1 2F gtccaagaatgacagctgcc tgggttttcaacaagcttcc 122bp 
 PTCH1 2F ttcgctctggagcagatttccaag gcttttaatcccaccgcgaag 167bp 
 RARB F1  tggatcaattacaggcttttagc gatctcccttgcactgaatg 187bp 
 SHH ccaattacaaccccgacatc agtttcactcctggccactg 133bp 
 SPRY1 acaaatccttgcttagggtcag gaaatccttttcggacaatcc 168bp 
 STRA6 SERAFI ggactactcctatggcagctg gccaggcaggcgtggtacag 123bp 
 WNT1 cgaccgtattctccgagatg tgggcgatttctcgaagtag 267bp 
     
telencephalon     
 CALRETININF ccttacctgcacctggccga ccagagcctttccttgccttc 143bp 
 COUPTF 2 SERAFI ggagaagctcaaggcactgca cctgcaagctttccacatggg 119bp 
 CTIP2 ctccgagctcaggaaagtgtc   tcatctttacctgcaatgttctcc   129bp 
 CUX1 cttgaaagggcaaaccagag   acctctatggcctgctccac   140bp 
 FOXP2 1F aatgtgggagccatacgaag gcctgccttatgagagttgc 137bp 
 GAD67F cgtcttcgaccccatcttcgt cgcagatcttgagccccagtt 141bp 
 REELIN atgtggaggtcgtcctagtaagc   ggaaagtggtgtacactcgg   272bp 
 SATB2 caacgcaactaataatcatctccc   gagaaagggctgagaacccg   291bp 
 TBR1 agcagcaagatcaaaagtgagc   atccacagaccccctcactag   149bp 
 VIP1 gttagtaacatctcagaagaccctg aactcttctggaaagtcggg 170bp 
     
of interest     
 FAF1 ttacaagtatccccgttcgc atcggtgatttgttcttccg 173bp 
 OSBPL9 ttcgtgctggactacaatgc aaggtgctgtcgtcctcatc 134bp 
 PCNA ggccagagctcttcccttac gcctccaacaccttcttgag 193bp 
164 
 
 SOX21 cgagtggaaactgctcacag cggtacttgtagtcggggtg 102bp 
 SPATA6 gaggaggatttctggccttc atcctgagtgtggcatttcc 106bp 
     
striatal immature     
 BRN4 F1 ataactagtaggggatcctcaccg   tggaactgagaatgctgtagg   70bp 
 DLX5 1F gccggagacagagacttcac   tcaaacactcctgtcatcgc   213bp 
 DLX6 1F accattcccagactgacgag   ttcctgattccagttcaggg   221bp 
 EBF1 F1 aatgtaagcaaggtggacgc   tcaaggtctaagccggacac   177bp 
 HELIOS 2F tctgtttggggaggacagac   gtgcttagctggtgcctacc   268bp 
 IK1 F1 acatgtcccaagtttcaggg   cattcgtaaatcctccgcac   230bp 
 NOLZ1 1F acattttgcaccccgagtac ggagtacggcttgaaactcg 281bp 
     
striatal mature     
 ADORA 2F cctgtgtacatgtgagcagcc   acacgaggcttcacctgac   175bp 
 ARPP21 1F ggaagctggttgacgatgtgtc ggcttctgtcgttctacgcc 138bp 
 CALB F1 atcaggacggcaatggatac   taagagcaagatccgttcgg   168bp 
 CHRM4 2F acgaacgatctttgccattc   tgttgacgtagcagagccag   140bp 
 DARPP 4F ttggaaaatccagaaaaccg   ctggtagaagccggtgagag   210bp 
 DRD1 F1 ttgtcatctccttggctgtg   aggccacccagatgttacag   120bp 
 DRD2 F1 ctgagggctccactaaaggag   cattcttctctggtttggcg   193bp 
 PDYN 2F tggcacactctatctcgctg   accgagtcaccaccttgaac   245bp 
 PENK 1F gctgtccaaaccagagcttc   tctggctccatgggataaag   159bp 
 TAC1 2F tggggttgaaaattcaaaaag   ggagtttccttccttttccg   234bp 
     
cge and mge     
 CRABP1 1F acttatcctgacgtttggcg   tattggtaggggaaaagggc   164bp 
 ER81 2F tggagactatttgccttggg   ggcctatgactcagtttggc 294bp 
 LHX8 F1 ggaaacgcttcccctatttc   tgcgaccaagagtctgtacg   107bp 
 ZCCHC12 1F aattctgtgcagctgattgc   caggggacgaactctgaaac   158bp 
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8.2 Antibodies used for Immunostaining 
ANTIBODY species company dilution reactivity in vitro in vivo m/rat 
      
5HT m abcam 1/50 good  
AMPK B2 rb custom 1/1000 ok, background  
AMPK P172 rb custom 1/100 no specific signal  
BRDU rat abcam 1/100 no signal (ok serafi)  
CALBINDIN rb swant 1/500 very bright good 
CALRETININ m swant 1/500 good good 
CALRETININ gt swant 1/1000 bad bad 
CALRETININ rb synaptic systems 1/500 good good 
CASPASE3 rb cell signalling 1/100 good good 
COUP TF1 m r&d 1/100 good good 
COUP TF2 m r&d 1/100 good good 
CTIP2 rat abcam 1/500 good good 
DARPP32 rb sc 1/200 good good 
DARPP32 m bd  very poor bad 
DAT rb  1/250   
DLX2 rb millipore 1/300 good-background bad 
DMRT5 rb custom 1/1000 overexpressed protein only  
DRD2/3 rb chemicon 1/200 no good  
ENK rb immunostar 1/400 weak ? 
ER rb sc 1/200 some background  
FOXA2 gt sc 1/200 very good good 
FOXP1 rb abcam 1/200 very good good 
FOXP2 gt abcam 1/100 good good 
FOXG1 rb abcam 1/250 bad  
GABA rb sigma 1/500 good, lots background ok 
GAD67 m millipore 1/500 poor  
GAD65/67 rb sigma 1/200 lots background  
VGAT gt sc 1/100 no good  
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GEPHRIN m synaptic systems 1/200 good, background good 
GFAP m dako 1/100 good good 
GFP rb invitrogen 1/500 good  
GFP m invitrogen 1/500 good  
GIRK rb alamone 1/200 unspecific ok 
GSH2 rb lifespan 1/500 tonnes of background bad 
HUNU m millipore 1/250 very good very good 
IKAROS rb gift mathias lab 1/100 no signal in vivo bad 
ISL1 rat dshb 1/10 good  
KI67 rb novocastra 1/500 good good 
LIM1/2 m dshb 1/10 no signal yet  
MAP2 ABC m sigma 1/500 good  
MEIS2 gt sc 1/500 ok i think good 
MSX1/2 ch dshb 1/40 no signal  
NANOG rb abcam 1/500 bad, no signal  
NESTIN m neuromics 1/300 very good good graft 
NESTIN m bd 1/300 very good  
NESTIN gt sc 1/500 ok, not as good  
NESTIN ch neuromics  bad, i think (ines says good)  
NESTIN m dshb 1/100 bad  
NESTIN rb millipore 1/500 very good good graft 
NEUN m millipore 1/250 good, very late  
NKX2.1 (TTF1) rb abcam 1/1000 good, but stopped working  
NUAK1 rb custom 1/100 no specific signal  
NURR1 rb sc 1/200 ok, background and faint  
OCT4 gt sc 1/500 very good  
OLIG2 gt r&d 1/200 good  
OTX2 rb millipore 1/300 good  
OTX2 gt r&d 1/500 very good  
OTX2 gt sc 1/100 good  
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PARVALBUMIN rb swant 1/50 not sure  
PAX2 rb covance 1/100 good good 
PAX5 gt sc 1/100 unsure maybe ok  
PAX6 m dshb 1/1000 very good ok 
PCNA m dako 1/200 bad  
PH3 rb abcam 1/250 very good good 
PITX3 rb zymed 1/400 bad  
PITX3 gt sc 1/50 ?  
PSD95 m thermo scientific 1/200 very good maybe ubiquitous 
REELIN m mbl 1/200 no signal yet  
SATB2 m abcam 1/10 good good 
SOMATOSTATI
N 
rb millipore 1/200 ?  
SOX1 rb abcam 1/200 ok, unsure of specificity good 
SUBP rb immunostar 1/500 good not sure 
TBR1 rb abcam 1/500 good good 
TBR2 rb abcam 1/300 very good good 
TH rb pelfreeze 1/500 very good good 
TH sh pelfreeze 1/500 useless  
TH m millipore 1/500 good good 
TRA-1-60 m santa cruz 1/100 very good  
TRA-1-81 m bd 1/100 very good  
TUJI m sigma 1/500 good  
TUJI rb covance 1/1000 good  
TUJI m covance 1/500 good  
 
